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8The Hepatitis C virus (HCV) was identified in 1989, after extensive research, (1-2) as a 
cause of  the so-called non-A non-B hepatitis. HCV is an RNA virus belonging to the genus 
Hepacivirus in the family of  Flaviviridae. Six major different genotypes of  the virus are 
discerned (3). HCV is transmitted via blood-blood contact, and consequently, the majority 
of  HCV patients in western countries are infected by the intravenous use of  drugs or by 
receiving blood transfusion before 1992, the year when screening tests became available. 
World wide more than 170 million people are chronically infected with HCV (4).
After an acute infection with HCV only about twenty percent of  the people is able to clear the 
virus, the others become chronically infected. of  the patients with a chronic HCV infection, 
about 20 percent develops progressive fibrosis developing into cirrhosis, ultimately leading 
to end-stage liver disease and hepatocellular carcinoma (5-6). Successful eradication of  the 
virus prevents progression of  the liver disease and leads to improved survival (7).
treatment of chronic HCV
The endogeneous cytokine interferon-alfa (IFN) has, amongst others, antiviral effects. 
Peginterferon-alfa (PEGIFN) is the pegylated form of  IFN. At this moment, combination 
therapy with PEGIFN and ribavirin (RBV) is standard treatment of  chronic HCV. RBV has 
weak antiviral effect when given as monotherapy, but has a synergistic effect in combina-
tion with (PEG)IFN. The precise underlying mechanism is still unclear, and several theories 
are being proposed including a direct antiviral effect by RBV acting as a mutagen through 
its incorporation into the HCV genome, subsequently resulting in error catastrophe (8-9), 
or indirect by modulating the expression of  interferon-stimulated genes (10-12). Mono-
therapy with IFN leads to eradication of  the virus (sustained virological response; SVR) 
in about 15 % of  patients, IFN combined with RBV induces an SVR in about 40 % of  pa-
tients (13-14), whereas current combination treatment with PEGIFN and RBV is capable 
of  inducing SVR in approximately 55 % (15-16). New developed anti-viral agents like tela-
previr and boceprevir show promising results, but for optimal response rates combination 
therapy of  these agents with PEGIFN and RBV still is necessary (17-18). Patient-related 
factors influencing SVR include genotype, gender, race, insulin resistance, single nucleo-
tide polymorphism of  IL-28B (19), but most notably also adherence to therapy.
Patients who fail to receive more then 80 % of  the dosage of  PEGIFN and RBV during 
more then 80% of  the expected treatment time had 50 % lower rates of  SVR (20). How-
ever treatment with PEGIFN and RBV leads to a broad spectrum of, sometimes severe, 
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9General introduction
side effects in the majority of  patients for which dose reductions and even discontinua-
tion of  therapy is often inescapable. These severe and the most common side effects are 
briefly discussed below.
side effects of PeGiFN and rBV
Disturbance of auto-immunity Introduction of  PEGIFN and RBV can induce systemic auto-
immune diseases such as sarcoidosis, systemic lupus erythematosus, rheumatoid arthri-
tis and diabetes mellitus (21-25). In addition, possibly involving the same pathogenesis, 
various skin abnormalities are described such as eczema, psoriasis and pyoderma gan-
grenosum as side effect of  PEGIFN and RBV (26-27). Again possibly as a manifestation of  
immune disturbance, pneumonitis is one of  the broad spectrum of  pulmonary problems 
PEGIFN and RBV can give (28).
Signaling of the central nervous system (PEG)IFN and RBV have – via several pathways - 
effects on the central nervous system. Immediately after the start of  treatment, this re-
sults in flu-like symptoms including fever, malaise and pains in bones, joints and muscles. 
As a more subacute extension of  this flu-like syndrome, treatment with (PEG)IFN is often 
associated with enduring malaise, lethargy and bodily pains. Central effects of  cytokines 
therapy also manifest in psychiatric side effects including depression and even suicide, 
anxiety, increased irritability, sleeping disorders and impaired concentration (29). Neu-
rological problems like parkinsonism (30), Bell’s palsy (31) and tinnitus (32) are also 
reported. Fatigue and decreased appetite with weight loss are common.
Inhibition of cell proliferation Bone marrow depression due to (PEG)IFN is common result-
ing in anemia, thrombopenia and neutropenia with risk of  bleeding (33) and infection 
(34). As RBV is associated with hemolysis, blood transfusion is sometimes necessary. 
Thinning of  hair and alopecia are frequently observed (35). Gastro-intestinal complaints 
such as diarrhoea, nausea and vomiting are frequently reported and might also be related 
to inhibition of  cell proliferation.
Cardiovascular complications Arrhythmia, cardiomyopathy and myocardial infarction are 
rare but can be fatal (36-37). Retinopathy, mostly asymptomatic, is quite commonly 
caused by PEGIFN, but also thrombosis of  the retinal vein is described (38-39). 
The above mentioned side effects frequently necessitate premature termination of  treat-
ment; Psychiatric side effects are the major reason of  discontinuation of  (PEG)IFN and 
RBV in registration trials (13, 40-41).
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Aim and outline of the thesis
Dose reduction or cessation of  therapy negatively impacts the efficacy of  antiviral treat-
ment and psychiatric side effects are the most frequent reason for dose reduction or ces-
sation of  therapy. In response, to prevent suboptimal treatment due to PEGIFN-induced 
psychopathology, one can closely monitor the psychiatric status of  the patients on anti-
viral therapy and treat the emerging psychiatric disturbance, for instance in close coop-
eration with a psychiatrist. When adopting that strategy, it would be helpful, to identify 
patients at increased risk for developing cytokine-induced psychiatric side effects. Another 
strategy (if  proven feasible and effective) would be to try to prevent the occurrence of  
psychiatric side effects, e.g. by psychopharmacological prophylactic treatment. Finally, 
PEGIFN-induced psychopathology can also be conceived as an ‘experiment of  nature’ 
which provides an opportunity to study the pathophysiology of  depression, anger, anxiety 
and sickness behavior.
The main focus of  this thesis is on PEGIFN-induced psychopathology. 
Chapter 1 reviews its current clinical features and its biochemical background. 
SSRI’s (Selective Serotonin Reuptake Inhibitors) are proven to be effective in the treatment 
of  PEGIFN-induced psychopathology (42-44), but the effect of  prophylactic treatment is still 
unclear. Chapter 2 discusses the prophylactic treatment with the SSRI escitalopram com-
pared to placebo in the prevention of  psychiatric side effects in a randomized clinical trial.
Chapter 3 describes in a substudy of  the previously mentioned randomized clinical trial 
the predictors of  psychopathology to identify patient patients at risk for cytokine-induced 
psychopathology.
PEGIFN induces changes in the cytokine network, the hypothalamic-pituitary-adrenal axis, 
the hypothalamic-pituitary-thyroid axis and in the brain serotonin (5-HT) function (45). 
Chapter 4 and 5 describes the peripheral parameters reflecting the brain metabolism be-
fore, during and after treatment with (PEG)IFN and RBV together with clinical parameters 
of  psychiatric disturbances. 
In animals, RBV has repeatedly been proven to be teratogenic (46-47). Little is known 
about the effects on offspring of  males treated with PEGIFN and RBV. There are some 
reports of  miscarriage but most pregnancies resulted in normal live born infants (48-50). 
It is however known that RBV is detectable in semen during antiviral treatment (51) and 
because to date the potential mutagenic effects of  RBV cannot be excluded, guidelines 
strongly recommend double contraception during and until 7 months after treatment for 
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male patients and their female partners. It is however questionable whether this is neces-
sary. Chapter 6 describes not only changes in sperm motility and morphology during and 
after treatment with PEGIFN and RBV, but also sperm DNA integrity. Sperm DNA integrity 
is currently the most reliable predictor of  spontaneous pregnancies and the occurrence 
of  miscarriage.
Patients chronically infected with hepatitis C virus (HCV) have a decreased health related 
quality of  life (HRQL) compared to the general population (52). Treatment of  chronic HCV 
with (PEG)IFN and RBV further diminishes HRQL due to its side effects. However, in case of  
successful treatment, an improvement of  HRQL-scores is observed (53-55). Chapter 7 de-
scribes the results of  an international, multicenter, randomized, controlled study in which 
a variety of  factors associated with HRQL at baseline (treatment naïve) and the long-term 
effects on HRQL after a course of  treatment with (PEG)IFN are studied.
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ABstrACt
Patients with a chronic hepatitis C virus (HCV) infection are frequently troubled by psy-
chiatric symptoms like depression, anxiety, anger and cognitive impairment. These symp-
toms already exist in the natural history of  the disease and frequently worsen during treat-
ment with peginterferon-alpha (PEGIFN). This review discusses the existing data on these 
symptoms and the different theories on their etiology in the natural history of  the disease 
as well as the psychopathology induced by PEGIFN. Psychopathology due to PEGIFN has 
a major impact on patients; however rates of  observed psychopathology differ largely due 
to several reasons. In treatment-naïve patients symptoms appear to be related not only 
to the frequent problematic social background of  the HCV patient, but also to the viral 
infection itself. Subsequently, theories on the biochemical mechanism of  PEGIFN-induced 
psychiatric disturbances are described. Not only changes in serotonin and its precursor 
tryptophan play a role, but for instance also the formation of  toxic metabolites and altera-
tion of  the other monoaminergic neurotransmitters like dopamine and (nor)adrenaline. 
Finally management strategies are discussed. Within these strategies serotonin reuptake 
inhibitors play a key role in the multidisciplinary management of  the HCV patients suffer-
ing from the psychiatric symptoms caused by both the infection and its treatment.
1204304 Proefschrift Erasmus Universiteit.indd   18 06-06-12   07:48
19Psychopathology in hepatitis C: its clinical features and underlying biochemical mechanisms
iNtroDUCtioN
More than 170 million people worldwide are chronically infected with hepatitis C virus 
(HCV) (1). This chronic infection can lead to liver fibrosis, eventually progressing to cir-
rhosis with complications such as liver failure, portal hypertension and hepatocellular 
carcinoma (2-3). Successful eradication of  the virus prevents progression of  liver disease 
and leads to improved survival (4-5). To eradicate the virus (as indicated by a sustained 
virological response: SVR) treatment with pegylated interferon-alpha (PEGIFN) and ribavi-
rin (RBV) is now standard of  care with SVR rates of  50-60 % (6-7). In the very near future 
new antiviral agents will be added to this standard of  care. These protease inhibotors 
VICTRELIS (boceprevir) and INCIVo (telaprevir) will augment treatment responses, but 
(for now) will not replace the use of  PEGIFN and RBV (8-11).
The treatment with PEGIFN and RBV is hampered by, sometimes severe, side effects such 
as induction of  auto-immune diseases, pancytopenia with infection and bleeding, but 
also psychopathology such as depression, anxiety, irritability and impaired concentration. 
The addition of  the new agents may shorten treatment duration in selected cases, but 
probably will not decrease the frequencies of  side effects, as these new agents cause for 
example dysgeusia, rash with pruritus and anemia. Notably, already in earlier stages of  
the disease and without receiving cytokine-based treatment, patients chronically infected 
with HCV are thought to have increased levels of  both somatic and neuropsychiatric com-
plaints, possibly in part as a direct result of  the viral infection.
The clinical features of  these neuropsychiatric symptoms in treatment naïve patients and 
in patients treated with PEGIFN will be discussed in this review. Subsequently, theories 
on the biochemical mechanism of  these PEGIFN-induced psychiatric disturbances and 
management strategies will be described.
Psychopathology in the natural history of HCV
Several studies have shown impaired quality of  life and mood disturbances in patients 
with a chronic liver disease (12-13), more detailed in those with a viral hepatitis (14) and 
especially in patients with a chronic HCV infection (15-16). In a population of  veterans 
with HCV (n=783), 34 % had symptoms of  moderate to severe depression and 37 % used 
antidepressants (15). In a similar HCV population (n=62) high scores were observed on 
questionnaires assessing anger (50%), anxiety (30.6 %) and depression (22.6%) (16).
There are several theories to explain this phenomenon. As a major part of  these patients 
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are infected via intravenous drug use, social factors and background are supposed to 
play an important role (17-18). However in a population of  HCV patients without a back-
ground of  drug abuse and with a stable social background the presence of  neuropsychi-
atric symptoms and impaired mood (depression and anxiety) was increased compared to 
healthy controls (19). Therefore, some authors suggest that the social stigmatization that 
HCV patients experience could contribute (20-21) or that processes or self-perception 
(awareness of  having a chronic infectious) disease would play an important role (22).
Several observations support the theory that HCV itself  is responsible for these psycho-
pathological symptoms and decrease in quality of  life. The presence of  a chronic infec-
tion possibly induces a state of  so called sickness behavior, characterized among other 
by depressive symptoms, fatigue, sleep disturbance and concentration impairment (23). 
Possibly in line with this, patients with HCV display lower levels of  tryptophan (TRP), the 
precursor of  serotonin (5-HT) compared to healthy controls, which might lead to mood 
lowering (24). In addition cerebral proton magnetic resonance spectroscopy showed al-
terations in HCV patients, suggesting altered monoaminergic neurotransmission (25). 
Finally, several studies demonstrated the presence of  hepatitis C virus in the brain and 
cerebral spinal fluid, which also might compromise cerebral function and give rise to 
psychiatric symptoms (26-30). Resuming, psychopathology in the untreated HCV-patient 
is quite common and seems not only caused by psychosocial factors but also by the 
(chronic) presence of  the virus itself.
Psychopathology due to PeGiFN
The endogenous cytokine IFN has (direct) antiviral, immuno-modulatory, and anti-an-
giogenic effects in the human body. Immunotherapy with exogenous administered IFN 
started in the eighties in patients with Hepatitis B and C infection but also in patients with 
melanoma, renal cell carcinoma and chronic myeloid leukemia. Almost every HCV patient 
experiences side effects of  this treatment (at least 90 %) and about 10 % develops a seri-
ous adverse event (31-32).
(PEG)IFN-induced psychopathology is one of  the best-documented psychiatric side effects 
of  medication. However, interpretation problems remain. For instance, most studies lack a 
control group not treated with (PEG)IFN, so it is not completely clear to which degree the 
reported side effects can be attributed to the direct physiological effects of  the cytokine. 
At least a part of  the observed psychopathology will be preexisting, as mentioned before, 
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and one can imagine that many patients with HCV, due to their personal history, are more 
psychologically vulnerable to the stress induced by the treatment. In addition different 
studies have used different methods: not only concerning the individual assessing the 
symptoms (e.g. hepatologist, oncologist, psychiatrist, researcher or the patient himself), 
but also with regard to the instruments used to rate the psychopathology. In addition, it is 
not self-evident if  e.g. symptoms of  fatigue should be viewed as somatic side effects (for 
instance due to anemia and hypothyroidism) or as part of  a depressive syndrome. Prob-
ably as a consequence, percentages of  observed psychopathology differ largely in studies 
in HCV-patients treated with (PEG)IFN, varying from 10-38 % of  (major) depression (33-
36), but when the whole cluster of  psychiatric complaints is taken together (depression, 
irritability, anxiety and impaired cognitive functioning) percentages can increase to 57.7 
% (37-39). To note the clinical relevance of  these side effects, in registration trials of  
(PEG)IFN, psychopathology was the major reason for discontinuation of  antiviral therapy 
and even suicides were reported (37, 40-41). Also in the registration trials of  the new an-
tiviral agents suicidal attempts and even suicides are reported (10-11).
theories on biochemical mechanism of PeGiFN-induced psychopathology
Several theories on the biochemical routes and mechanisms by which (PEG)IFN signals 
the brain and evokes psychopathology have been proposed. The most important ones are 
discussed here. Probably, after injection of  the exogenous cytokine, cascades of  other cy-
tokines are activated, that signal the brain via the vagal nerve (after activation of  cytokine 
receptors on the nerve) and via the blood. Maybe, IFN or cytokines induced by IFN cross 
the blood-brain-barrier and subsequently impact on neural systems via cytokine receptors 
in the brain, such as those for Interleukin (IL)-1 (23). Alternatively, at the blood-brain-bar-
rier, compounds like nitric oxide (No) and prostaglandins might be induced that diffuse in 
the brain parenchyma. Furthermore, lowering of  the plasma concentrations of  the amino 
acid tryptophan (TRP) might affect neurotransmission in the brain and hormonal changes 
might play a role. Finally shortage of  co-factors, the production of  neurotoxic compounds 
and changes in No might play a role. The proposed biochemical effector mechanisms are 
discussed shortly below.
1) Changes in the hormonal status and stress regulation Thyroid dysfunction due to (PEG)IFN 
is not uncommon and thyroid dysfunction and especially hypothyroidism is associated 
with depression (42-43). However, a clear association between levels of  thyroid hormone 
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and clinical symptoms in hepatitis C-patients during (PEG)IFN therapy could not be estab-
lished (44). The hypothalamic-pituitary-adrenal (HPA) axis is involved in stress regulation 
and dysregulation of  the HPA-axis probably plays an important role in the pathogenesis 
of  mood disorders. Also, the hypothalamic-pituitary-adrenal (HPA) axis is disturbed by 
(PEG)IFN treatment and accordingly, this might play a role in IFN-induced psychiatric 
disturbance (45-48).
2) Changes in the cytokine network Depressive disorders are associated with a proinflam-
matory status (23). The pro inflammatory cytokine IL-6 appears to play an important role 
in the pathophysiology of  depression (49-51), is proven to be increased by (PEG)IFN and 
its concentration has even been found to be correlated with depressive symptoms and 
anxiety (52-53). Remarkably Bull et al. reported an association between the type of  IL-6 
polymorphism of  patients and the PEGIFN-induced depressive symptoms (54).
3) Changes in brain monoaminergic activity (See Figure 1) As changes in monoaminergic 
(amongst others serotonergic and dopaminergic) neurotransmission are thought to un-
derlie mood and anxiety disorders, selective serotonin reuptake inhibitors (SSRIs) are 
thought to enhance serotonergic neurotransmission. Indeed SSRIs are effective against 
IFN-induced depression, and IFN-induced psychiatric side effects have been attributed 
to changes monoaminergic neurotransmission. IFN-based treatment impacts on several 
parameters related to 5-HT function. For instance, two studies showed a relationship be-
tween depressive symptoms during IFN treatment and the polymorphisms in the 5-HT 
transporter gene (54-55). Platelet 5-HT levels are correlated with levels of  5-HT in the 
brain (56-57) and platelet 5-HT levels decrease during treatment with PEGIFN (58). TRP 
depletion (TRP is the precursor of  5-HT) is known to induce depression and anxiety in 
vulnerable persons (59). Possibly in line with this, plasma concentrations of  TRP decrease 
due to (PEG)IFN and this decrease is found to be correlated in some, but not all studies, 
with depressive symptoms but probably also with anxiety and irritability (60-62). This de-
crease in TRP is thought to be induced by stimulation of  indoleamine-2,3-dioxygenase by 
(PEG)IFN which degrades TRP to kynurenin (KYN) (63). A small study by Schaefer et al. 
reported an improvement in psychiatric complaints in patients with insufficient response 
to selective serotonin reuptake inhibitors (SSRI’s), with the addition of  TRP (64). Further-
more, guanosine-triphosphatecyclohydrolase-1, an enzyme responsible for the production 
of  neopterin and tetrahydrobiopterin (BH4), is also stimulated by (PEG)IFN. BH4 plays 
a fundamental role in the biosynthesis of  the monoamines dopamine, noradrenaline, 
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adrenaline, and 5-HT (65-67) and changes in BH4 are related to mood disorders (68-69). 
Neopterin levels are already elevated in HCV patients compared to the general population 
(70-71) and further increase due to PEGIFN administration (72-73) possibly leads to BH4 
depletion. Higher serum neopterin levels have been related to depression (74).
(PEG)IFN also alters nitric oxide (No) synthesis (75-76), which in turn might alter the 
regulation of  monoaminergic neurotransmission (77-78). Nitrate concentrations rose in 
Figure 1|Hypothesis on effects of  administration of  interferon-alpha (IFN) on pathways in the brain. IFN stimulates 
a) the enzyme indoleamine-2,3-dioxygenase (IDo) that converts tryptophan into kynurenine, b) the enzyme kynuren-
ine hydroxylase (KYN oH-ase) that hydroxylates kynurenine to the neurotoxic 3-hydroxykynurenine, c) the enzyme 
guanosine-triphosphate-cyclohydrolase-1 (GTP-CH1) that stimulates the formation of  7,8-dihydroneopterin triphos-
phate (NH2PPP) from GTP. In conditions of  immune activation, the synthesis and release of  neopterin by activated 
macrophages/microglia is initiated at the expense of  tetrahydrobiopterin (BH4). BH4 is an important co-factor of  
phenylalanine-hydroxylase (PHA) that hydroxylates phenylalanine to tyrosine, the precursor of  the bioactive dopamine 
and noradrenaline. BH4 is also co-factor of  tryptophan-hydroxylase (TPH) which converts tryptophan to 5-hydroxy-
tryptophan, the precursor of  the bioactive serotonin. Shortage of  BH4 will change levels op dopamine, noradrenaline 
and serotonin.
(Reprinted and adapted from ‘Chronic low-grade inflammation in elderly persons is associated with altered trypto-
phan and tyrosine metabolism: role in neuropsychiatric symptoms; Capuron L, Schroecksnadel S, Féart C, Aubert 
A, Higueret D, Barberger-Gateau P, Layé S, Fuchs D; Biol Psychiatry. 2011 Jul 15;70(2):175-82 with permission from 
Elsevier). 
1204304 Proefschrift Erasmus Universiteit.indd   23 06-06-12   07:48
C
h
ap
te
r 
1
24
patients treated with IFN who developed a depression within four weeks after start of  
treatment (79). No-synthesis is reflected by the ratio of  the amino acid citrulline to argi-
nine and this ratio decreases in patients with melanoma treated with PEGIFN (80). Finally, 
changes in BH4 will cause changes in No-synthesis (81).
4) Changes in neurotoxic metabolites (See Figure 1) Cytokines induced by IFN also induce 
the enzyme kynurenine hydroxylase, and therefore treatment with (PEG)IFN could lead to 
an increase of  the production of  neurotoxic metabolites of  KYN such as 3-hydroxykyn-
urenine and quinolinic acid (82-83). A recent study showed changes in KYN levels and not 
of  TRP in cerebrospinal fluid during treatment with IFN and found these changes to be 
correlated with depressive symptoms (84).
As an overarching theory, the induction of  the sickness behaviour has been proposed to 
explain the psychiatric side effects of  IFN-based therapy. Sickness behaviour is thought to 
be a common, inborn and coordinated set of  adaptive behavioural changes that develop in 
individuals during the course of  an infection or trauma, facilitating coping with the infec-
tion or trauma. Sickness behaviour in animals includes fever, lethargy, social withdrawal, 
loss of  appetite and hyperalgesia. This behaviour would facilitate cure and counteract 
further spread of  the infectious agent in the group. Proinflammatory cytokines (especially 
IL-1 and IL-6) induce this sickness behaviour and are usually terminated by endogenous 
anti-inflammatory molecules. In HCV patients chronic sickness behaviour could be seen 
due to the persistent presence of  the infection, like in other groups of  patients with 
a chronic infection or cancer. The administration of  the exogenous cytokine (PEG)IFN 
then will maintain and even further increase symptoms of  sickness behaviour, resembling 
symptoms of  depression and other psychiatric symptoms. 
management strategies 
A previous or actual history of  psychiatric disturbance appears to be a predictor for PEGIFN-
induced psychopathology (85-86), however not all studies confirm this (87-88). Current 
guidelines on treatment of  HCV with PEGIFN and RBV state the need for a careful psychiat-
ric assessment before start of  treatment (6-7) with the, still present, exclusion of  treatment 
of  PEGIFN and RBV in patients with an untreated or poorly controlled psychiatric illness. A 
recent study showed however that with a routine medical interview preexistent psychiatric 
disturbances like depression can easily be overlooked, so the authors advocate a standard-
ized manner for screening of  psychopathology with (self  report) questionnaires (89).
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If  patients with a preexisting psychiatric illness are screened and treated for (PEG)IFN 
induced psychopathology then they do not differ in adherence, drop-out rate or even re-
sponse to therapy compared to patients without psychiatric history (86, 90-95). Also ac-
tive use of  illicit drugs is no longer an absolute contraindication for antiviral therapy (6). 
This group has a high rate of  coexisting psychopathology already before treatment (95-
97), so their psychopathology should also be discerned and treated carefully.
A multidisciplinary approach is needed for all groups patients to obtain good results: in-
tegrated care with a hepatologist, psychiatrist and trained nurses leads to more initiation 
of  treatment, prevention and adequate treatment of  PEGIFN-induced mood disturbances 
and in that way improves adherence to treatment (91, 93), also in patients without psy-
chiatric history (98).
In research on screening for psychiatric disturbance prior to antiviral treatment a variety 
of  observer-based and self-reporting rating scales is used, but comparative studies are 
lacking. The use of  a combination of  scales and scales focussing not only on depression, 
but also on anger, anxiety and other psychiatric symptoms is possibly most valuable. 
These scales are not only useful before the start of  treatment with PEGIFN, but also dur-
ing treatment. They provide a standardized manner to screen for psychopathology, such 
that these symptoms can be detected and treated (if  necessary) early. Informing patients 
before treatment with PEGIFN about the symptoms they can develop will help the patients 
to recognize and cope with these complaints.
The key medical treatment option for psychiatric side effects is the use of  SSRIs. SSRIs 
are proven to be effective in the treatment of  PEGIFN-induced psychopathology (33, 99-
100). Musselman et al. showed a beneficial effect of  prophylactic use of  an SSRI to pre-
vent depression in oncology patients treated with IFN (99). In hepatitis C patients conflict-
ing data about prophylactic use of  SSRIs are reported. Kraus et al. (101) and Schaefer et 
al. (102) showed a beneficial effect of  SSRIs in patients retreated with IFN with a previous 
IFN-induced depression or previous psychiatric medical history. In a randomized, placebo-
controlled trial also in treatment naïve patients treated with peginterferon and ribavirine 
prophylactic use of  SSRI’s had a beneficial effect on several symptoms like sadness, hos-
tile feelings and inner tension and also on the incidence of  a major depression according 
the current DSM guidelines (103). other, smaller studies in treatment-naive patients did 
not show this beneficial effect (104-106), or only in selected patients (107).
1204304 Proefschrift Erasmus Universiteit.indd   25 06-06-12   07:48
C
h
ap
te
r 
1
26
In summary, psychopathology in HCV patients is a common phenomenon and becomes a 
major problem when these patients are treated with PEGIFN. The extent of  these symp-
toms and the underlying biochemical mechanisms become increasingly clear. Awareness 
of  psychopathology in this setting with accurate screening and multidisciplinary treat-
ment of  (severe) psychiatric disturbances with a low threshold to use SSRIs is needed.
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Background Treatment of  hepatitis C with peginterferon and ribavirin is associated with 
psychiatric side effects, frequently necessitating dose reduction or therapy cessation. 
Aim: We assessed the efficacy of  prophylactic escitalopram to prevent psychiatric side-
effects during peginterferon and ribavirin treatment in a randomized, double-blind, place-
bo-controlled trial. 
methods 79 hepatitis C patients were treated with peginterferon and ribavirin. Patients 
received escitalopram (n=40, 10 mg) or placebo (n=39), which was initiated together with 
peginterferon and ribavirin. Primary outcomes were an increase of  2 points or more on 
the items reported sadness, inner tension and impaired concentration of  the Montgom-
ery-Asberg Depression Rating Scale, and hostile feelings of  the Brief  Anxiety Scale. Sec-
ondary outcome was the development of  depression diagnosed by the Mini International 
Neuropsychiatric Interview. Measurements were performed at baseline, week 4, 12 and 24 
during antiviral treatment, and 24 weeks thereafter. 
results The incidence of  psychiatric side effects was significantly lower in patients treated 
with escitalopram compared to placebo for all primary and secondary outcomes, except 
for impaired concentration: reported sadness 27.5 vs. 48.7% (p=0.052), inner tension 
17.5 vs. 38.5% (p=0.038), impaired concentration 55.0 vs. 66.7% (p=0.288) and hostile 
feelings 22.5 vs 43.6% (p=0.046) (escitalopram vs. placebo, Χ2-test). The sum-scores of  
all four endpoints showed an overall beneficial effect of  excitalopram (p=0.009, Mann-
Whitney U test). Depression occurred in 12.5% of  the patients in the escitalopram-group 
vs. 35.9% in the placebo-group (p=0.015, Χ2-test).
Conclusions Prophylactic treatment with escitalopram is effective in the prevention of  
psychiatric side effects during interferon-based treatment of  hepatitis C.
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iNtroDUCtioN
Chronic hepatitis C virus (HCV) infection is a major cause of  liver cirrhosis and hepato-
cellular carcinoma, and the most common indication for liver transplantation in Europe 
and the United States (1). The current standard therapy with peginterferon (PEGIFN) and 
ribavirin (RBV) yields sustained virological response rates (SVR) of  50-80% (2-4). How-
ever, treatment with standard interferon or PEGIFN is associated with the development 
of  severe psychiatric side effects, most notably depression. In addition, increased hostile 
feelings (5), feelings of  malaise and fatigue (6), concentration difficulties (7-8) and anxiety 
(9-10) are recognized psychiatric adverse effects.
The psychiatric side effects negatively affect quality of  life during treatment and lead to 
early dose reduction, treatment interruption or even treatment cessation. This threatens 
treatment success because continued use of  at least 80% of  the prescribed dosage for 
at least 80% of  the planned treatment duration, is crucial to the achievement of  a sus-
tained viral response (11). A variety of  case reports and open-label studies (12) and one 
randomized-controlled study (13), indicate that selective serotonin inhibitors (SSRIs) al-
leviate overt depression developed during PEGIFN therapy. Consequently, one can adopt 
the strategy to closely monitor patients for the development of  depression and start subse-
quent antidepressant treatment. However, prophylactic treatment could also be considered 
because this might not only be effective against the development of  a full-blown depressive 
disorder, but also against the development of  subthreshold psychiatric symptoms (e.g. 
depressed mood without the presence of  a full-blown depressive disorder or irritability per 
se). Both effects will potentially result in improved quality of  life during treatment for all 
patients, improved treatment adherence and possibly improved response rates.
We designed a randomized, double-blind, placebo-controlled trial studying the effects 
of  prophylactic SSRI treatment on the development of  psychiatric side effects of  antivi-
ral therapy in HCV. The primary aim was to investigate whether prophylactic treatment 
with escitalopram during treatment with PEGIFN and RBV was able to prevent psychiatric 
symptoms to a clinically significant degree (defined as an increase of  two points on ob-
server-based rating scales reflecting anxiety, loss of  concentration, depression (Montgom-
ery and Asberg Depression Rating Scale: MADRS), and hostile feelings (BAS: Brief  Anxiety 
Scale). As secondary aim, we compared the incidence of  syndromal depression (defined 
as major depression according to DSM IV criteria) according to current classification (14) 
between the two treatment groups.
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Setting and participants
Patients between 18-70 years of  age, with chronic hepatitis C as shown by detectable 
serum HCV-RNA, with hepatitis C genotype 1 to 4, with an indication for antiviral therapy 
according to current clinical HCV guidelines, and who had provided written informed con-
sent were considered eligible for the study. The following exclusion criteria were used: 
presence of  contra-indications for antiviral therapy, abnormal values for thyroid stimulat-
ing hormone, a concurrent psychiatric axis I diagnosis according to DSM-IV-criteria (such 
as a major depressive episode, bipolar disorder or psychotic disorder), concurrent use 
of  psychotropic drugs (such as monoamine-oxydase-inhibitors, St John’s worth, lithium, 
serotonin-agonists and anti-epileptics), a history or other evidence of  severe illness or ma-
lignancy and any other condition which would make the patient, according to the opinion 
of  the investigator, unsuitable for the study.
The human medical ethics committees of  the participating centers approved the study, the 
trial was registered at www.clinicaltrials.gov (Clinical Trials.gov Identifier: NCT00133276) 
and the study was performed according to the Declaration of  Helsinki and ICH-GCP guide-
lines. All patients were well aware that during the study anti-depressants could be given 
in the absence of  concurrent psychiatric disease and/or absence of  a psychiatric history.
Antiviral treatment and follow-up
Antiviral therapy consisted of  peginterferon alfa-2a (Pegasys®, Roche) at a dose of  180 
microgram weekly subcutaneously for 24 or 48 weeks depending on genotype and re-
sponse to treatment together with ribavirin (Copegus®, Roche). At the start of  the trial 
patients with genotype 2 and 3 were treated with standard 800 mg RBV per day, however 
as the importance of  RBV became more evident, patients with genotype 2 and 3 were 
also offered the same weight-based dose given to genotype 1and 4 patients. Control visits 
during treatment were scheduled at week 0 (baseline), week 2, 4, 8, 12, 16, 20 and 24. 
Week 24 indicated the end of  this study. Depending on genotype and virological response 
treatment was continued according to international guidelines. Based on these guidelines 
total treatment duration was 24 weeks in genotypes 2 and 3, and 48 weeks in genotypes 1 
and 4. When, in genotype 1 and 4 patients, there was no early virological response at week 
12 (less than 2 log drop) or when HCV-RNA was still positive at week 24, antiviral treat-
ment was stopped prematurely. The concomitant use of  paracetamol, methadone and 
benzodiazepines was allowed. Twenty-four weeks after completion of  antiviral therapy, a 
follow-up visit was scheduled.
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Randomization and intervention
Patients were randomly assigned to use either escitalopram or placebo, for a period of  26 
weeks, in identical looking tablets initiated together with antiviral treatment (escitalopram 
and placebo were provided by Lundbeck). The dose of  escitalopram was 5 mg daily during 
the first two weeks, 10 mg once daily until week 24 and thereafter 5 mg during 2 weeks. 
A biostatistician made a randomization list, yielding 50 numbers with placebo and 50 
numbers with verum in blocks of  four. The coded list remained at the pharmacy and the 
clinical research department during the course of  the study. The study medication and 
placebo were stored at the Pharmacy Department of  the Erasmus MC, Rotterdam, the 
Netherlands and delivered in blisters of  10 tablets. Patients, investigators and treating 
clinicians were blind to the use of  escitalopram or placebo.
Outcomes and follow-up
The primary outcome measure was pre-defined as an increase at one of  the time points 
during treatment of  two points or more compared to baseline on the items reported 
sadness (depressed mood), inner tension and concentration difficulties of  the Montgom-
ery–Asberg Depression Rating Scale (MADRS) or on the item hostile feelings of  the Brief  
Anxiety Scale (BAS). The secondary outcome measure was pre-defined as the presence of  
syndromal depression as diagnosed by the Mini International Neuropsychiatric Interview 
(M.I.N.I). Patients were censored after achievement of  the event.
Psychiatric evaluation took place at baseline and at 4, 12 and 24 weeks after the start 
of  treatment, and at 24 weeks after completion of  antiviral therapy. No assessments 
took place in case PEGIFN and RBV were stopped prematurely (e.g. because of  viral non-
response).
one of  the investigators (GB) performed the psychiatric ratings after extensive training.
In case of  emerging clinically significant psychiatric disorders, referral to the outpatient 
clinic of  one of  the psychiatric departments of  the participating centers was arranged. In 
other instances, e.g. when depressive disorder developed at the end of  the antiviral treat-
ment and was expected to abate after cessation of  antiviral therapy, management was 
done by the treating clinicians. The study code was broken only when clinically deemed 
necessary by the participating and coordinating center e.g. in order to treat with open-
label antidepressant therapy. The investigator performing the psychiatric evaluations was 
blinded to the status of  patients who required breaking of  the blind.
The presence of  a major depressive episode was confirmed with the relevant module of  
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the M.I.N.I., which is a short structured diagnostic interview for DSM-IV-TR and ICD-10 
(15) psychiatric disorders and was designed to perform a short but accurate structured 
psychiatric interview (16). Depressive symptoms were assessed using the MADRS, a clini-
cian rated depression scale and one of  the most commonly used symptom severity scales 
in depression (17), consisting of  10 items each of  which is scored from 0 to 6. In addition, 
the BAS was used specifically for the item hostility in order to assess hostile feelings (18).
For confirmation, as self-report questionnaires, the Beck Depression Inventory (BDI) and 
the Symptom Check List-90 (SCL-90) were used. The BDI is a well-validated and reliable 
21-item self-report questionnaire designed to measure depressive symptoms (19). Five 
somatic items (e.g. measuring fatigue and loss of  appetite) of  the BDI were also recorded. 
The SCL-90 was used to assess if  other domains of  psychic functioning besides mood were 
affected. The SCL-90 is a well-validated, multidimensional self-report symptom inventory, 
designed to assess various dimensions of  psychopathology, including hostile feelings (20).
Statistical analysis
Based on literature of  PEGIFN-induced psychopathology we estimated an incidence of  the 
primary outcome measure of  50% in the placebo group. A reduction to 30% due to pro-
phylactic use of  escitalopram was expected. The number of  patients needed was calcu-
lated using two-sided Χ2-test for equal proportions and equal group size (nQuery Advisor 
4.0 software, Virgina Commonwealth University, Richmond, VA, USA). For a power of  0.80 
at Χ2=0.05, 37 patients per arm were required. To account for potential non-evaluability, 
80 patients were included.
Analysis was performed on intention-to-treat basis. The study population was defined as all 
patients in whom baseline psychiatric evaluation was performed and who received at least 
one dose of  study medication in combination with one dose of  PEGIFN and RBV. Study 
groups were defined according to their initial assignment (placebo or escitalopram). Data 
from all different evaluation points of  the two study groups were incorporated in the analysis 
as long as patients were still on antiviral treatment at that point in time, irrespective if  they 
were still using study medication, received open-label SSRI treatment or used no study medi-
cation or SSRI at all. In case of  non-evaluability, the patient was censored at that time point.
To test for differences between patients with escitalopram or placebo the Chi-square test 
of  the primary outcome measures was used. Furthermore a total sum-score of  the four 
primary outcome measures was calculated and compared with the non-parametric Mann-
Whitney U-test.
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The relation between patient characteristics at baseline and the primary and secondary 
outcomes were examined by a univariate score-test. The independence of  these factors 
was assessed by multiple logistic regression analysis.
Mean differences of  the crude observed item scores or sum scores of  the BAS, MADRS, 
BDI and SCL-90 over the evaluation time-points during treatment (week 4, 12, 24) were 
analyzed with repeated measurement analysis using an unstructured covariance matrix of  
the time. At the time of  follow-up these scores were compared between the two treatment 
groups with student t-test. 
The level for statistical significance was set at p<0.05.
resULts
Study population
Eighty-five patients were screened and 80 patients met the eligibility criteria for the study 
and were randomized. of  the patients considered non-eligible, one had a history of  an 
antidepressant-induced manic episode, one had a current depressive episode according 
to the M.I.N.I., one was co-infected with Human Immunodeficiency Virus, one used pro-
hibited medication, and one reported severe psychosocial problems which were expected 
to hamper treatment adherence. After randomization, one patient declined treatment, so 
79 patients participated in the study. Patients were enrolled between May 2005 and June 
2007; 57 in Erasmus MC Rotterdam, 19 in Radboud University Nijmegen Medical Center 
and 3 in Academic Medical Center Amsterdam. 
Baseline characteristics of  the 79 patients are summarized in Table 1. In the escitalopram 
group, slightly more females participated and less (substance-induced) depressive epi-
sodes were reported; otherwise baseline characteristics were comparable. As diagnosed 
with the M.I.N.I., 24 (30%) patients had a history of  one or more depressive episodes: 
8 (20%) in the escitalopram group, and 16 (41%) in the placebo group (p=0.042, Pear-
son Chi-Square). Eleven patients (14%) reported having overdosed or attempted suicide. 
Twenty-nine patients (37%) reported a history of  psychosis, mostly related to the use of  
illicit drugs such as cocaine and amphetamines. None of  them was actively psychotic at 
entrance of  the study. Twenty-eight patients (35%) had been hospitalized in mental health 
and/or addiction centers. No recurrences of  psychosis were observed during the study. At 
the time of  inclusion 22 (28%) patients had an ongoing contact with either mental health 
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services or addiction services. Twelve (15%) were daily users of  benzodiazepines and 10 
(13%) were using methadone.
of  the whole group, 47 patients (59%) were born in the Netherlands, 40 patients (51%) 
were employed or housewife/househusband, 33 (42%) were on a form of  social benefit, 
one was retired (1.3%) and 5 (6.3%) had no source of  income. Fifty-four patients (68%) 
lived with a partner and/or with children, 17 (22%) were living single and 8 (10%) were 
hospitalized or detained. 
Figure 1|Trial profile
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Baseline results of  the scores of  the different items and sum scores of  the MADRS, BAS, 
BDI and SCL-90 were comparable between the escitalopram and placebo groups, with the 
exception of  the item loss of  interest of  the MADRS. For a comparison: SCL-90 sumscores 
(mean±SD) at baseline were 130.64±35.9 in the escitalopram-group and 136.53±40.5 in the 
placebo-group; in the Dutch population mean sum scores are 108-115 in men and 117-129 
in females. The flow of  patients according to treatment allocation is summarized in Figure 1.
Outcome measures
The cumulative incidence of  an increase of  2 points or more on the items reported sadness, 
inner tension of  the MADRS and the item hostile feelings of  the BAS and the incidence of  
a depressive episode according to the M.I.N.I. were all significantly more frequent (p<0.05) 
in the placebo group compared to the escitalopram group (Figure 2 and 3, and Table 2).
The use of  one sum score of  the four primary endpoints revealed an overall significant 
effect of  escitalopram (p=0.009, Mann-Whitney U-test); the mean number of  times a pa-
Figure 2|Cumulative incidence (%) of  primary outcomes: reported sadness, inner tension, impaired concentration 
(Montgomery –Asberg Depression Rating Scale (MADRS)) and Hostile feelings (Brief  Anxiety Scale (BAS))
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tient had an increase of  2 points or more 
on one of  the four primary outcome mea-
sures (scoring range 0-4) was 1.23 in the 
escitalopram-group and 1.97 in the place-
bo-group. In addition, 15 patients in the es-
citalopram group did not have any increase 
(score 0) compared to 4 patients in the 
placebo-group. In 11 patients it was con-
sidered necessary to break the study code: 
in 4 patients in the escitalopram group and 
in 7 patients in the placebo group.
Some patient characteristics (table 1) were 
associated with the primary and secondary 
outcomes at baseline. The recent use of  
cannabis or hard drugs was associated with an impaired concentration (both p=0.02) at 
baseline, admission to an addiction facility was associated with reported sadness at base-
line (p=0.01) and one or more depressive episodes prior to treatment was associated with 
the development of  a depression during treatment (p < 0.001). However, after correction 
of  these covariates with logistic regression modelling the treatment effects of  escitalopram 
and placebo remained similar.
Additional analyses
The descriptive of  the crude observed scores are given in Table 3. At week 4, 12 and 24 pa-
tients treated with escitalopram had significant lower total scores on the MADRS and lower 
scores on the item hostile feelings of  the BAS.  Specifically at week 4 and 24 the scores on 
the item inner tension of  the MADRS were lower in the escitalopram group; there were also 
significant differences between escitalopram and placebo at the sleep item at week 4 and 
the appetite item at week 12 and 24, in favor of  the escitalopram group (data not shown).
At week 4, 12 and 24 patients treated with escitalopram had lower scores on the BDI total 
score, BDI-somatic items, SCL total score, SCL-depression, SCL-anxiety, SCL-insufficiency 
in thinking and acting and SCL-hostility (Table 3). No differences at week 4 and 12 were 
observed between the two groups on the item SCL-somatic complaints. 
Figure 3|Cumulative incidence (%) of  secondary out-
come: MINI (Mini-International Neuropsychiatric In-
terview) depression according Diagnostic Statistical 
Manual-IV criteria
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table 1 | Characteristics of  all patients: general characteristics at baseline, route of  transmission and genotype of  
hepatitis C virus, and psychiatric history, current treatment and substance abuse.
Characteristics escitalopram (n=40) Placebo (n=39) total (n=79)
General
   Mean (SD) age, years 48.5 ± 9.7 44.6 ± 7.5 46.5 ± 8.8
   Mean (SD) body weight, kg 79.1 ± 14.4 82.5 ± 14.3 80.8 ± 14.4
   Mean (SD) BMI 26.1 ± 3.6 25.8 ± 4.3 26.0 ± 3.9
   Sex (% males) 67.5 89.7 78.5
Route of  transmission
   IVDU and/or tattoo 19 26 45
   Iatrogenic 14 9 23
   Sexual contact 1 1
   Unknown 6 4 10
Genotype
   1 & 4 18 18 36
   2 & 3 22 21 43
Psychiatric history, current treatment and substance abuse
   one or more depressive episodes 4 10 14
    one or more depressive episodes including  
substance induced
8* 16* 24
   Suicides attempts/overdose 5 6 11
   Psychosis 14 15 29
   Admission to psychiatric hospital 4 7 11 
   Admission to addiction facility 11 17 28
   Current contact with Mental Health or Addiction Service 9 13 22
   Daily use of: methadone or benzodiazepines 9 (6+3) 3 (2+1) 12 (8+4)
   Daily us of: tobacco 25 29 54
   Last week use of: alcohol 15 15 30
   Last week use of: cannabis 6 10 16
   Last month use of  non-iv hard drugs 2 3 5
* Statistically significant difference between escitalopram and placebo group (Chi-square): p≤0.05.
table 2|The occurrence of  psychiatric side-effects during antiviral therapy with peginterferon and ribavirin: the effects 
of  prophylactic treatment with escitalopram or placebo.
escitalopram: 
events (%) n=40
Placebo: 
events (%) n=39
p-value 
(χ2) 
increase of at least 2 points of:
   mADrs Reported sadness 11 (27.5) 19 (48.7) 0.052
Inner tension 7 (17.5) 15 (38.5) 0.038
Impaired concentration 22 (55.0) 26 (66.7) 0.288
   BAs Hostile feelings 9 (22.5) 17 (43.6) 0.046
   occurrence of depression
   MINI Depression 5 (12.5) 14 (35.9) 0.015
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Baseline Week 4 Week 12 Week 24
treatment effect 
over time
Follow-up
escitalopram Placebo escitalopram Placebo escitalopram Placebo escitalopram Placebo escitalopram Placebo
N=40 N=39 N=39 N=38 N=38 N=38 N=33 N=34 N=28 N=34
MADRS Sum score 4.58 ± 3.9 4.69 ± 4.7 6.69 ± 5.4 10.29 ± 7.3 8.26 ± 7.2 10.92 ± 6.6 7.39 ± 6.1
12.00 ± 
6.0P=0.0024
5.04 ± 6.9 7.24 ± 7.0
BAS Hostile feelings 0.83 ± 1.0 0.95 ± 1.0 0.79 ± 1.2 1.24 ± 1.1 1.03 ± 1.4 1.71 ± 1.0 0.91 ± 1.2 1.56 ± 1.3 P=0.0095 0.61 ± 1.0 0.94 ± 1.3
N=40 N=38 N=38 N=38 N=37 N=38 N=32 N=34 N=28 N=32
BDI Sum score 9.05 ± 7.9 8.21 ± 7.7 8.87 ± 7.7 13.53 ± 10.1 10.76 ± 9.6 14.66 ± 9.2 8.09 ± 6.7 14.56 ± 8.8 P=0.0042 6.89 ± 8.6 9.59 ± 8.0
Somatic items 3.25 ± 2.5 2.82 ± 2.8 4.08 ± 2.7 5.71 ± 3.7 4.57 ± 3.1 6.42 ± 3.5 3.91 ± 2.9 6.50 ± 3.4 P=0.0044 2.21 ± 2.1 4.34 ± 4.1
N=39 N=38 N=37 N=38 N=37 N=38 N=32 N=33 N=28 N=32
SCL Sum score 130.64 ± 35.9 136.53 ± 40.5 124.74 ± 29.2 156.37 ± 56.3 131.57 ± 40.9 158,97 ± 50.0 125.59 ± 33.4 160.61 ± 50.1 P=0.0004 119.71 ± 34.8* 149.78 ± 55.6* 
Depression 24.79 ± 9.3 25.74 ± 8.6 23.79 ± 8.0 29.24 ± 11.6 25.41 ± 10.4 30,26 ± 1,2 23.94 ± 7.9 30.36 ±10.8 P=0.0043 23.11 ± 11.1 27.75 ±11.6
Anxiety 14.51 ± 5.1 14.82 ± 5.5 12.63 ± 3.4 16.66 ± 7.1 13.84 ± 4.0 16,95 ± 6,5 13.00 ± 4.2 17.09 ± 6.7 P=0.0007 12.71 ± 3.4 16.38 ± 6.6
Insufficiency 14.92 ± 5.1 15.50 ± 5.0 14.24 ± 4.9 18.42 ± 7.0 15.59 ± 6.8 19,47 ± 7,0 15.16 ± 5.7 19.52 ± 6.9 P=0.0017 13.50 ± 5.5* 17.88 ± 7.4 *
Hostility 8.49 ± 3.6 8.08 ± 2.4 7.21 ± 2.0 9.63 ± 4.6 8.19 ± 2.9 9,76 ± 3,4 8.13 ± 3.2 9.85 ± 3.5 P=0.0028 7.46 ± 1.8 8.78 ± 3.8
Somatic 18.33 ± 5.6 19.58 ± 6.7 20.92 ±6.5 25.32 ± 9.4 21.22 ± 6.9 24,76 ± 9,1 19.72 ± 8.1 25.21 ± 9.6 P=0.017 17.14 ± 4.6 21.75 ± 9.5
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All patients were asked to fill in the questionnaires, including those in whom the study code was broken. Incomplete 
questionnaires (administrative failure) were not taken into consideration.
Treatment effect over time was obtained using repeated measurement analysis using an unstructured covariance 
matrix of  the time.
At follow up, escitalopram and placebo groups were compared using student t-test, * denotes significant differences 
(p ≤ 0.05)
table 3|Mean scores with standard deviation of  the different rating scales in the escitalopram and placebo group (at 
baseline, during antiviral therapy and during follow-up)
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Baseline Week 4 Week 12 Week 24
treatment effect 
over time
Follow-up
escitalopram Placebo escitalopram Placebo escitalopram Placebo escitalopram Placebo escitalopram Placebo
N=40 N=39 N=39 N=38 N=38 N=38 N=33 N=34 N=28 N=34
MADRS Sum score 4.58 ± 3.9 4.69 ± 4.7 6.69 ± 5.4 10.29 ± 7.3 8.26 ± 7.2 10.92 ± 6.6 7.39 ± 6.1
12.00 ± 
6.0P=0.0024
5.04 ± 6.9 7.24 ± 7.0
BAS Hostile feelings 0.83 ± 1.0 0.95 ± 1.0 0.79 ± 1.2 1.24 ± 1.1 1.03 ± 1.4 1.71 ± 1.0 0.91 ± 1.2 1.56 ± 1.3 P=0.0095 0.61 ± 1.0 0.94 ± 1.3
N=40 N=38 N=38 N=38 N=37 N=38 N=32 N=34 N=28 N=32
BDI Sum score 9.05 ± 7.9 8.21 ± 7.7 8.87 ± 7.7 13.53 ± 10.1 10.76 ± 9.6 14.66 ± 9.2 8.09 ± 6.7 14.56 ± 8.8 P=0.0042 6.89 ± 8.6 9.59 ± 8.0
Somatic items 3.25 ± 2.5 2.82 ± 2.8 4.08 ± 2.7 5.71 ± 3.7 4.57 ± 3.1 6.42 ± 3.5 3.91 ± 2.9 6.50 ± 3.4 P=0.0044 2.21 ± 2.1 4.34 ± 4.1
N=39 N=38 N=37 N=38 N=37 N=38 N=32 N=33 N=28 N=32
SCL Sum score 130.64 ± 35.9 136.53 ± 40.5 124.74 ± 29.2 156.37 ± 56.3 131.57 ± 40.9 158,97 ± 50.0 125.59 ± 33.4 160.61 ± 50.1 P=0.0004 119.71 ± 34.8* 149.78 ± 55.6* 
Depression 24.79 ± 9.3 25.74 ± 8.6 23.79 ± 8.0 29.24 ± 11.6 25.41 ± 10.4 30,26 ± 1,2 23.94 ± 7.9 30.36 ±10.8 P=0.0043 23.11 ± 11.1 27.75 ±11.6
Anxiety 14.51 ± 5.1 14.82 ± 5.5 12.63 ± 3.4 16.66 ± 7.1 13.84 ± 4.0 16,95 ± 6,5 13.00 ± 4.2 17.09 ± 6.7 P=0.0007 12.71 ± 3.4 16.38 ± 6.6
Insufficiency 14.92 ± 5.1 15.50 ± 5.0 14.24 ± 4.9 18.42 ± 7.0 15.59 ± 6.8 19,47 ± 7,0 15.16 ± 5.7 19.52 ± 6.9 P=0.0017 13.50 ± 5.5* 17.88 ± 7.4 *
Hostility 8.49 ± 3.6 8.08 ± 2.4 7.21 ± 2.0 9.63 ± 4.6 8.19 ± 2.9 9,76 ± 3,4 8.13 ± 3.2 9.85 ± 3.5 P=0.0028 7.46 ± 1.8 8.78 ± 3.8
Somatic 18.33 ± 5.6 19.58 ± 6.7 20.92 ±6.5 25.32 ± 9.4 21.22 ± 6.9 24,76 ± 9,1 19.72 ± 8.1 25.21 ± 9.6 P=0.017 17.14 ± 4.6 21.75 ± 9.5
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24 weeks post-antiviral treatment
At 24 weeks post-treatment, the MADRS-, BDI- and SCL-90-sum scores and BAS-hostile 
feelings score all returned to baseline in patients treated with escitalopram. In contrast, 
among the placebo-treated patients the BAS-hostile feelings score but not the MADRS-, 
BDI- and SCL-90-sumscores returned to baseline (Table 3).
Safety and tolerability
Three serious adverse events (SAE’s) were observed during the study period. A 35-year old 
female developed a severe, persistent trombocytopenia; after cessation of  all medication 
the trombocytopenia resolved. A 49-year old male, with as risk factor smoking, developed 
bilateral pulmonary embolism. A 53-year old female with recompensated liver cirrhosis 
had a new episode of  decompensated liver disease with ascites. These SAE’s occurred all 
in the escitalopram group, but none was considered to be related to the use of  escitalo-
pram. No dose reductions of  PEGIFN or RBV were necessary due to psychopathology, also 
because of  the possibility to break the study code and start open label treatment with 
antidepressants.
The use of  escitalopram had no influence on either hematological or biochemical param-
eters (liver enzymes).
Response to antiviral treatment
The response to antiviral treatment in the escitalopram and in the placebo group was simi-
lar. The respective SVRs for escitalopram and placebo were, 46% and 50% for genotype 1, 
83% and 80% for genotype 2 and respectively 73% and 86% for genotype 3. None of  the 
5 patients with genotype 4 reached SVR.
Concomitant use of benzodiazepines
The concomitant use of  paracetamol and benzodiazepines was allowed. Before and 
after the start of  antiviral therapy, the use of  benzodiazepines was similar among both 
groups. At baseline 3 patients in the escitalopram-group and one patient in the placebo-
group already used benzodiazepines. After antiviral therapy was started, 10 additional 
patients in the escitalopram-group and 13 in the placebo-group had benzodiazepines 
prescribed.
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Patient withdrawal and patients lost to follow up during the study
Patient withdrawal was higher in the escitalopram-group (12 out of  40) than in the pla-
cebo- group (5 out of  39). The difference was not statistically significant (p=0.1 Fisher’s 
Exact Test). There were several reasons for patient withdrawal: occurrence of  side-effects 
(escitalopram three, placebo zero), viral nonresponse (escitalopram two, placebo two), 
and no obvious reason (escitalopram two, placebo zero). In two patients (one escitalo-
pram, one placebo) data was not complete (administrative failure). Six patients were lost 
to follow up (four escitalopram, two placebo).
DisCUssioN
In this randomized double-blind placebo-controlled study, we demonstrated the efficacy 
of  prophylactic escitalopram in the prevention of  psychiatric side-effects during antiviral 
therapy for chronic hepatitis C. When started concomitantly with PEGIFN and RBV, escita-
lopram not only reduced the number of  psychiatric events (increases to a clinically signifi-
cant degree in depressed mood (reported sadness), anxiety (inner tension), concentration 
difficulties and in hostile feelings), but also the occurrence of  a depressive syndrome. The 
study was designed such that the risk of  premature discontinuation of  antiviral treatment 
was minimized. When judged clinically necessary by the treating physician, the study code 
was broken and the patient was started on open label psychopharmacological treatment 
when indicated. Adherence to antiviral therapy was considered more important than to 
address the question whether prophylactic escitalopram-treatment itself  would improve 
adherence and SVR. The concomitant use of  escitalopram was safe and the SVR rates 
were similar in the two treatment groups. It is important to note that apart from observ-
ing a beneficial effect of  escitalopram on three of  the four pre-defined observer based 
outcome measures (symptom level), and on depression (syndromal level), these findings 
were corroborated with the use of  self-administered questionnaires.
In agreement with the literature (7, 21-23), a substantial percentage of  patients treated 
with placebo developed clinically relevant psychiatric side effects. Escitalopram had a 
beneficial effect on both the occurrence and the intensity of  these side effects, such that 
the incidence of  psychiatric side-effects was approximately halved compared to placebo. 
During follow up, no late adverse events related to escitalopram were observed; in con-
trary, although not being the aim of  study, the beneficial effects of  escitalopram seemed 
to be sustained 24 weeks after the end of  antiviral therapy.
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Results from three small open-label studies on the prophylactic treatment with antide-
pressants suggest that SSRIs are capable of  preventing depression during PEGIFN-based 
treatment for HCV infection (24-26). In the first study, eight patients underwent success-
ful antiviral re-treatment with concomitant SSRI prophylaxis with lower depression scores 
compared to those during the initial PEGIFN and RBV treatment (24). In the second study, 
11 patients who were scheduled for IFN-based treatment and who were considered to 
have a clinical indication for antidepressant treatment, received SSRI prophylaxis. A com-
parison was made with 11 patients with a comparable psychiatric history and with 11 
patients without such a history. In the prophylaxis group, less depression occurred (25). In 
the third study, 10 patients with a past history of  but no current depression, were treated 
with escitalopram during antiviral treatment. Depression could be prevented in 9 out of  
10 patients (26).
By now, five randomized controlled trials on prophylaxis with SSRIs have been performed. 
In oncology patients treated with high-dose IFN, paroxetine successfully attenuated de-
pression (27). However, no beneficial effect could be demonstrated in the four trials in 
HCV patients. The first HCV-trial enrolled only 33 patients and different formulations of  
antiviral therapy were used (28). The second trial, performed by the same investigators 
but now using PEGIFN-based therapy only, did also not show a beneficial effect of  par-
oxetine over placebo. However, this study had to be concluded prematurely because of  
recruitment difficulties (29). The third study was also closed prematurely due to a slow 
inclusion and had a very high drop-out rate 29 out of  61 patients) (30). The fourth study 
was the largest, studying the effects of  14 weeks escitalopram vs. placebo in 129 patients 
with hepatitis C treated with PEGIFN plus RBV (31). In comparison with other studies, the 
occurrence of  depression was low. No beneficial effect of  escitalopram could be demon-
strated. With the appropriate sample size and power and 24-week treatment duration, we 
could demonstrate a significant beneficial effect of  prophylactic treatment with escitalo-
pram. A strong point of  this study is the fact that those separate individual items consid-
ered to represent the most important types of  IFN-induced psychopathology (reported 
sadness (i.e. mood lowering), inner tension (i.e. anxiety), concentration difficulties and 
aggression) were used as primary outcomes instead of  only total composite scores or the 
occurrence of  a full blown depression (32-35). The study-design was practically-oriented 
with the use of  a fixed dose of  escitalopram, the permitted use of  psychotropic medica-
tion such as methadone and benzodiazepines, the concomitant start of  escitalopram and 
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antiviral therapy, and with demographic characteristics of  the participating HCV patients 
fitting well into every day practice of  Western hospitals. 
Although no official data is available, in Dutch clinical practice many HCV patients have a 
history of  intravenous drug use and/or tattoo. For a comparison, US-veterans with HCV show 
an increased prevalence of  psychiatric history and/or use of  antidepressants (36), and a ma-
jor part of  these patients has been infected via intravenous drugs. But also HCV itself  may 
induce psychopathological symptoms, suggested by a study showing increased presence of  
neuropsychiatric symptoms and impaired mood (depression and anxiety) in HCV patients 
without a background of  drug abuse and with a stable social background (37). This might ex-
plain the high prevalence of  a previous psychiatric history among our participating patients.
A weak point of  the study might be the fact that patients with genotype 1 and 4 were 
treated for 48 weeks with peginterferon and ribavirin but received escitalopram or placebo 
for 26 weeks only. However, it is known that the occurrence of  most psychiatric side-
effects is within the first 24 weeks of  antiviral therapy and is relatively rare thereafter (9, 
38-39). one could also argue that as no lead in period with escitalopram was used, the 
SSRI might not have been fully active in the first weeks of  antiviral therapy; consequently, 
the effect of  prophylactic SSRI treatment might have been even greater. In addition, one 
might argue that despite an adequate randomization procedure, the placebo group dis-
played a greater vulnerability to the development of  IFN-induced psychiatric disturbance, 
as shown by a tendency to have a history of  more depressive episodes in the past and 
more admissions in psychiatric and addiction facilities. This might also explain why the 
scores of  self-administered questionnaires did not return to baseline at 24 weeks post-
treatment in the placebo-group. Finally, one could argue whether all or selected patients 
should receive prophylactic escitalopram because it cannot be excluded from this trial 
that patients with a psychiatric history benefit the more from escitalopram treatment; this 
warrants future study.
In conclusion, the substantial reduction of  psychiatric side-effects in combination with 
the safety of  escitalopram, suggests that prophylactic escitalopram treatment could be 
considered in hepatitis C patients treated with PEGIFN and ribavirin.
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ABstrACt
objective Psychiatric side effects of  interferon (IFN)-based therapy are the most impor-
tant cause of  early treatment discontinuation in chronic hepatitis C virus (HCV) infected 
patients. We aimed to identify those HCV patients who benefit most from prophylactic 
treatment with selective serotonin reuptake inhibitors (SSRIs) during antiviral therapy 
(AVT) and to quantify the effect of  prophylactic treatment in these patients. 
method We analyzed risk factors for depression and studied the effect of  prophylactic 
escitalopram on depressive symptoms among 78 HCV patients included in a prospective 
randomized controlled trial of  escitalopram versus placebo during AVT with PEGIFN and 
ribavirin (RBV). At baseline, week 4, 12 and 24 of  AVT, the Mini International Neuropsy-
chiatric Interview and the Symptom Check List-90 (SCL-90) were conducted to diagnose 
depression and monitore depressive symptoms on treatment, respectively. 
results Depression occurred in 14 patients of  the placebo-group and in 5 patients of  the 
escitalopram-group (Pearson χ2, p=0.01). The combination of  a history of  depression 
and previous intravenous drug use (IVDU) was independently associated with IFN-induced 
depression (odds ratio: 12.60; 95% confidence interval 2.47–64.34, p<0.01). Moreover, 
SSRI treatment was associated with a significant reduction in depressive symptoms (esti-
mated mean depression score 35 versus 22 on the SCL-90 by week 4, for placebo versus 
SSRI respectively (Pearson χ2 p=0.02). 
Conclusion. HCV-infected patients with a history of  depression and IVDU carry the highest 
risk to develop IFN-induced depression. In this subset of  patients, prophylaxis with esci-
talopram in HCV-infected patients results in the most substantial decrease of  IFN-induced 
depressive symptoms.
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iNtroDUCtioN
Chronic hepatitis C virus (HCV) infection is a major health problem with 170 million peo-
ple being infected worldwide. Antiviral therapy (AVT) with pegylated interferon (PEGIFN) 
and ribavirin (RBV) leads to sustained virologic response (SVR) in 41-84% of  patients 
after 24 to 48 weeks of  therapy. However, this AVT is associated with many side effects. In 
fact, psychiatric side effects of  AVT have shown to be the most important cause of  early 
treatment discontinuation. Irritability and depression are the most frequently reported 
psychiatric side effects with an incidence of  24% and 37% respectively (1-3). In our 
previously described retrospective cohort of  HCV-infected patients treated with PEGIFN/
RBV (4), we found a similarly high incidence of  depression (30%) and association of  
previous intravenous drug use (IVDU) with new onset depression during AVT. Despite this 
high incidence of  depression, depressive symptoms may be overlooked by routine clinical 
interviews, which are usually focused on physical rather than psychiatric complaints (3). 
Although new direct-acting antiviral regimens are being developed, these agents still re-
quire PEGIFN as a backbone of  therapy and it can therefore be anticipated that interferon 
(IFN)-induced depression will remain a major challenge in the treatment of  HCV.
Several baseline characteristics have been identified as predictors of  depression of  which 
higher depression scores at baseline and depression with previous IFN-based therapy 
are the most consistent ones in literature. A recent study suggested that antidepressant 
prophylaxis for each patient might prevent depressive symptoms and a major depressive 
episode (5), although other research groups could not demonstrate a significant advan-
tage for SSRI prophylaxis in reducing the likelihood of  developing major depression (6-7). 
A disadvantage of  prophylactic SSRI treatment is that a significant amount of  patients 
who would never have developed depressive symptoms would receive antidepressant treat-
ment. Since IFN-induced depression affects only a subgroup of  patients and has shown 
to be highly responsive to SSRI treatment, we hypothesized that the efficacy of  SSRI 
prophylaxis in the prevention of  IFN-induced depression would vary among HCV-infected 
patients. Therefore, we aimed to identify those HCV patients who would benefit the most 
from prophylactic SSRI treatment during PEGIFN/RBV and to quantify the effect of  pro-
phylactic treatment in these patients.
PAtieNts AND metHoDs 
We studied all patients included in a recent randomized, double-blind, placebo-controlled 
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trial that investigated the effect of  prophylactic treatment with escitalopram versus placebo 
(5). We defined ‘benefit’ of  SSRI prophylaxis as absence of  a depressive syndrome according 
to current DSM-IV classification (8) and/or significant reduction in estimated mean depres-
sion score during AVT when dosed escitalopram instead of  placebo. First, we studied base-
line covariates in relation to the development of  depression. After identification of  baseline 
risk factors for the development of  IFN-induced depression, we compared depression scores 
during AVT to identify which patients would benefit from antidepressant prophylaxis.
The original trial pursued to obtain a study population representative of  the HCV-infect-
ed patient population in Western countries and therefore permitted use of  psychotropic 
medication such as methadone and benzodiazepines. The existence of  a depressive syn-
drome at screening was an exclusion criterion. Both treating clinician and psychiatrist were 
blinded with regard to type of  study drug, which was initiated simultaneously with antiviral 
therapy (5). Psychiatric evaluation was performed at baseline, week 4, 12 and 24 of  AVT 
and at 24 weeks of  follow-up after cessation of  AVT and included conduct of  the relevant 
module of  the Mini International Neuropsychiatric Interview (M.I.N.I) and the Symptom 
Check List-90 (SCL-90). The M.I.N.I. is a short structured diagnostic interview for DSM-IV-
TR and ICD-10 psychiatric disorders and was used to diagnose the event ‘depressive epi-
sode’, or, briefly, ‘depression’. The SCL-90 is a well-validated, multidimensional self-report 
symptom inventory, designed to assess various dimensions of  psychopathology, including 
depressive symptoms. The SCL-90 was used to study the degree and course of  depressive 
symptoms over time. The score of  the depression scale is constructed with the results of  
16 questions and interpreted according to its classification in one of  the 7 groups (very 
low, low, below average, average, above average, high, very high). In the general Dutch popu-
lation, the observed range is 16 – 76 with 16 – 19 corresponding to the classifications very 
low until below average, 20 – 23 to average, 24 to above average, 25 – 35 to high and ≥ 36 
to very high (9). For our analysis, the following baseline covariates were collected: patient 
characteristics (gender, age, genotype 1 or other, race, living situation), data on psychiatric 
history (history of  depression, history of  psychosis, or previous suicide attempt; admission 
to a psychiatric hospital or admission to a center for addiction treatment; IVDU as route of  
transmission, former or current use of  alcohol, tobacco, hard or soft drugs or psychotro-
pic medication), routine laboratory examinations (sodium, albumin, bilirubin, prothrombin 
time, gammaglutaminyl transferase (GGT), alanine transaminase (ALT), thyroid function, 
creatinin) and two specific laboratory values hypothesized to underly psychiatric side ef-
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fects of  IFN-based AVT (serotonin, tryptophan) prior to initiation of  AVT. Further, relation 
between success of  AVT, SVR and risk factors for depression were investigated.
stAtistiCs
Univariate logistic regression analysis was used to identify baseline factors associated 
with the development of  depression in the placebo-group. In a multivariate logistic model, 
we investigated the same factors with the addition of  the prophylactic therapy as to de-
termine which factors were associated with depression in the total group with correction 
for study treatment (escitalopram/placebo). Determinants with statistical significance at 
the 0.20 level in the univariate analysis were included in the multivariate analysis with 
backward selection based on the likelihood ratio. Data were analyzed using SPSS 17.0 
statistical software (SPSS Inc., Chicago, IL, USA). In general, strong co-linearity between 
two factors hampers the interpretation of  the results of  a multivariate logistic model. The 
baseline characteristic ‘previous IVDU’ almost fully covered patients who reported a past 
depressive episode. However, previous depression and psychiatric co-morbidity have been 
described in relation to IFN-induced depression. Therefore, we investigated these two co-
variates in the same multivariate model, and separately.
To study the development and severity of  depressive symptoms over time, we investigated 
the scores on the SCL-90 subscale depression as continuous variable. The mean depres-
sion score of  the SCL-90 was estimated using SAS mixed procedures with an autoregres-
sive covariance structure taking the repeated measurement structure of  the data into 
account. Covariates that had been identified as risk factors for depression with the above 
described logistic regression analysis were selected; these covariates (depression in his-
tory, previous IVDU) and the interaction with study treatment were studied in the mixed 
procedure as fixed effects.
resULts
Seventy-eight patients were included: 40 patients were randomized to escitalopram and 38 
patients to placebo. Table 1a summarizes the baseline characteristics of  these patients. In 
the escitalopram group, more female patients participated (p=0.04, Pearson Chi-square) 
and fewer patients had ever used hard drugs (p=0.04, Pearson Chi-square); otherwise 
baseline characteristics were comparable. overall, 23 (29%) patients had a history posi-
tive for depression, 34 patients (44%) had been hospitalized in mental health centers or 
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escitalopram
N=40
Placebo
N=38
total 
N=78
Male gender, n (%) 27 (68)* 33 (87)* 60 (77)
Age, years, mean (range) 48 (22-68) 45 (30-61) 47 (22-68)
Born in the Netherlands, n (%) 22 (55) 25 (66) 47 (60)
Living situation with partner, n (%) 31 (78) 22 (58) 53 (68)
other, n (%) 9 (23) 16 (42) 25 (32)
Paid job, n (%) 20 (50) 15 (39) 35 (45)
Route of  transmission intravenous drug use, n (%) 19 (48) 20 (53) 39 (50)
other, n (%) 21 (53) 18 (47) 39 (50)
Race Caucasian, n (%) 34 (85) 34 (89) 68 (87)
other, n (%) 6 (15) 4 (11) 10 (8)
Genotype 1, n (%) 16 (40) 15 (39) 28 (36)
2, n (%) 7 (18) 5 (13) 3 (4)
3, n (%) 14 (35) 15 (39) 12 (15)
4, n (%) 2 (3) 3 (8) 28 (36)
Unknown, n (%) 1 (3) 0 (0) 1 (1)
Psychiatric medical history
one or more episodes of  depression, 
n (%)
8 (20) 15 (39) 23 (29)
Suicides attempts/overdose, n (%) 5 (13) 6 (16) 11 (14)
Psychosis, n (%) 15 (38) 20 (53) 35 (45)
Ever use of  hard drugs, n (%) 19 (48)* 27 (71)* 46 (59)
Intravenous use of  hard drugs 
in past 3 months, n (%)
1 (3) 0 (0) 1 (2)
Non-intravenous use of  hard drugs 
in past 3 months, n (%)
2 (5) 3 (8) 5 (6)
Admission to addiction facility, n (%) 11 (28) 17 (45) 28 (36)
Current contact with Mental Health 
or Addiction Service, n (%)
9 (23) 13 (34) 22 (28)
* Statistically significant difference between escitalopram and placebo group (Pearson Chi-square, p<0.05)
table 1a|Baseline characteristics of  participants of  the study on prevention of  depression
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table 1b|Results of  multivariate logistic regression analyses on incidence of  depression with antiviral therapy for 
chronic HCV
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addiction centers and 22 patients (28%) were in contact with outpatient mental health 
service or addiction service at the time of  intake. Forty-seven patients (60%) reported to 
have ever used hard drugs of  which the majority (46 of  47 patients, 98%) reported IVDU; 
these 47 patients will be referred to as patients with previous IVDU from here. At screening, 
6 of  these 46 patients reported IVDU within the past 3 months. Baseline scores of  SCL-90 
were comparable between the escitalopram and placebo groups. SVR was achieved in 23 
(35%) and 19 patients (29%) of  the placebo and escitalopram arm, respectively (p=0.59).
Depression occurred in 14 of  38 (37%) patients randomized to placebo and in 5 of  40 (13%) 
patients randomized to escitalopram (Pearson Chi-square, p=0.01). In the univariate logistic 
analysis in placebo-dosed patients, history of  depression, past IVDU and IVDU as route of  
transmission were associated with the occurrence of  depression during AVT. More important-
ly, the combination of  history of  depression and IVDU was strongly associated with the oc-
currence of  depression. No association was found between the occurrence of  depression and 
baseline scores of  the psychiatric questionnaires or baseline laboratory results (table 1b).
Multivariate logistic regression analysis was hampered by co-linearity of  history of  de-
pression and previous IVDU; 17 of  the 23 patients (74%) with a history of  depression 
had used intravenous drugs. Thirty-seven percent of  patients who had ever injected drugs 
reported to have a history of  depression. This co-linearity was even stronger with the 
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Figure 1a.|Estimated mean depression scores during AVT in all placebo-dosed patients, according to the presence of  
depression in history or previous IVDU
AVT, antiviral therapy; IVDU, intravenous drug use
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presence of  the event depression; within this group 85% of  patients with a history of  
depression reported to have ever injected drugs and 73% of  patients who ever injected 
hard drugs had a history of  depression. Multivariate analysis including the covariates “his-
tory of  depression”, “previous IVDU” and “gender”, resulted in “history of  depression” as 
covariate associated with the event depression: odds ratio (oR): 9.50, 95% confidence 
interval (C.I.) 2.08 – 43.50, p=0.004 in the placebo-arm and oR: 10.61, 95% C.I. 3.25 – 
34.64, p<0.001 in the overall study group, corrected for study medication. A subsequent 
multivariate analysis was performed to overcome the described co-linearity, combining 
history of  depression and previous IVDU as single covariate with other baseline covari-
ates in a model. We included the following clinically relevant covariates in our multivari-
ate analysis: female gender, younger age and living situation (alone or with partner) as a 
measure for lack of  social support (table 1b) (10-13).
SVR rate was not significantly different in patients with (8, 57%) and without (34, 67%) a 
history of  depression and IVDU (p=0.14). 
Figure 1b.|Estimated mean depression scores in patients on AVT with escitalopram or placebo, according to the 
presence of  a history of  depression and/or previous IVDU in this subgroup of  patients AVT, antiviral therapy; IVDU, 
intravenous drug use With a history of  depression and IVDU, escitalopram prevents the development of  depressive 
symptoms (p-value 0.03).
Without a history of  depression and/or IVDU, escitalopram prevents the development of  depressive symptoms 
(p-value 0.04).
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Treatment effect of escitalopram.
Figure 1a shows the scores on the depression scale of  the SCL-90 of  placebo treated pa-
tients over time. one patient did not complete the SCL-90 questionnaire at week 0, there-
fore, this patients was not included in this analyses of  depression score over time. In all 
patients, the development of  depressive symptoms was most prominent within the first 4 
weeks after start of  AVT. Patients with a history of  IVDU or depression showed significantly 
higher scores on the SCL-90 depression scale. Thus, patients with a history of  depression 
and IVDU appear to be the most vulnerable subgroup for the development of  depressive 
symptoms with AVT.
We selected patients with the presence of  one of  these two risk factors in both placebo 
arm and escitalopram arm. Subsequently, we compared the development and change 
in depressive symptoms over time (Figure 1b). Within this group escitalopram showed a 
significant decrease of  9.78 points on the depression score of  patients with a history of  
depression and IVDU (95%C.I. 0.93 – 18.62, p=0.03) by preventing the development of  
depressive symptoms over time. Patients without both risk factors did not experience a 
C
h
ap
te
r 
3
Figure 2.|Estimated mean treatment effect of  escitalopram on depression score during antiviral therapy, accord-
ing to the presence of  determinants of  depression. 
Mean treatment effect with 95% C.I.
IVDU, intravenous drug use; C.I., confidence interval.
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positive treatment effect against development of  depressive symptoms; mean treatment 
effect of  escitalopram was 3.14 points (95%C.I. -3.21 – 9.48, p=0.33) (figure 2).
DisCUssioN
our study shows that chronic hepatitis C patients with a history of  depression and IVDU are 
most vulnerable for the development of  overt depression during treatment with PEGIFN and 
RBV. Furthermore, it shows that the development of  depressive symptoms in these patients 
can be prevented with prophylactic treatment with the SSRI escitalopram.
our study is important for clinical practice because it the first to identify patients at base-
line who are prone for IFN-induced depression irrespective of  prior IFN-treatment, and 
who are most likely to benefit from primary prevention with SSRI prophylaxis. Previously, 
several baseline covariates have been identified as risk factors for IFN-induced depression 
with elevation of  depression scores just prior to initiation of  AVT being the most consis-
tent one (14-15). In our study we found no correlation between mood, anxiety and depres-
sion scores at baseline and depression, probably because patients with depression at 
baseline were excluded from the study and our study focussed on new onset IFN-induced 
depression. other previously described risk factors for IFN-induced depression are depres-
sion with a previous IFN-based regimen for chronic HCV, younger age, lower social sup-
port, the personal trait “low self-directedness“ and reporting depressed feelings (10-11, 
14, 16-17). We aimed to identify patients at risk for IFN-induced depression irrespective 
of  prior treatment, as and not all patients received prior IFN-based AVT and depression 
is not always detected or documented. With respect to age, we could not demonstrate 
an association between age as continuous variable and the event depression in our study 
population. The other described parameters provide the possibility for identification of  
patients prone for depression at baseline. However, the identification of  these parameters 
sometimes demands more than a standard medical interview. Hence, it can be difficult to 
apply the identification of  these parameters in clinical practice. Genetic traits have also 
been investigated and even been identified as related to IFN-induced depression. These 
genetic predictors have not been confirmed in other studies yet, or have been confined to 
a very specific group of  patients (12, 18).
Regarding prevention, previous research on prophylactic antidepressant treatment of  the 
general HCV population has been inconsistent (5-6, 19-20). In high-dose IFN treatment for 
malignant melanoma, prophylactic treatment with paroxetine effectively prevented IFN-
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induced depression. In HCV patients, Morasco et al (6) did demonstrate a reduction in 
depression of  almost 50% with their double-blind placebo-controlled trial, but the study 
was underpowered to detect a clinically relevant significant difference. Hence, the authors 
concluded that prophylaxis was not beneficial. Diez-Quevedo et al (7) studied the effects 
of  14 weeks escitalopram vs. placebo on new onset depression in 129 HCV patients. Rates 
of  depression were remarkably low (5.4%) and did not differ between placebo (3.2%) and 
escitalopram (7.6%). The results are difficult to translate to clinical practice as patients 
with baseline mental disorders and/or recent or concomitant drug use were excluded. 
This selection of  patients might explain the low depression rate in the total group of  pa-
tients. Schafer et al (19) demonstrated the beneficial effect of  antidepressant prophylaxis 
in psychiatric HCV-infected patients on AVT, resulting in even lower rates of  depression 
in HCV patients with psychiatric disorders than a control group of  HCV patients without 
psychiatric risk factors. A recently conducted double-blind randomized placebo-controlled 
trial with escitalopram proved the efficacy of  prophylactic treatment with a significant de-
crease in the incidence of  depression in patients randomized to escitalopram (5). Taken 
these studies together, HCV-infected patients constitute a heterogenic group of  patients 
with varying degrees of  psychiatric co-morbidity and results of  such trials might be dif-
ficult to compare. In combination with the fact that about 70% of  HCV-infected patients 
will not suffer depression with IFN-based AVT, this asks for refinement of  the indication for 
prophylactic SSRI treatment. The results of  the current study suggest that it is possible to 
select these patients who benefit the most from SSRI prophylaxis.
An alternative strategy to prophylactic SSRI treatment is to detect and treat psychiatric 
symptoms as soon as they develop during AVT. Kraus et al (21) have demonstrated the high 
responsiveness of  IFN-induced depression for serotonergic antidepressant medication, when 
initiated after early detection with a psychometric instrument (21). Nevertheless, we would 
favour pre-emptive treatment of  patients at high risk for depression, rather than to wait for 
these symptoms to occur, especially since these symptoms may be underreported and are 
known to develop early in the course of  AVT. Furthermore, it may be difficult to implement the 
use of  psychological instruments in the routine clinic of  somatically oriented hepatologists 
and infectious disease specialists. Also, inherent to the disorder, depressed patients might 
not be compliant to all medical appointments including the psychometric assessments. We 
offer a practical strategy to prevent depressive symptoms in vulnerable patients with a mini-
mal risk of  excessive treatment. Although we could not demonstrate a difference in SVR with 
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SSRI prophylaxis in patients who would experience less depressive symptoms during AVT, 
Leutscher et al (3) have shown the presence of  depression to be associated with a poorer 
rate of  SVR. Therefore, prevention of  IFN-induced side effects would mean an important 
step forward in the treatment of  chronic hepatitis C. Further, our analysis is based on a ran-
domized-controlled trial. Both clinician and patient could be expected to be at least or even 
more motivated to avoid early drop-out. Therefore, it is unclear whether SSRI prophylaxis in 
patients prone for the development of  depression and depressive symptoms would positively 
affect drop-out rate in clinical practice and, as a consequence, increase rate of  SVR.
It should be noted that the size of  our study population was limited. Therefore, less strong 
associations between baseline characteristics and depression may have remained unde-
tected in our analysis. Nevertheless, the study population contained sufficient power to 
detect a strong association between history of  depression and IVDU with PEGIFN/RBV 
therapy in the placebo-dosed patients and the total group of  participants, when corrected 
for the use of  SSRI. A second remark that should be made is that, for the analysis of  
depressive symptoms over time, we used the results of  a single screening tool, i.e. the 
depression scale of  the SCL-90. Some studies use other or multiple screening tools to 
describe depressive symptoms. However, the SCL-90 is a validated and frequently used 
screening tool for psychiatric symptoms. We diagnosed the event depression according to 
DSM-IV criteria and investigated predictors for depression in relation to the actual event. 
The SCL-90 was therefore not used as a screening tool for depression, but as a measure 
of  degree of  depressive symptoms over time.
In conclusion, prophylactic treatment with escitalopram reduces depressive symptoms 
significantly in HCV-infected patients with a history of  both depression and IVDU during 
AVT and should therefore be considered in this subset of  patients. 
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ABstrACt
introduction Treatment of  hepatitis C with pegylated interferon-alpha (PEGIFN) frequently 
leads to psychopathology such as depression, anxiety and anger. Simultaneously PEGIFN 
induces disturbances in peripheral indicators of  brain metabolism, which led to the hy-
pothesis that these changes are correlated (as shown in some earlier studies) thus pro-
viding information on changes in brain functioning. This study aimed to explore these 
changes in psychopathology and peripheral parameters of  the brain metabolism and their 
relationship. 
methods 79 patients receiving PEGIFN and ribavirin were evaluated - at baseline, 4, 12 
and 24 weeks after starting treatment, and 24 weeks after stopping treatment - with dif-
ferent psychometric questionnaires during treatment with either escitalopram (a selective 
serotonin reuptake inhibitor) or placebo in an randomized controlled trial into the pro-
phylactic potential of  escitalopram. At the same time points in 76 patients plasma levels 
were measured of  serotonin (5-HT), its metabolite 5-hydroxyindolacetic acid (5-HIAA), 
its precursor tryptophan (TRP), several indicators of  and co-factors of  5-HT, noradrena-
line and dopamine synthesis (phenylalanine to tyrosine ratio (PHE/TYR-ratio), neopterin 
(NEoP), the ratio of  TRP and tyrosine to other large amino acids, possibly toxic metabo-
lites (kynurine (KYN)) and the ratio between citrulline (CITR) and arginine (ARG), an index 
of  overall No synthesis. 
results Decreases of  TRP, CITR/ARG-ratio and 5-HT, and increases in PHE/TYR-ratio, 
NEoP and KYN were found. Changes in TRP levels and in the ratio of  TRP to the other 
large neutral amino acids were not related to emerging psychopathology. Changes in PHE/
TYR-ratio and TYR/LNAA-ratio were correlated with changes in mood, which indicates an 
important role for not only 5-HT but also noradrenaline and dopamine in the development 
of  PEGIFN-induced psychopathology.
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Peginterferon-alpha induced changes in peripheral indicators of  monoaminergic 
neurotransmission and their correlation with psychopathology
iNtroDUCtioN
A chronic infection with hepatitis C virus (HCV) can progress to severe liver damage, 
eventually leading to the development of  end-stage liver cirrhosis and hepatocellular car-
cinoma. For this reason, a chronic hepatitis C-infection is the leading indication for liver 
transplantation in the U.S (1). The standard treatment consists of  pegylated interferon-
alpha (PEGIFN) and ribavirin (RBV) and successful treatment prevents the progression to 
liver cirrhosis. However, this treatment is associated with several, sometimes severe, side 
effects such as anemia, malaise and auto-immune phenomena, but also with psychopa-
thology such as depression, aggression, anxiety and reduced concentration (2-6). Even 
cases of  suicide attributed to treatment with PEGIFN are reported (7). SSRI’s (Selective 
Serotonin Reuptake Inhibitors) are found to be effective in the treatment of  PEGIFN-in-
duced psychopathology (8-10).
To investigate the efficacy of  the SSRI escitalopram in the prevention of  these psychiatric 
side effects, we performed a double-blind, placebo-controlled clinical trial. In the frame-
work of  this trial, we performed an extensive laboratory study into the underlying patho-
physiology of  PEGIFN-induced psychiatric side effects.
Changes in the cytokine network, the hypothalamic-pituitary-adrenal axis and brain mono-
aminergic system, including that of  serotonin (5-HT) are hypothesized to cause PEGIFN-
induced psychopathology (11). With regard to its influence on the central 5-HT-ergic sys-
tem, firstly, (PEG)IFN induces the enzyme indoleamine 2,3-dioxygenase (IDo) catabolising 
the amino acid tryptophan (TRP), the precursor of  5-HT (12). At the blood-brain barrier, 
TRP competes with the other large neutral amino acids (LNAA: tyrosine (TYR), phenylala-
nine (PHE), valine, leucine and isoleucine) for gaining entrance into the central nervous 
system. The ratio of  the concentration of  TRP to those of  the other LNAA (TRP/LNAA-
ratio) reflects the central availability of  TRP and is an index for the rate of  central 5-HT 
synthesis. Indeed, in several studies treatment with (PEG)IFN was found to lower both 
TRP concentrations and the TRP/LNAA-ratio and in some (but not all) of  these studies, 
relationships were observed between measures for depression and decrease in the TRP/
LNAA-ratio (13-14). Next to depression, aggression and irritability have been found to be 
related to decreased concentrations of  TRP (2).
With regard to the other mono-amines, tyrosine is the main precursor of  dopamine and 
noradrenaline and its availability to the brain is reflected by the TYR/LNAA-ratio which, as 
TRP and TRP/LNAA-ratio, has also been found to be lowered in depressed patients (15).
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Secondly, (PEG)IFN is hypothesized to influence the metabolism of  the pteridine tetrahy-
drobiopterin (BH4), an important cofactor in the biosynthesis of  5-HT (16), dopamine and 
noradrenaline: (PEG)IFN increases the concentration of  neopterin (NEoP), a metabolite 
of  one of  the precursors of  BH4, which might cause lower levels of  BH4 resulting in a 
decrease in 5-HT synthesis. This may add to the reported reduction of  BH4 levels by RBV 
(17). BH4 is also a cofactor for the enzyme (phenylalanine-hydroxylase) which hydroxyl-
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Figure 1|Hypothesis on effects of  administration of  interferon-alpha (IFN) on pathways in the brain. IFN stimulates 
a) the enzyme indoleamine-2,3-dioxygenase (IDo) that converts tryptophan into kynurenine, b) the enzyme kynuren-
ine hydroxylase (KYN oH-ase) that hydroxylates kynurenine to the neurotoxic 3-hydroxykynurenine, c) the enzyme 
guanosine-triphosphate-cyclohydrolase-1 (GTP-CH1) that stimulates the formation of  7,8-dihydroneopterin triphos-
phate (NH2PPP) from GTP. In conditions of  immune activation, the synthesis and release of  neopterin by activated 
macrophages/microglia is initiated at the expense of  tetrahydrobiopterin (BH4). BH4 is an important co-factor of  
phenylalanine-hydroxylase (PHA) that hydroxylates phenylalanine to tyrosine, the precursor of  the bioactive dopamine 
and noradrenaline. BH4 is also co-factor of  tryptophan-hydroxylase (TPH) which converts tryptophan to 5-hydroxy-
tryptophan, the precursor of  the bioactive serotonin. Shortage of  BH4 will change levels op dopamine, noradrenaline 
and serotonin.
(Reprinted and adapted from ‘Chronic low-grade inflammation in elderly persons is associated with altered trypto-
phan and tyrosine metabolism: role in neuropsychiatric symptoms; Capuron L, Schroecksnadel S, Féart C, Aubert 
A, Higueret D, Barberger-Gateau P, Layé S, Fuchs D; Biol Psychiatry. 2011 Jul 15;70(2):175-82 with permission from 
Elsevier).
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ates PHE to TYR and the ratio of  PHE to TYR (PHE/TYR-ratio) has been regarded as a 
measure of  BH4 activity (18-19) with an increased PHE/TYR-ratio suggesting reduced 
BH4 synthesis and resulting impaired synthesis of  5-HT, noradrenaline and dopamine. 
Thirdly, the induction of  IDo by (PEG)IFN increases the conversion of  TRP to kynurenine 
(KYN) of  which several metabolites are thought to have neurotoxic properties and thus 
may contribute to the development of  depression (20-21). See figure 1.
Finally, possibly also by interfering with BH4 synthesis, PEGIFN influences the synthesis of  
Nitric oxide (No), the latter also modulating 5-HT-ergic function. The ratio between citrul-
line (CITR) and arginine (ARG) (CITR/ARG-ratio) is thought to reflect No synthesis (22).
The aim of  our study was to explore the influence of  treatment with PEGIFN and RBV on 
these peripheral indices for central monoaminergic (5-HT, dopamine and noradrenaline) 
function, for No-ergic function and for neurotoxic influences, and their correlation with 
psychological parameters.
mAteriAL & metHoDs
Patients and treatment
80 patients, with a chronic hepatitis C-infection with genotype 1, 2, 3 or 4, participated 
in a double-blind randomized controlled trial comparing escitalopram versus placebo 
in the prevention of  psychiatric symptoms during therapy with PEGIFNα-2a and RBV 
(23). During the (first) 26 weeks of  treatment with PEGIFN and RBV patients received 
escitalopram or placebo. 
Psychiatric evaluation 
At baseline, week 4, 12, 24 and 24 weeks after stopping antiviral treatment (follow-up 
(FU)) symptoms of  sadness, inner tension, impaired concentration and irritability were 
assessed by a trained physician using the Montgomery-Asberg Depression Rating Scale 
(MADRS) (24) and Brief  Anxiety Scale (BAS) (25). The presence of  a major depressive 
episode was assessed with the relevant module of  the Mini-International Neuropsy-
chiatric Interview (M.I.N.I.). The M.I.N.I. is a short structured diagnostic interview for 
DSM-IV TR and ICD-10 psychiatric disorders and was designed to perform a short but 
accurate structured psychiatric interview (26). At the same time patients completed 
the Beck Depression Inventory (BDI) (27) and the Symptom Check List-90 (SCL-90) as 
self-report questionnaires (28). 
In case of  a major psychopathology the study code was broken and, if  indicated, open-label 
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psychopharmacological treatment was prescribed by a psychiatrist. This study was approved 
by the local Medical Ethics Committee and all patients gave written informed consent.
For further details of  this study we refer to the publication by de Knegt et al. (23). 
Biochemical analysis
At the same time points 5-HT, TRP, 5-HIAA (5-hydroxyindolacetic acid, the metabolite of  
5-HT), LNAA, PHE, TYR, isoleucine, leucine and valine, CITR, ARG, NEoP and KYN were 
measured in plasma. EDTA blood was obtained by venipuncture. Almost all samples were 
taken in the morning, and patients were instructed to have a low-fat meal that morning. 
After immediate centrifugation (20 min at 2650 gmax) plasma was separated and frozen 
at -80°C. 5-HT and 5-HIAA were measured as described before (29). The amino acids PHE, 
TYR, TRP, CITR, ARG, isoleucine, leucine and valine were measured by means of  high-
performance liquid chromatography (30). The TRP/LNAA-ratio and TYR/LNAA-ratio were 
calculated as 100 times the concentration of  respectively TRP and TYR divided by the 
summed concentrations of  the other large neutral amino acids. NEoP was measured after 
acid oxidation as described earlier (19, 31). Concentrations of  KYN were also determined 
by using reversed phase high performance liquid chromatography as described before (32).
Statistical analysis
All patients were included in the analysis when they still used PEGIFN, irrespective of  use 
of  (blinded) escitalopram, placebo or open-label antidepressants or other psychoactive 
medication, in the biochemical analysis. In case the PEGIFN was discontinued due to 
non-response to treatment or a serious adverse advent, data were censored from that time 
point for further analysis. 
To explore the difference between the escitalopram and placebo group regarding the dif-
ferent biochemical and psychometric variables, only these patients were included in the 
analysis if  they still used the blinded study medication. only patients treated with (blind-
ed) placebo were used to determine the correlation between the different biochemical 
variables and the observed psychopathology.
Data were stored and analysed using SPSS software, version 17.0 and SAS 9.2. outcomes 
of  the biochemical analysis at 4, 12, 24 and FU were compared to those at baseline ap-
plying a repeated measurements model and log transformation in case of  non-normal 
distribution. Mean values at baseline and at FU were compared with reference values 
of  healthy subjects (extracted from the database of  the Laboratory of  Psychiatry) using 
one-sample t-test. A bivariate model was used (with the variable t categorical and not-
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significant) to estimate the correlation between changes in laboratory parameters and 
changes in psychiatric ratings. All reported P values are two-sided and a significance level 
of  α ≤ 0.05 was used.
resULts
Patients
79 patients started treatment with PEGIFN and RBV. Characteristics at baseline are 
summarized in Table 1. In the escitalopram group, more females participated and less 
substance-induced depressive episodes were reported; otherwise baseline characteristics 
were comparable. As diagnosed with the M.I.N.I., 24 (30%) patients had a history of  one 
or more depressive episodes.
Psychiatric evaluation 
We observed significantly less psychiatric side effects for those treated with escitalopram 
as compared to placebo for all primary and secondary outcome measures, except for im-
paired concentration. Regarding the other psychometric measurements, patients treated 
with escitalopram scored significantly lower than placebo on sum scores and all subscales 
of  the BDI and SCL-90 at all different evaluation points, except for SCL-90 somatic com-
plaints at week 4 and 12 (Table 2). Changes in the different psychometric measurements 
and its differences between treatment with escitalopram and placebo were already ob-
served from week 4 and persisted until week 24.
Biochemical analysis
one center did not participate in the biochemical analysis so 76 blood samples were 
obtained at baseline. At that time point no differences between patients treated with esci-
talopram or placebo were seen in the different laboratory parameters.
At baseline, mean values of  our patients differed from mean values of  the healthy subjects 
subjects (all p< 0.01) respectively 5-HIAA (33.76 ± 1.6 vs. 42 ± 11 nmol/l), TRP (43.71 ± 
0.9 vs  46 ± 6.1), TYR/LNAA-ratio (14.47 ± 0.4.vs. 11.4 ± 2.17), PHE/TYR-ratio (0.82 ± 
0.02 vs. 0.94 ± 0.15), NEoP (28.41 ± 1.5 vs. 16.7 ± 3.6) and 5-HT (28.47 ± 3.0 vs. 9.2 ± 
5.5). The other parameters did not differ.
During antiviral treatment, at every time points and in both groups, a decrease of  the con-
centration of  TRP was observed, together with a direct and persistent increase in NEoP, 
KYN/TRP-ratio and PHE/TYR-ratio and decrease in CITR/ARG-ratio (additional table and 
Figure 2).
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table 1|Baseline characteristics of  patients
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table 2|Mean scores with standard deviation of  the different rating scales (Montgomery –Asberg Depression Rating 
Scale (MADRS), Brief  Anxiety Scale (BAS), Beck Depression Inventory (BDI) and the Symptom Check List-90 (SCL-
90)) in the escitalopram and placebo group.  * = significant differences (p < 0.05) between escitalopram and placebo 
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Figure 2|Mean values and standard error of  the different biochemical parameters at baseline, week 4 and week 
12, week 24 and at follow up (FU) with values of  escitalopram and placebo users.
a) 5HT = serotonin, b) 5-HIAA = 5-hydroxyindolacetic acid, c) TRP = tryptophan, d) TRP/LNAA-ratio = tryptophan 
to large neutrophil amino acids ratio, e) TYR/LNAA-ratio = tyrosine to large neutrophil amino acids ratio, f) PHE/
TYR-ratio = Phenanyl-Tyrosine ratio, g) neopterin, h) kynurenin, i) KYN/TRP-ratio = kynurenine to tryptphan ratio, 
j) CITR/ARG-ratio = Citruline-Arginine ratio 
 # = Significant difference (P < 0.05) compared to baseline, * = significant difference (p<0.05) between escitalo-
pram en placebo (with correction for non-normal distribution and multiple measurements)
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KYN levels increased significantly at week 4 (mean = 2.52 µmol/l), week 12 (mean = 2.70 
µmol/l) and week 24 (mean =2.61 µmol/l) compared to baseline (mean = 2.31 µmol/l) 
in the whole group, while 5-HT plasma levels decrease after the introduction of  PEGIFN.
The pattern of  PEFIFN-induced biochemical alterations is roughly similar when the escita-
lopram and placebo groups are analyzed separately (additional Table 3 and Figure 2) with 
the exception of  the 5-HT levels in plasma showing a more profound decrease in the esci-
talopram group. When analyzing the biochemical data for a possible difference between 
the escitalopram and placebo groups, 5-HT levels differ at week 4,12 and 24 (p< 0.03) as 
different levels of  CITR/ARG-ratio do at week 12 (p= 0.01).
24 weeks after cessation of  antiviral therapy (FU) all different parameters have returned 
to their baseline levels except for 5-HIAA (increase from mean 33.76 nmol/l to 42.10 
nmol/l), CITR/ARG-ratio (increase from mean 0.53 to 0.63) and TYR/LNAA-ratio (de-
crease from mean 14.47 to 13.23). 
Mean values at FU of  TRP, TYR/LNAA-ratio, PHE/TYR-ratio, NEoP and 5-HT still differed 
from mean values in the reference population (all p<0.01). CITR/ARG was higher at FU 
compared to the reference population (mean = 0.54, p= 0.01).
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Correlation between biochemical variables and the observed psychopathology.
Changes compared to baseline in TYR/LNAA-ratio correlated negatively with changes 
compared to baseline of  the BDI sum score (ρ = -0, 41). Changes compared to baseline 
of  the PHE/TYR-ratio correlated with the different self-rating scores of  the BDI sum score 
(ρ = 0,44) and SCL sum scores (ρ = 0,46) and different subscales of  the SCL-90 (anxiety : 
ρ = 0,35 – hostility : ρ = 0,30 – depression : ρ = 0,47 – insufficiency : ρ = 0,35) and MADRS 
sum score (ρ = 0,46) 
DisCUssioN
In this study we evaluated changes in peripheral biochemical parameters induced by the 
introduction of  PEGIFN in patients with hepatitis C and correlated these with observed 
psychiatric disturbances in order to understand the pathophysiology underlying PEGIFN-
induced psychiatric disturbance.
Firstly, interestingly almost all baseline values of  our patients were different from those 
obtained from healthy subjects. Two earlier studies also reported reduced baseline levels 
of  TRP in hepatitis C patients (33-34). Possible explanations of  this phenomenon are the 
presence of  changed IDo activity in macrophages of  patients with HCV due to the chronic 
infection and neuroinvasion of  the virus (35). However, also comparable changes were 
seen in cancer patients: additional analysis of  a database of  cancer patients treated with 
IFN showed also lower TRP, higher TYR/LNAA-ratio, higher PHE/TYR-ratio, higher NEoP 
levels, higher 5-HIAA levels and higher KYN levels at baseline. So changes in the monoami-
nergic system seem not only be induced by a chronic infection like HCV but also by ma-
lignancies. These changes may play a role in the complaints cocnceptualized as sickness 
behaviour, such as fatigue and concentration difficulties observed in these patients (36).
Secondly, and mostly in accordance with existing literature, we observed consistent 
changes in peripheral levels of  several biochemical parameters: a decrease of  the precur-
sor of  5-HT, TRP (13-14, 16, 37-39), increase in the PHE/TYR-ratio (16, 37-38) and NEoP 
(16, 37-39) (index for co-factor function in mono-amine synthesis) and an increase of  KYN 
(possibly giving rise to neurotoxic metabolites) and in KYN/LNAA-ratio (13, 38-40). Fi-
nally, we observed a decrease in the CITR/ARG-ratio (22), which may reflect impaired No-
synthesis, which may in turn influence 5-HT synthesis. However, in contrast with earlier 
studies (13), we did not observe changes in TRP/LNAA-ratio (14, 16, 37-38) (the marker 
C
h
ap
te
r 
4
1204304 Proefschrift Erasmus Universiteit.indd   82 06-06-12   07:48
83
Peginterferon-alpha induced changes in peripheral indicators of  monoaminergic 
neurotransmission and their correlation with psychopathology
for the availability of  TRP in the brain). Also in contrast with literature, rather consistent 
changes in TYR/LNAA-ratios were measured (14, 16, 37). In oncology patients treated 
with IFN (37-38) a decrease in 5-HIAA was seen, in contrast to our study. Summarized, 
one can hypothesize that the observed biochemical changes in the peripheral blood influ-
ence brain function more or less directly or may be seen as an index of  processes in the 
brain.
Thirdly, not unexpected, only minor differences between patients treated with escitalo-
pram and placebo in the different peripheral parameters were seen. As the prophylactic 
use of  escitalopram had a protective effect on the development of  psychiatric disturbanc-
es, this strongly suggests that if  brain 5-HT-ergic neurotransmission is indeed affected 
by cytokine treatment and if  the emerging psychopathology is mediated by decrease in 
5-HT synthesis via the mechanisms investigated in this study, escitalopram has its effect 
downstream in the cascade of  the brain/5HT-ergic neurotransmission in the prevention/
treatment of  symptoms like depression, anger, anxiety and impaired concentration.
Fourthly, our data only suggest a correlation between the development of  psychopathol-
ogy and change in PHE/TYR-ratio and changes in the TYR/LNAA-ratio. This is in contrast 
to previous studies showing a correlation between levels of  peripheral 5-HT, TRP and KYN 
and the development of  psychiatric complaints in HCV patients as well in cancer patients 
(13-14, 39). However other studies could not establish a consistent relation in any of  
these parameters (38, 40). As mentioned before, the increased PHE/TYR-ratio possibly re-
flects a decreased BH4 activity, a co-factor in the biosynthesis of  5HT, noradrenaline and 
dopamine. Also changes in the TYR/LNAA-ratio may cause changes in levels of  dopamine 
as TYR, the precursor of  dopamine and the TYR/LNAA-ratio reflect the dopamine avail-
ability in the brain. Earlier studies showed increased levels of  PHE/TYR-ratio in patients 
with chronic inflammation, for instance HIV (41-42) and in a recent study of  Capuron et 
al.(43) correlation between neuropsychiatric symptoms and increased PHE/TYR-ratio lev-
els was observed in elderly patients. 
A strong point of  our study is the broad evaluation of  not only precursors of  5-HT but also 
of  indicators of  the biosynthesis of  5-HT, dopamine and noradrenaline and formation of  
toxic metabolites in a relatively large study population. The most prominent limitation of  
our study is the reliance on peripheral indicators of  the brain metabolism, possibly bear-
ing a more remote relationship with central processes than hypothesized.
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Resuming, in the main study, PEGIFN induced different psychopathological symptoms 
which could partly be prevented by prophylactic use of  escitalopram. PEGIFN induced 
changes in several biochemical parameters, which are thought to reflect the metabolism 
of  monoaminergic neurotransmitters in the brain. However, only some of  these changes 
were correlated with changes in mood, notably changes in PHE/TYR-ratio and TYR/LNAA-
ratio, reflecting not only changes in 5-HT metabolism but also in that of  noradrenaline 
and dopamine. Indicators of  tryptophan metabolism did not appear to be of  significance.
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Additional table|mean values and standard error of  the different biochemical parameters at baseline, week 4 and 
week 12, week 24 and at follow up (FU) with values of  escitalopram and placebo users. 5HT = serotonin, 5-HIAA = 
5-hydroxyindolacetic acid, TRP = tryptophan, TRP/LNAA- ratio = tryptophan to large neutrophil amino acids ratio, 
TYR/LNAA-ratio = tyrosine to large neutrophil amino acids ratio, PHE/TYR-ratio = Phenanyl-Tyrosine ratio, NEoP = 
neopterine, KYN = kynurenine, KYN/TRP-ratio = kynurenine to tryptophan ratio, CITR/ARG-ratio = Citruline-Arginine 
ratio, 
* = Significant difference (P < 0.05) compared to baseline, # = significant difference (p<0.05) between escitalopram 
en placebo (with correction for non-normal distribution and multiple measurements)
Week total escitalopram Placebo
 5Ht (nmol/l) 0 28.47 ± 3.0 (n=71) 24.09 ± 3.2 (n=37) 33.22 ± 5.1 (n=34)
4 17.00* ± 6.2 (n=59) 9.42*# ± 2.4 (n=28) 23.86*# ± 11.6 (n=31)
12 10.46* ± 1.7 (n=57) 6.56*# ± 1.6 (n=22) 14.54*# ± 3.0 (n=27)
24 10.06* ± 1.5 (n=45) 6.59*# ± 1.6 (n=19) 12.84*# ± 2.6 (n=21)
FU 33.26 ± 5.6 (n=45) 24.84 ± 5.5 (n=20) 39.76 ± 9.0 (n=25)
5-HiAA (nmol/l) 0 33.76 ± 1.6 (n=75) 36.58 ± 2.7 (n=38) 30.87± 1.6 (n=37)
4 40.20 ± 4.4 (n=73) 37.14 ± 5.8 (n=36) 43.18 ± 6.9 (n=37)
12 37.98 ± 5.6 (n=66) 34.09 ± 4.0 (n=32) 32.95 ± 3.3 (n=28)
24 37.30 ± 4.8 (n=65) 44.49 ± 10.1 (n=29) 32.17 ± 3.4 (n=28)
FU 42.10* ± 4.2 (n=62) 35.11 ± 2.7 (n=28) 47.85* ± 7.2 (n=34)
trP (µmol/l) 0 43.71 ± 0.9 (n=76) 42.23 ± 1.4 (n=38) 45.20 ± 1.4 (n=38)
4 39.57*± 0.9 (n=74) 37.80*± 1.3 (n=37) 41.21*± 1.3 (n=37)
12 38.44* ± 1.0 (n=70) 37.73* ± 1.3 (n=32) 38.57* ± 1.3 (n=32)
24 37.06*± 1.0 (n=67) 36.47*± 1.4 (n=29) 38.26*± 1.4 (n=29)
FU 43.40 ± 1.0 (n=60) 43.39 ± 1.4 (n=26) 42.56 ± 1.2 (n=34)
trP/LNAA-ratio 0 7.84 ± 0.4 (n=76) 7.99 ± 0.3 (n=38) 7.68 ± 0.2 (n=38)
4 7.92 ± 0.2 (n=74) 7.88 ± 0.3 (n=37) 7.95 ± 0.2 (n=37)
12 7.67 ± 0.2 (n=70) 7.51 ± 0.2 (n=32) 7.56 ± 0.3 (n=32)
24 7.98 ± 0.2 (n=67) 8.00 ± 0.3 (n=29) 7.83 ± 0.3 (n=29)
FU 8.05 ± 0.2 (n=60) 8.24 ± 0.3 (n=26) 7.90 ± 0.2 (n=34)
tYr/LNAA-ratio 0 14.47 ± 0.4 (n=76) 15.03 ± 0.6 (n=38) 13.92 ± 0.5 (n=38)
4 15.69* ± 0.4 (n=74) 15.97* ± 0.7 (n=37) 15.40* ± 0.5 (n=37)
12 15.44* ± 0.4 (n=70) 16.09 ± 0.8 (n=32) 14.56* ± 0.4 (n=32)
24 14.92* ± 0.4 (n=67) 14.91 ± 0.7 (n=29) 14.81* ± 0.5 (n=29)
FU 13.23* ± 0.3 (n=60) 13.64* ± 0.6 (n=26) 12.92 ± 0.4 (n=34)
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PHe/tYr-ratio 0 0.82 ± 0.02 (n=76) 0.84 ± 0.03 (n=38) 0.80 ± 0.03 (n=38)
4 0.95* ± 0.02 (n=74) 0.99* ± 0.03 (n=37) 0.92* ± 0.02 (n=37)
12 0.93* ± 0.02 (n=70) 0.93* ± 0.03 (n=32) 0.93* ± 0.02 (n=32)
24 0.97* ± 0.02 (n=67) 0.99* ± 0.04 (n=29) 0.96* ± 0.03 (n=29)
FU 0.87* ± 0.2 (n=60) 0.86 ± 0.03 (n=26) 0.88* ± 0.02 (n=34)
 NeoP (nmol/l) 0 28.41 ± 1.5 (n=76) 30.03 ± 2.5 (n=37) 27.14 ± 1.6 (n=38)
4 57.78* ± 1.6 (n= 74) 58.44* ± 2.6 (n=37) 56.22* ± 2.0 (n= 37)
12 60.27* ± 1.6 (n=74) 60.06* ± 2.7 (n=34) 60.77* ± 2.1 (n=33)
24 62.21* ± 2.3 (n=67) 64.78* ± 4.3 (n=29) 59.15* ± 2.9 (n=29)
FU 23.27 ± 1.0 (n=60) 24.19 ± 1.8 (n=26) 22.56 ± 1.0 (n=34)
KYN (µmol/l) 0 2.31 ± 0.09 (n=76) 2.28 ± 0.1 (n=37) 2.35 ± 0.1 (n=38)
4 2.52* ± 0.09 (n=74) 2.40 ± 0.1 (n=37) 2.64* ± 0.1 (n=37)
12 2.70* ± 0.09 (n=70) 2.67* ± 0.1 (n=32) 2.73* ± 0.1 (n=32)
24 2.61* ± 0.09 (n=67) 2.68* ± 0.1 (n=24) 2.54 ± 0.1 (n=24)
FU 2.22 ± 0.08 (n=60) 2.33 ± 0.1 (n=26) 2.17 ± 0.1 (n=34)
KYN/trP-ratio 0 39,86 ± 1.5 (n=76) 39,61 ± 2.3 (n=38) 40.53 ± 1.9 (n=38)
4 49.03* ± 1.5 (n=74) 48.16* ± 2.5 (n=37) 49.73* ± 1.8 (n=37)
12 54.23* ± 2.0 (n=70) 53.28* ± 2.6 (n=32) 56.47* ± 3.4 (n=32)
24 54.69* ± 1.6 (n=67) 56.93* ± 2.8 (n=29) 52.83* ± 2.6 (n=29)
FU 39.13 ± 1.2 (n=60) 40.15 ± 1.8 (n=26) 38.35 ± 1.7 (n=34)
Citr/ArG-ratio 0 0.53 ± 0.03 (n =76) 0.56 ± 0.05 (n=38) 0.52 ± 0.03 (n =38)
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ABstrACt
introduction Treatment of  hepatitis C with peginterferon induces psychiatric side effects. 
This might include changes in serotonergic function.
methods Twenty-two hepatitis C patients were treated with peginterferon. At different 
time-points, psychometric assessment was performed using the Profile of  Mood States 
(PoMS). Plasma samples were taken to study serotonergic parameters.
results Anger and depression increased compared to baseline, starting with anger (>week 
3), followed by depression (>week 7). other scores did not show consistent changes. No 
consistent changes were observed in tryptophan, tryptophan/large neutral amino acids-ra-
tio, biopterin and 5-hydroxyindoleacetic acid. The tyrosine/large neutral amino acids-ratio, 
neopterin, phenylalanine/tyrosine-ratio, and prolactin concentrations increased compared 
to baseline. Prolactin levels were associated with the occurrence of  depression and anger. 
Discussion Particularly anger and depression increased during treatment. Neither a de-
crease in tryptophan and tryptophan availability was seen, nor a relationship between these 
parameters and the development of  psychopathology. Therefore, other mechanisms in the 
induction of  psychopathology should be considered. The observed increases in neopterin 
and phenylalanine/tyrosine-ratio are indicative for changes in tetrahydrobiopterin, which is 
involved in the metabolism of  serotonin, noradrenaline and dopamine, and possibly mediat-
ing the increase in prolactin. The increase in prolactin levels and its relationship with depres-
sion and anger needs further exploration.
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Psychiatric side effects and fluctuations in serotonergic 
parameters in the treatment of  chronic hepatitis C infection
iNtroDUCtioN
About 170 million people are chronically infected with hepatitis C virus (HCV), of  whom 
about 20 percent develop end stage liver disease (1). As a result, hepatitis C is now the 
leading indication for liver transplantation in developed nations. Successful treatment 
with a combination of  (peg)interferon-alpha ((PEG)IFN) and ribavirin (RBV) leads to a per-
manent eradication of  the virus which prevents progression to end stage liver disease and 
reduces mortality caused by HCV (2-3). Besides somatic side effects such as headache, 
thyroid dysfunction and anemia, this treatment is associated with sometimes severe psy-
chiatric side effects. These psychiatric side effects comprise a wide variety of  symptoms 
and syndromes: depression, aggression, anxiety and cognitive symptoms such as reduced 
concentration and memory (4). The exact pathophysiology of  these side effects is still 
unknown but is thought to be mediated by IFN-induced changes in the cytokine network, 
the hypothalamic-pituitary-adrenal axis, the hypothalamic-pituitary-thyroid axis and in the 
brain serotonin (5-HT) function (5). 
With regard to its influence on the central 5-HT-ergic system, firstly, (PEG)IFN induces 
the enzyme indoleamine 2,3-dioxygenase (IDo) catabolising the amino acid tryptophan 
(TRP), the precursor of  5-HT. At the blood-brain barrier, TRP competes with the other 
large neutral amino acids (LNAA: tyrosine, phenylalanine, valine, leucine and isoleucine) 
for gaining entrance into the central nervous system (CNS). The ratio of  the concentra-
tion of  TRP to those of  the other LNAA (TRP/LNAA-ratio) reflects the central availability 
of  TRP and is an index for the rate of  central 5-HT synthesis. Indeed, in several studies 
treatment with (PEG)IFN was found to lower both TRP concentrations and the TRP/LNAA-
ratio and in some of  these studies, relationships were observed between measures for 
depression and decrease in the TRP/LNAA-ratio (6-8). Next to depression, aggression and 
irritability have been found to be related to decreased concentrations of  TRP (9).
Secondly, (PEG)IFN is hypothesized to influence the metabolism of  the pteridine tetra-
hydrobiopterin (BH4), an important co-factor in the biosynthesis of  5-HT (8). (PEG)IFN 
increases the concentration of  neopterin, a metabolite of  one of  the precursors of  BH4, 
which might cause lower levels of  BH4 resulting in a decrease in 5-HT synthesis. This may 
add to the recently reported reduction of  BH4 levels by RBV (10). BH4 is also a cofactor 
for the enzyme which hydroxylates phenylalanine (PHE) to tyrosine (TYR) and the ratio of  
PHE to TYR (PHE/TYR-ratio) has been regarded as a measure of  BH4 activity (11-12). An 
increased PHE/TYR ratio suggests reduced BH4 synthesis. In addition, BH4 is involved in 
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the biosynthesis of  noradrenaline (precursor: PHE) and dopamine (precursor: TYR).
Thirdly, the induction of  IDo by (PEG)IFN increases the conversion of  TRP to kynurenine 
of  which several metabolites are thought to have neurotoxic effects and thus may contrib-
ute to the development of  depression (13-14).
In this study of  HCV-infected patients treated with PEGIFN, the course of  several pe-
ripheral indicators for CNS 5-HT-ergic function were explored as well as the correlation 
between these 5-HT-ergic indices and psychological parameters, most notably depres-
sion and aggression. We hypothesized that TRP/LNAA, 5-HIAA and prolactin (PRL) 
levels would decrease during PEGIFN treatment. As far as we know this study is the 
first one that provides insight into the very early changes in different changes in the 
5-HT-ergic system with assessments already in the first days and weeks after the intro-
duction of  PEGIFN.
mAteriAL AND metHoDs
Dutch patients, participating in the international DITTo-Study (15), received antiviral 
treatment with a standard dose of  peginterferon-alfa 2a (Pegasys, Hoffmann-LaRoche, 
Basel, Switzerland) 180 microgram once weekly and 1000-1200 mg RBV daily (Copegus, 
Hoffmann-LaRoche) during the first six weeks of  treatment. Thereafter all patients con-
tinued their treatment with PEGIFN, some with RBV some without RBV and some with 
additional histamine, according to their virological response and randomization accord-
ing to the study protocol. At day 0, 1, 4, 7 and 8 and at week 2, 3, 4, 6, 7, 8, 10 and 12, 
plasma samples were obtained for biochemical analysis. At the same time points patients 
completed the (Dutch shortened version of  the) Profile of  Mood States (PoMS), a self-
rating questionnaire assessing five domains of  psychic functioning: depression-dejection 
(range: 0-32), anger-hostility (range: 0-28), fatigue-inertia (range: 0-24), tension-anxiety 
(range: 0-24) and vigor-activity (range: 0-20). These domains cover the most frequently 
occurring psychiatric side effects of  IFN-based treatment. The PoMS has been extensively 
used and is particularly suitable for frequently repeated assessments of  psychological 
functioning. With the exception of  vigor, higher scores indicate more complaints. Data on 
patient characteristics (mode of  transmission and concomitant psycho-active medica-
tion) and disease-related characteristics (genotype, HCV-RNA) were also collected. Use of  
benzodiazepines was permitted whereas use of  antidepressants and antipsychotic drugs 
was a reason for exclusion. Laboratory and psychometric data from patients after the time 
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point when prohibited medication was prescribed were excluded from the analysis, as 
were data after cessation of  PEGIFN. This study was approved by the local Medical Ethics 
Committee and all patients have given written informed consent.
Biochemical analysis
TRP and the TRP/LNAA-ratio were assessed, as indices for the availability of  TRP to the 
CNS. The BH4 activity was estimated by the determination of  the PHE/TYR-ratio. In addi-
tion, the levels of  the pteridins neopterin and biopterin were measured. The ratio of  tyrosine 
to the LNAA (TYR/LNAA-ratio) was used as an index for central dopamine synthesis. Lastly, 
peripheral 5-hydroxyindoleacetic acid (5-HIAA) and PRL were assessed. 5-HIAA is the main 
metabolite of  5-HT and reflects total 5-HT turnover. As the secretion of  PRL is at least par-
tially controlled by 5-HT, PRL levels were considered indicative of  the central activity of  5-HT.
EDTA blood was obtained by venipuncture. Samples were not taken under fasting condi-
tions. However, almost all samples were taken early in the morning. After immediate cen-
trifugation (20 min at 2650 gmax) plasma was separated and frozen at -80°C. The amino 
acids PHE, TYR, TRP, isoleucine, leucine and valine were measured with high-performance 
liquid chromatography (16). The TRP/LNAA-ratio was calculated as 100 times the con-
centration of  TRP divided by the sum of  concentrations of  the other large neutral amino 
acids. The TYR/LNAA-ratio was calculated in the same manner, substituting TYR for TRP. 
The pteridines were measured after acid oxidation as described earlier (12, 17). The con-
centrations of  5-HIAA were measured twice by high performance liquid chromatography 
(electrochemical detection with limit in plasma: 1 nmol/L) (18). The mean recovery (± SD) 
of  5-HIAA added to plasma was 72±8%. PRL levels were measured in serum by Immuno-
lite 2000 using two-site chemiluminescent immunometric assay.
Statistical analysis
Scores of  the different items of  the PoMS and the concentrations of  the biochemical 
parameters at the different time points were compared with their respective baseline val-
ues with repeated measurements analysis using a linear mixed regression with random 
intercept and slope over time. In addition, scores of  the different items of  the PoMS were 
compared to baseline with the Mann-Whitney-U-test. Data on TRP at baseline were com-
pared to healthy controls from our neuropsychiatric laboratory (corrected for gender and 
age), using the t-test. Associations between (changes in) psychometric parameters and 
(changes in) biochemical parameters were tested with linear mixed analysis using SAS 
9.2. Scores on the items anger and depression were divided in two groups: patients who 
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table 1|Scores on the subscales of  the Profile of  Mood States (PoMS) at baseline and during therapy with PEGIFN
t
im
e
d
0
d
1
d
4
d
7
d
8
W
2
W
3
W
4
W
6
W
7
W
8
W
1
0
w
1
2
D
ep
re
ss
io
n
N
1
8
2
0
2
0
1
7
2
0
1
9
1
8
1
8
1
6
1
4
1
3
8
9
M
ed
ia
n
3
.0
3
.0
4
.0
5
.5
4
.0
7
.0
4
.0
8
.0
2
.5
9
.0
*
6
.5
*
5
.0
*
4
.0
*
R
an
ge
2
8
2
6
2
5
2
7
2
4
2
8
2
7
2
4
3
0
2
9
2
8
3
0
2
8
A
ng
er
N
1
8
2
0
1
9
1
7
2
0
1
9
1
8
1
8
1
6
1
4
1
3
8
9
M
ed
ia
n
2
.5
3
.5
4
.0
8
.0
6
.0
9
.0
7
.5
*
8
.0
*
6
.5
*
1
1
.5
*
9
.0
*
1
4
.0
1
3
.0
R
an
ge
2
7
2
5
2
8
2
4
2
3
2
5
2
8
2
2
2
8
2
4
2
6
2
5
2
4
Fa
ti
gu
e
N
1
6
1
9
1
8
1
5
1
8
1
8
1
7
1
7
1
5
1
4
1
3
8
9
M
ed
ia
n
1
.5
1
1
.0
1
0
.5
1
2
.0
7
.5
1
3
.0
8
.0
1
3
.0
*
1
0
.0
*
1
2
.5
*
1
1
.0
6
.5
*
7
.0
R
an
ge
2
3
2
4
2
4
2
2
2
4
2
3
2
4
2
2
2
4
2
4
2
3
2
3
2
3
te
ns
io
n
N
1
8
2
0
2
0
1
7
2
0
1
9
1
8
1
8
1
6
1
4
1
3
8
9
M
ed
ia
n
5
.0
5
.5
6
.0
1
0
.0
6
.0
7
.0
3
.0
6
.5
2
.5
6
.5
3
.0
3
.5
5
.0
R
an
ge
1
7
1
9
1
8
1
8
1
9
1
9
2
2
1
8
2
3
1
9
1
8
1
9
1
8
V
ig
or
N
1
8
2
0
2
0
1
7
1
9
1
9
1
8
1
8
1
6
1
4
1
3
8
9
M
ed
ia
n
7
.0
6
.0
6
.5
6
.0
6
.0
5
.0
*
7
.0
6
.5
5
.5
5
.5
*
5
.0
6
.5
6
.0
R
an
ge
1
9
1
9
1
9
1
0
1
8
1
9
1
8
1
9
1
9
1
9
1
9
1
9
1
8
* 
S
ig
n
if
ic
an
t 
d
if
fe
re
n
ce
 (
p
 <
0
.0
5
) 
co
m
p
ar
ed
 t
o 
b
as
el
in
e 
(M
an
n
-W
h
it
n
ey
 t
es
t)
1204304 Proefschrift Erasmus Universiteit.indd   96 06-06-12   07:48
Hoofdstuk Naam 97
t
im
e 
p
oi
nt
 o
f 
tr
ea
tm
en
t
d
0
d
1
d
4
d
7
d
8
W
2
W
3
W
4
W
6
W
7
W
8
W
1
0
W
1
2
T
R
P
 (
m
m
ol
/l
) 
   
   
   
   
   
   
N
2
1
2
2
2
1
1
8
2
2
2
1
2
2
1
8
1
5
1
3
1
0
7
8
M
ea
n
4
0
.3
6
3
8
.7
7
4
0
.3
8
4
3
.3
4
4
0
.5
5
3
9
.4
5
3
6
.9
5
*
3
6
.9
6
*
3
7
.0
2
*
3
4
.7
1
*
3
6
.2
5
3
6
.1
4
3
8
.2
7
S
D
7
.9
5
7
.8
5
9
.6
4
8
.0
2
8
.5
6
7
.6
7
7
.0
7
6
.0
6
7
.5
7
5
.8
2
6
.6
7
5
.5
4
6
.0
4
T
R
P
/L
N
A
A
-r
at
io
  
  
  
  
  
  
  
N
2
1
2
2
2
1
1
8
2
2
2
1
2
2
1
8
1
5
1
3
1
0
7
8
M
ea
n
7
.5
1
7
.2
2
7
.0
1
*
7
.2
0
7
.1
5
7
.3
6
7
.3
1
7
.5
5
7
.4
9
7
.1
4
7
.3
0
7
.4
1
7
.2
1
S
D
0
.9
8
0
.9
1
0
.8
2
1
.1
4
0
.6
8
0
.8
2
0
.8
5
1
.1
1
0
.8
7
0
.8
4
0
.4
3
1
.1
0
0
.7
2
T
Y
R
/L
N
A
A
-r
at
io
  
  
  
  
  
  
 N
2
1
2
2
2
1
1
8
2
2
2
1
2
2
1
8
1
5
1
3
1
0
6
8
M
ea
n
1
3
.0
5
1
4
.0
6
*
1
3
.5
2
1
5
.0
8
1
2
.8
6
1
4
.0
7
1
4
.0
0
*
1
3
.6
5
*
1
3
.4
4
*
1
3
.7
3
*
1
2
.2
4
*
1
4
.2
2
*
1
2
.6
0
S
D
5
.3
7
5
.6
4
5
.2
6
3
.6
1
4
.9
4
6
.0
2
5
.5
5
5
.8
7
6
.3
0
5
.1
9
4
.5
1
1
.9
8
5
.3
1
N
eo
p
te
ri
n
 (
n
m
ol
/l
) 
   
   
   
  N
2
1
2
2
2
1
1
8
2
2
2
1
2
2
2
0
1
7
1
4
1
2
7
6
M
ea
n
3
0
.1
4
9
9
.4
4
*
8
7
.8
6
*
6
8
.3
7
*
6
3
.4
5
*
5
5
,4
7
*
5
5
.0
0
*
5
5
.6
3
*
5
9
.1
6
*
5
5
.9
6
*
5
4
.0
7
*
6
1
.5
8
*
4
9
.4
7
*
S
D
1
3
.2
2
2
9
.6
6
2
5
.8
8
1
7
.5
9
1
9
.1
9
1
6
.3
9
1
5
.6
9
1
5
.9
1
1
5
.2
8
1
2
.5
5
1
6
.3
1
1
4
.2
7
1
4
.3
9
B
io
p
te
ri
n
 (
n
m
ol
/l
) 
   
   
   
  N
2
1
2
2
2
1
1
8
2
2
2
1
2
2
2
0
1
7
1
4
1
2
7
6
M
ed
ia
n
7
.3
6
9
.3
1
*
7
.9
0
*
8
.0
0
7
.6
8
6
.9
2
6
,6
1
*
6
,4
0
*
6
.1
6
*
6
.0
1
*
6
.5
2
6
.9
4
7
.7
9
S
D
1
.8
4
2
.1
2
2
.4
8
2
.4
4
1
.9
2
1
.4
8
1
,5
5
1
,8
1
1
.5
8
2
.3
1
1
.9
7
1
.2
1
1
.7
5
P
H
E
/T
Y
R
-r
at
io
  
  
  
  
  
  
  
  
N
                     
2
1
2
2
2
1
1
8
2
2
2
1
2
2
1
8
1
5
1
3
1
0
7
8
M
ea
n
0
.8
0
0
.9
6
*
1
.0
0
*
0
.9
4
*
0
.9
9
*
0
.9
3
*
0
.9
4
*
0
.9
5
*
0
.9
4
0
.9
4
1
.0
5
1
.0
5
0
.9
6
S
D
0
.2
0
0
.2
2
0
.2
0
0
.1
9
0
.1
8
0
.2
1
0
.2
2
0
.2
3
0
.2
3
0
.1
7
0
.1
9
0
.1
5
0
.2
4
5
-H
IA
A
 (
m
m
ol
/l
) 
  
  
  
  
  
  
N
                 
1
7
1
8
1
7
1
4
1
8
1
7
1
7
1
7
1
4
1
2
1
1
0
7
9
M
ea
n
4
9
.8
7
3
9
.7
6
4
6
.4
9
5
2
.9
9
4
1
.1
7
3
2
.9
5
*
2
9
.9
1
*
5
0
.9
4
*
4
0
.0
3
2
9
.1
7
3
0
.4
7
5
1
.6
7
6
2
.3
9
S
D
3
9
.5
6
2
0
.5
4
3
1
.2
6
4
5
.4
5
3
1
.5
7
9
.5
2
8
.5
1
7
3
.0
9
1
8
.1
1
7
.5
5
8
.2
6
5
1
.7
8
8
7
.9
4
P
ro
la
ct
in
 (
µg
/l
) 
   
   
   
   
   
N
2
2
2
2
2
1
1
8
2
1
2
1
2
2
2
1
1
8
1
6
1
4
8
1
0
M
ea
n
5
.6
6
.8
7
.2
*
7
.4
8
.5
*
7
.6
*
8
.1
*
8
.3
*
9
.5
*
9
.6
*
8
.8
*
8
.4
*
1
1
.8
*
S
D
2
.4
3
.7
3
.7
3
.4
6
.0
3
.2
4
.0
3
.8
4
.4
5
.7
4
.1
3
.8
6
.3
table 2|5-HT-ergic parameters at baseline and during treatment with PEGIFN
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5 Figure 2| Relationship between levels of  prolactin (µg/l) during treatment wih PEGIFN and the chance (0-1) on an 
increase on depression-scale of  the PoMS compared to baseline
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Figure 1|Relation between baseline levels of  prolactin (µg/l) and change (0-1) on increase of  anger-scale of  the PoMS 
compared to baseline during treatment with PEGIFN
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0 1 4 7 8 15 22 29 43 50 57 70 84
Days
P Pr olactin < 7
Pr olactin > 7
did show an increase compared to baseline and those who did not. To relate the different 
5-HT-ergic values with the items anger and depression, three different approaches were 
used: changes compared to baseline, changes compared to previous visit and baseline 
values of  these different 5-HT-ergic values. All reported p-values are 2-sided, and a signifi-
cance level of  α = 0.05 was used.
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Twenty-two patients, 16 men and 6 women, participated in the study. Mean age was 44.2 
years (range: 31-58). The mode of  transmission for 8 of  the patients was unknown, for 
twelve of  them it was through intravenous drug use and/or tattooing and for the remaining 
2 it was iatrogenic. Thirteen patients were infected with HCV genotype 1, 2 patients with 
genotype 2, 5 patients with genotype 3 and 2 patients with genotype 4. During treatment 
with PEGIFN, 10 patients received benzodiazepines and 6 patients were clinically diag-
nosed with PEGIFN-induced depression and were prescribed antidepressants. Diagnosis 
of  depression and prescription of  antidepressant took place in all cases after day 29. As 
mentioned, after initiation of  antidepressants, psychometric and laboratory data were ex-
cluded from analysis. No antipsychotic drugs were used. In the course of  time, data went 
missing due to administrative failure or discontinuation of  antiviral therapy (Table 1 and 2).
With non-parametric testing, mean scores on the item fatigue, tension and vigor did not 
show any consistent changes compared to baseline during the first 12 weeks of  treat-
ment. However, scores on the item anger increased significantly compared to baseline 
from week 3 until week 8. Also scores on the items depression increased, though only 
from week 7 (Table 1). With repeated measures analysis, statistically significant trends 
were found for increase in depression (p=0.036), anger (p=0.001) and vigor (p=0.002), 
all signifying an increase in complaints.
Baseline levels of  TRP were significantly lower (p<0.01) and neopterin levels were signifi-
cantly higher (p<0.01) compared to the healthy controls. 
Laboratory values in the first week as tested with repeated measurements analysis yielded 
statistically significant increases for neopterin and the PHE/TYR-ratio at all four time 
points in the first week. Biopterin and PRL were found to be increased at two time points, 
whereas the TRP/LNAA-ratio and the TYR/LNAA-ratio were only decreased once (Table 2). 
After the first week, neopterin and PRL were consistently increased at all time points. Levels 
of  TRP were decreased at weeks 3, 4, 6 and 7, whereas the TRP/LNAA-ratio was not found 
to be changed, and the TYR/LNAA-ratio was increased at weeks 3 to 10. The PHE/TYR-ratio 
was increased at weeks 1 to 4, biopterin was decreased (after the aforementioned increase at 
day 1 and 4) at weeks 3 to 7, and 5-HIAA was found to be decreased at week 2 to 4 (Table 2).
In the multivariate analysis changes in TRP, TYR/LNAA-ratio, neopterin, biopterin, PHE/
TYR-ratio and 5-HIAA were not associated with changes in the scores on the items depres-
sion and anger. Contrary to expectation, change in the TRP/LNAA-ratio was positively as-
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sociated with increased anger (p=0.03). No relationship was seen between change in the 
TRP/LNAA-ratio and change in depression. 
Patients with higher concentrations of  PRL at baseline were associated to have an in-
crease in anger: the chances on an increase on the anger subscale, compared to baseline 
were consistently higher at all time points during treatment with PEGIFN in patients with 
PRL levels at baseline higher than 7 µg/l compared to patients with PRL levels at baseline 
lower than 7 µg/l (p<0.01; Figure 1). At all time points during treatment, higher PRL lev-
els were associated with an increase on the item depression compared to baseline at the 
same time point (p=0.03; Figure 2).
Furthermore, we compared the laboratory values of  the patients who developed clinical 
depression in the course of  treatment with the remaining patients who did not. No differ-
ences were observed between the groups at baseline and at day 29 regarding the concen-
trations of  TRP, TYR, neopterin and PRL, and with regard to the TRP/LNAA-ratio and PHE/
TYR-ratio, with the exception of  the TRP/LNAA-ratio being higher (8.61 + 1.2 vs. 7.03 + 
0.6) and the PHE/TYR-ratio being lower (0.79 + 0.2 vs. 1.03 + 0.2) in the 6 patients that 
went on to develop depression. 
Finally, to investigate if  changes in laboratory values were more predictive than the abso-
lute concentrations or ratios on a specific point in time, we analyzed the changes in the 
concentrations of  TRP, TYR, neopterin and PRL, and in the TRP/LNAA-ratio and PHE/TYR-
ratio occurring over the first week compared to baseline and over the first 4 weeks com-
pared to baseline, again in the patients who developed clinical depression in the course of  
treatment and who did not. No differences were observed between the two groups.  
DisCUssioN 
In this study on 22 HCV patients treated with PEGIFN, we assessed psychopathology in 
combination with an exploration of  a set of  laboratory parameters considered indicative of  
the hypothetic 5-HT-ergic dysfunction underlying PEGIFN-induced psychiatric side effects. 
During treatment, scores on the items anger and depression (and vigor to a lesser degree) 
tended to increase. The increase in irritability is in accordance with the data reported by 
Russo et al 9, who described aggression as the main psychiatric side effect of  IFN.
Regarding the exploration of  5-HT-ergic parameters, baseline levels of  TRP were signifi-
cantly lower compared to the general population, in accordance with earlier publications 
(19). With regard to levels of  TRP and TRP/LNAA-ratio, indices for the availability of  TRP 
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for the CNS 5-HT synthesis, only for TRP a decrease was observed in the at some time 
points. No consistent changes in 5-HIAA were observed. Secondly, concerning indicators 
for the BH4 activity, the PHE/TYR-ratio increased in the first four weeks, in part in line with 
data from studies on cancer patients treated with (PEG)IFN, suggestive for a lower BH4 
activity, potentially resulting in an impaired synthesis of  5-HT, dopamine and noradrena-
line (8, 20-21). Due to the observed consistent increase in neopterin levels one could have 
expected a decrease in biopterin. However, this was not the case. 
Contrary to our expectations, levels of  PRL, a hormone under the control of  5-HT and 
dopamine, increased soon after the start of  PEGIFN and remained elevated during treat-
ment. These findings are in accordance with two recent studies (22-23), but in contrast 
with another (24). In case of  decreased 5-HT-ergic neurotransmission, one might expect 
a decrease in PRL. Perhaps the observed augmented secretion is due to a decreased do-
paminergic inhibition of  PRL secretion caused by a PEGIFN-induced decreased dopamine 
synthesis. Decreased dopamine synthesis in turn, might be due to reduced BH4 synthesis, 
reflected in our study by an increase in the PHE/TYR-ratio. Also augmented stress due to 
the side effects caused by PEGIFN treatment could cause higher levels of  prolactin (25).
A substantial proportion of  patients were clinically diagnosed with depression, in all cases 
after the 6th week of  antiviral treatment. We did not succeed to identify these patients 
with the use of  laboratory parameters, as these were mostly not different between pa-
tients who did develop depression and who did not. The higher TRP/LNAA-ratio and the 
lower PHE/TYR-ratio at day 29 in patients who developed depression later are counterin-
tuitive, as one would expect that lower TRP availability to the CNS and less BH4 activity 
would induce depression. Furthermore, changes in laboratory parameters compared to 
baseline did not seem to matter.
No consistent correlations could be found between scores on the items anger and depres-
sion and different 5-HT-ergic parameters. Some but not all studies showed a correlation 
between 5-HT-ergic parameters and depressive symptoms. Neither Bannink (20) nor Wich-
ers (14) could find a relationship between changes in TRP and the TRP/LNAA-ratio and 
depressive symptoms. on the whole, these findings suggest a more broad exploration of  
the metabolism of  TRP and 5-HT, e.g. by studying kynurenine and PRL. Whereas in hu-
mans TRP can only be measured in the peripheral blood, PRL might reflect more directly 
the central monoaminergic activity. In this study we observed an interesting relationship 
between baseline levels PRL and an increase in anger and between PRL and depression. 
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Limitations of  our study were the small patient numbers, the wide intra-subject and inter-
subject variability of  the different parameters and the number of  missing data due to 
treatment cessation or administrative failure. 
The data should be interpreted against the background of  the high rates of  psychopatho-
logy found in HCV patients, comprising a broad spectrum of  psychiatric and addiction 
disorders (26, 27). Currently, the differing theories on the pathophysiology underlying 
the psychiatric disturbance in HCV patients presume biological (e.g. the possibility of  
a CNS infection by HCV), psychiatric and sociological factors (27). In view of  this, the 
extrapolation from data from IFN-induced depression to depression in general should be 
undertaken with care.
In summary, we observed both anger and depression as psychiatric side effects of  antivi-
ral therapy, although no consistent changes were seen in laboratory parameters reflecting 
TRP availability to the brain, whereas changes were seen in indices of  BH4 activity, as well 
as in PRL levels. only PRL concentrations at baseline and during treatment were found to 
be related to emerging psychiatric side effects. This warrants further research.
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ABstrACt
Background and aims 
Limited data are available on the effect of  treatment with peginterferon alfa and ribavirin 
on human semen quality. We conducted a study to investigate the effects of  chronic hepa-
titis C and treatment with peginterferon alfa and ribavirin on spermatogenesis and sperm 
DNA integrity.
methods Serum and semen samples of  23 hepatitis C patients were collected before, 
during and after treatment. Seminal and endocrinological parameters and sperm DNA 
integrity (expressed as DNA fragmentation index) were analyzed.
results Baseline oligozoospermia (sperm concentration <15x106/l) and asthenosper-
mia (<32% moving spermatozoa) both occurred in 9 patients (39%). Median seminal 
volume decreased significantly during treatment (1.6 ml to 0.9 ml, p=0.005). No sig-
nificant changes in progressive motility and sperm concentration were found. A signifi-
cant increase of  luteinizing hormone (p=0.011) but not of  follicle stimulating hormone 
(p=0.241) was seen during treatment. Median DNA fragmentation index of  hepatitis C 
patients before treatment was comparable with that of  22 healthy controls: 19.2% (range 
2.6-42.8%) vs. (15.8%, range 6.4-25.7, p=0.51). Median DNA fragmentation index was 
higher in methadone users, 32.2% vs. 12.6% (p=0.039) and in patients using antipsy-
chotics (olanzapine and risperidon); 34.0% vs. 12.7%, p=0.01. Sperm DNA integrity was 
not altered during treatment and follow-up.
Conclusions Semen abnormalities were found in a relatively large proportion of  hepatitis 
C patients, but treatment did not lead to further impairment of  sperm quality. Sperm DNA 
integrity, which is associated with poor reproductive outcome and with a higher miscar-
riage risk, was not altered by treatment with peginterferon alfa and ribavirin.
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iNtroDUCtioN
A treatment regimen with peginterferon alfa and ribavirin (PEGIFN/RBV) is the standard 
of  care for chronic hepatitis C virus (HCV) infection and despite the development of  suc-
cessful direct antiviral agents, this treatment combination will remain the backbone of  
antiviral therapy against HCV (1). In animals, RBV has repeatedly been proven to be tera-
togenic. Malformations of  limbs, spine, ribs, eyes and central nervous system have been 
shown in rodents in addition to reductions in sperm count and alterations in morphology 
of  spermatozoa (2-3) after exposure to RBV. Contradicting results have been found in 
studies investigating the effect of  interferon alfa on semen quality (4-5). In women, most 
reports on direct maternal exposure to PEGIFN/RBV or RBV alone prior to or during 
pregnancy describe normal pregnancies (6-9), however there are some reports of  miscar-
riage, elective terminations and birth defects (10-11). Little is known about the effects on 
offspring of  males treated with PEGIFN and RBV. Again, there are some reports of  miscar-
riage but most pregnancies resulted in normal live born infants (12-14). In a prospective 
observational cohort study pregnant women who were exposed both directly and indirectly 
to RBV, were followed till delivery and their live born infants were followed for one year. In 
this study the incidence of  birth defects after both direct and indirect RBV exposure did 
not significantly differ from that in the general population, but enrolment was too short to 
obtain the required sample size (10). 
It is however known that RBV is detectable in semen during antiviral treatment (15) and be-
cause to date the potential mutagenic effects of  RBV cannot be excluded, guidelines strongly 
recommend double contraception during and until 7 months after treatment for male pa-
tients and their female partners (16-17). It is however questionable whether this is necessary.
There is some evidence that a proportion of  HCV patients have semen abnormalities prior 
to treatment and that semen quality further deteriorates during the first weeks of  treat-
ment (15, 18). However, limited data are available on semen quality during follow up and 
no data are available on sperm DNA integrity (sperm DNA damage) induced by PEGIFN/
RBV treatment. 
Sperm concentration and sperm motility are important parameters for male fertility. 
Sperm DNA integrity is associated with a lower spontaneous conception rate and pos-
sibly with a higher miscarriage risk (19-20). In addition, luteinising hormone stimulates 
the production of  testosterone and FSH activates spermatogenesis. Serum levels of  in-
hibin B are positively correlated with the number of  spermatozoa produced (21) and are 
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negatively correlated with the FSH levels. Serum concentrations of  free testosterone (non 
SHBG-bound testosterone) reflect the functioning of  Leydig cells in the testis.
We conducted a study to investigate the occurrence of  semen abnormalities in patients with 
HCV infection and to investigate the effect of  PEGIFN/RBV treatment on spermatogenesis, 
sperm DNA integrity and endocrinological parameters prior to, during and after treatment.
metHoDs
Study design. This study is a single center observational study. Treatment naïve male pa-
tients with a chronic HCV infection for whom antiviral therapy with PEGIFN/RBV was 
planned could be included in the study. Patients with a hepatitis B and human immunode-
ficiency virus (HIV) co-infection were excluded from participation. 
Semen analysis. Semen samples were obtained at baseline, week 12, 24, 48 and 24 weeks 
after treatment discontinuation (FU24). Semen samples were obtained by masturbation 
at the Andrology unit after at least 3 days of  abstinence. Semen samples were analyzed 
on volume, concentration and motility according to WHo standard criteria (22). Sperm 
motility was assessed by categorizing the spermatozoa in 2 groups: progressively motile 
and non-progressively motile spermatozoa. The first group contains active moving sper-
matozoa. The last group contains cells which don’t move at all or cells that move but 
remain at the same position. Sperm morphology was not included in the study protocol. 
Since this semen parameter is considered an unreliable marker to determine fertility due 
to the great inter- and intra observer variability. However, data on morphology was avail-
able in some of  the patients.
Sperm DNA integrity analysis. Sperm DNA integrity was measured using the sperm chroma-
tin structure assay (SCSA). The SCSA was performed as described by Evenson and Jost 
(23), using a FACS cytometer (Becton Dickinson, San Jose, CA). In brief, frozen samples 
were quickly thawed, diluted to a concentration of  1-2 x 106 sperm cells/ml, exposed 
to acid detergent solution, and stained with acridine orange. Data collection of  the fluo-
rescence pattern in 5000 cells was performed at 3 minutes after acid treatment. Debris, 
bacteria and leukocytes were gated out during acquisition as recommended (23). The 
extent of  DNA damage is expressed as the DNA fragmentation index (DFI). Cell Quest 
Pro and Winlist software were used to calculate the DFI of  each sample. All samples were 
measured in duplicate. A DFI larger than 30% is considered abnormal. Median DFI values 
and dichotomized values (DFI < 30% and DFI ≥ 30%) were used in the analyses. DFI data 
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were compared with DFI data of  22 proven fertile men who donated a semen sample be-
fore vasectomy.
Serum analysis. Serum samples were collected at baseline, week 12, 24, 48 and at FU24. 
Luteinising hormone (LH), follicle stimulating hormone (FSH), free testosterone and in-
hibin B were determined to investigate testicular function before, during and after treat-
ment. Levels of  free testosterone were calculated as described by de Ronde et al. (24). 
The methods used to estimate hormone levels were luminescence-based immunometric 
assays for LH, FSH and SHBG (Immulite Siemens DPC, Los Angeles, CA, USA), coated 
tube radio immunoassay for testosterone (Siemens DPC) and an enzyme-immunometric 
assay for inhibin B (Diagnostic Systems Laboratory, Webster, TX, USA). 
Statistical analysis. Fisher’s exact tests were used to compare dichotomized variables. Con-
tinuous variables were expressed as medians with range. Wilcoxon signed rank tests and 
Mann-Whitney U tests were performed to compare continuous variables. A p-value below 
0.05 was considered statistically significant. In case of  the comparison of  baseline sam-
ples with on-treatment and follow-up samples a correction for multiple testing was made 
and thus a p-value below 0.0125 was considered statistically significant. Multivariate lin-
ear regression was applied to determine which baseline factors influenced sperm DNA in-
tegrity at baseline. SPSS version 17.0 (SPSS inc., Chicago, IL) was used for this analysis.
 
resULts
Patients. A total of  23 male patients were included in the analysis. Baseline samples 
were available in 23 patents. on-treatment and follow up samples form 19 patients were 
available. The remaining 4 patients withdrew informed consent after providing a base-
line semen and blood sample. Baseline characteristics are summarized in table 1. Seven 
patients used methadone and 2 patients smoked cannabis on a regular basis. other co-
medication included selective serotonin reuptake inhibitors, benzodiazepines and anti-
psychotics which were used in 9 patients. All patients were naïve to antiviral treatment 
and were treated with peginterferon alfa-2a and RBV (10-15 mg/kg), except for 7 patients, 
who received high dose RBV (25-29 mg/kg). Two patients were treated for 12 weeks, 13 
patients for 24 weeks and 4 patients for 48 weeks. Data on semen samples taken at week 
48 are not shown in the figures because only 4 samples were available. Sustained virologi-
cal response (SVR) was achieved in 11 patients. 
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(43%) had a low seminal volume (seminal volume <1.5ml), 9 patients (39%) had oligozoo-
spermia (sperm concentration <15 x 106/ml) and 9 patients (39%) had asthenozoosper-
mia (progressive motility <32%). Data on sperm morphology were available in 9 patients; 
4 out of  9 (44%) had teratozoospermia (defined as <4% normal spermatozoa) at baseline.
Seminal volume was significantly decreased at week 12 of  treatment (p=0.005) but not 
at week 24 and 48 (figure 1a). Median sperm concentration at baseline was 29 x 106/ml 
(range 3-344 x 106/ml). Median sperm concentrations at week 12, 24, 48 and FU24 were 
38, 27, 37 and 54 x 106/ml respectively. The median percentage of  progressive motility 
at baseline was 37% (range 2-64%). Median progressive motility percentages at week 12, 
24, 48 and FU24 were 37%, 39%, 42% and 43% respectively. Eleven out of  19 patients 
(58%) had a decrease in sperm concentration and 10 out of  19 had a decrease in pro-
gressive motility during treatment, however both sperm concentrations and progressive 
motility were not significantly altered (figure 1b and c). At baseline median percentage 
of  normal spermatozoa was 5% (range 0–11%). During treatment percentage of  normal 
spermatozoa decreased, however this decrease was not significant (p=0.167) (figure 1d). 
Semen parameters during treatment did not significantly differ between patients receiving 
high dose or standard dose RBV.
Sperm DNA integrity analysis. Data on sperm DNA integrity were available in 18 patients. At 
baseline 4 of  18 patients (22%) had a DFI >30%, which is considered abnormal. Median 
table 1|Baseline characteristics
Number of patients 23
Age (mean, range in years) 43 (22-62)
BMI (mean, range in kg/m2) 24 (17-31)
Cirrhosis (metavir score) 1
HCV Genotype 
 1 13 (57%)
 2 4 (17%)
 3 6 (4%)
Methadone 7/23 (30%)
Smoking 19/23 (89%)
Treatment duration 24/48 weeks 12/11
Low seminal volume 10 (43%)
oligozoospermia 9 (39%)
Asthenozoospermia 9 (39%)
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DFI at baseline was 19.2% (range 2.6 - 42.8%), 15.4% (range 1.5- 45.6%) at week 12, 
17.5% (6.6 – 35.5%) at week 24, 13.1% (range 2.8 – 28%) at week 48 and 17.6% (range 
2.6 -73.5%) at week FU24. DNA fragmentation index did not significantly change during 
treatment and follow up (figure 2). The median DFI of  18 HCV patients at baseline did 
not significantly differ from the median DFI of  22 proven fertile healthy controls: 19.2%, 
range 2.6 - 42.8% vs. 15.8%, range 6.4-25.7 (p=0.51).
Endocrinological parameters. Changes in gonadotrophic hormones, free testosterone and 
inhibin B are shown in figure 3. A slight increase in both FSH (figure 3a) and LH (fig-
Figure 1|Seminal volume (A), semen concentration (B), progressive motility (C) and seminal morphology (D) during 
treatment (median, range)
Seminal volume was significantly decreased significantly at week 12 (p=0.005), but not at week 24. No significant 
changes in sperm concentration and progressive motility were observed during treatment. A non-significant decrease 
in spermatozoa with normal morphology was observed during treatment
Figure 1a
Figure 1c
Figure 1b
Figure 1d
1204304 Proefschrift Erasmus Universiteit.indd   113 06-06-12   07:48
114
C
h
ap
te
r 
6
ure 3b) was seen during treatment which 
was significant for LH (p=0.011) but 
not for FSH (p=0.241). During follow up 
LH and FSH returned to baseline levels. 
There was a trend towards a decline of  
free testosterone and inhibin B (figure 3c 
and 3d) during treatment, however these 
declines did not reach statistical signifi-
cance (p=0.074 and 0.138).
Factors influencing semen parameters and 
sperm DNA integrity. At baseline, metha-
done users had a higher DFI compared to 
patients not using methadone, 32.2% vs. 
12.6% (p=0.039) and DFI was higher in 
patients using antipsychotics (olanzapine and risperidon) compared to non-users (34.0% 
vs. 12.7%, p=0.01) (figure 4). In a multivariate linear regression model both variables re-
mained significant (p=0.035 for methadone and p=0.005 for antipsychotics). Sperm DNA 
integrity was significantly correlated with progessive motility (r= -0.674, p<0.001). There 
was no difference in sperm volume, concentration and motility as well as sperm DNA 
integrity between baseline and follow up in patients who achieved SVR (table 2). other 
factors influencing sperm concentration and progressive motility could be identified. Can-
nabis use was not associated with increased DFI.
table 2|Median semen parameters at baseline and during follow up in both SVR (n=10) and non SVR patients (n=9).
sVr Parameters Baseline Follow up P
Volume 2.0 1.9 0.79
Concentration 26.0 x 106 51.0 x 106 0.11
Motility 38.0% 44.0% 0.84
Sperm DNA integrity 12.6% 18.0% 0.11
Non-sVr P
Volume 1.5 1.10 0.25
Concentration 60.5 x 106 59.0 x 106 0.31
Motility 22.5% 36.0% 0.18
Sperm DNA integrity 21.9% 17.2% 0.35
Figure 2|Sperm DNA integrity expressed as the DNA frag-
mentation index (DFI) during treatment (median, range)
No significant changes in sperm DNA integrity were ob-
served during treatment and during follow up
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Figure 3|Follicle stimulating hormone (FSH) (A), luteinizing hormone (LH) (B), free testosterone (C) and inhibin B (D) 
during treatment (median, range)
An significant increase in LH was observed during treatment (p=0.011). FSH was not significantly influenced by pe-
ginterferon alfa and ribavirin treatment (p=0.241). A decrease in free testosterone and Inhibin B was observed during 
treatment with a trend towards significance for testosterone (p=0.074)
Figure 3a
Figure 3c
Figure 3b
Figure 3d
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6 DisCUssioN
This study is the first to report on semen abnormalities, endocrinological parameters as 
well as sperm DNA integrity in HCV patients prior, during and after antiviral treatment with 
PEGIFN/RBV. In this study approximately 40% of  HCV patients had semen abnormalities 
at baseline. Sperm concentration and motility, which are predictors of  male fertility, did 
not significantly change during treatment with PEGIFN/RBV and during follow up. We did 
find a significant decrease of  semen volume at week 12 of  treatment, which could pos-
sibly be explained by a decrease in sexual arousal during antiviral treatment (25). We also 
report on semen morphology, however, this parameter is considered unreliable because 
of  a great inter- and intra- observer variability and secondly, this parameter is a poor 
predictor of  fertility. For this reason morphology is no longer part of  the standard semen 
analysis at our Andrology unit and data was not available in most patients. A decline in 
the amount of  spermatozoa with normal morphology was observed during treatment, this 
decline however, was not significant. 
Sperm DNA integrity is currently the most reliable predictor of  spontaneous pregnan-
cies and the occurrence of  miscarriage. Potentially, it may be associated with the risk of  
birth defects. Sperm DNA damage, expressed as DFI, is increased in patients with various 
forms of  cancer, treatment with radiotherapy and several andrological abnormalities (20, 
26). The median DFI of  HCV patients did not significantly differ from healthy controls and 
during therapy the DFI levels were not significantly altered. These findings are in disagree-
Figure 4|DFI in patients using methadone (A) antipsychotics (B) (median, range)  
DFI was significantly increased in patients using methadone and antipsychotics
Figure 4a Figure 4b
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ment with a case report on sperm DNA integrity during PEGIFN/RBV therapy for HCV 
(27). In this report about a patient receiving viraferon and RBV for chronic HCV, DFI levels 
increased during therapy and returned to baseline levels after treatment discontinuation. 
At last we investigated alterations in gonadotrophic and gonadal hormones during anti-
viral treatment. An increase in FSH and LH was observed during treatment together with 
a decrease, although not significant, in free testosterone and inhibin B (down regulator 
of  FSH). All endocrinological parameters returned to baseline levels during follow up. 
These results indicate a compensated minimal deterioration of  testicular function dur-
ing treatment with PEGIFN/RBV treatment. However, differences are small and should be 
interpreted with caution.
A possible explanation for semen abnormalities could be a direct effect of  the virus on 
spermatogenesis (18). However, a decrease in the number of  patients with semen abnor-
malities after achieving SVR would then be expected (table 2). This was not the case in our 
study. Another explanation could be that semen abnormalities are not related to the virus 
but to confounding factors often seen in HCV patients like the use of  methadone, cocaine, 
alcohol or specific medication (28-29). In our study DFI levels were significantly higher in 
methadone users and in patients who used antipsychotics. Despite the strong correlation 
between DFI levels and progressive motility, the use of  methadone and antipsychotics 
were not associated with decreased progressive motility. 
our findings are not entirely in agreement with previous findings of  Hofer et al. (15). 
They found a significant decrease in sperm concentration at week 4 and a significant 
decrease in normal cell morphology at week 12 in a cohort of  15 patients. No significant 
changes in motility were found. They concluded that antiviral treatment leads to sub-
stantial alterations in both quantitative and qualitative parameters. However, changes in 
semen quality were only minimal, not consistent and only measured at week 4, 12 and 
24 of  treatment and not during follow up. Furthermore, sperm DNA integrity, a more 
reliable parameter of  semen quality and teratogenity, was not assessed. An interesting 
finding of  this study was the presence of  RBV in sperm. They found a twofold higher 
concentration in semen compared to serum concentrations at week 4 and 12 of  antiviral 
treatment. Unfortunately data on RBV concentrations during follow up are still lacking 
and the clinical significance of  detectable RBV in semen also remains unclear. In case 
RBV is transmittable to female partners then blood concentrations would be extremely 
low due to the small volume of  semen samples.  
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In conclusion, sperm DNA integrity in HCV patients is comparable with healthy controls 
and is not affected by treatment with PEGIFN/RBV. Based on these findings and the find-
ings of  birth registry trials it would be questionable whether double contraception until 
7 months after treatment cessation, or even during treatment, is necessary for male pa-
tients. Semen abnormalities were present in a proportion of  HCV patients and considering 
the fact that these abnormalities did not resolve after achieving SVR, a plausible alterna-
tive cause for these abnormalities could be the confounding factors found in HCV patients, 
such as the use of  methadone or antipsychotics.
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ABstrACt 
Background Hepatitis C decreases health related quality of  life (HRQL) which is further 
diminished by antiviral therapy. HRQL improves after successful treatment. This trial ex-
plores the course of  and factors associated with HRQL in patients given individualized or 
standard treatment based on early treatment response (Ditto-study). 
Methods The Short Form (SF)-36 Health Survey was administered at baseline (n= 192) 
and 24 weeks after the end of  therapy (n= 128). 
results At baseline HRQL was influenced by age, participating center, severity of  liver 
disease and income. Exploring the course of  HRQL (scores at follow up minus baseline), 
only the dimension general health increased. In this dimension patients with a relapse or 
sustained response differed from non-responders. Men and women differed in the dimen-
sion bodily pain. Treatment schedule did not influence the course of  HRQL. 
Conclusions Main determinants of  HRQL were severity of  liver disease, age, gender, par-
ticipating center and response to treatment. our results do not exclude a more profound 
negative impact of  individualized treatment compared to standard, possibly caused by 
higher doses and extended treatment duration in the individualized group. Antiviral thera-
py might have a more intense and more prolonged negative impact on females.
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BACKGroUND
Patients chronically infected with hepatitis C virus (HCV) have a decreased health related 
quality of  life (HRQL) compared to the general population (1,2). The impact of  the disor-
der is comparable with other stressful life events and chronic diseases, like diabetes (3). 
In part, the reduction in HRQL is due to the mental components of  HRQL. With regard to 
these mental components, patients aware of  their diagnosis have a more reduced HRQL 
than those who are unaware (4). Furthermore, many HCV patients have a previous or ongo-
ing addiction and/or psychiatric problems, reflected in lower HRQL. In addition, patients 
with hepatitis C are stigmatized in society and the majority of  the population of  hepatitis 
C patients has a lower social economic status compared to the general population (5).
The reduction of  HRQL is probably also due to physical and psychiatric symptoms as 
a direct consequence of  this chronic infection and its sequelae (such as cirrhosis). The 
chronic inflammation is believed to signal the brain and to give rise to neurovegetative 
symptoms (e.g. malaise and fatigue) and to amongst others depression and concentration 
difficulties (6). Possibly, also the brain itself  is infected by HCV (7).
Finally, treatment of  chronic HCV with (peg)interferon-alpha ((PEG)IFN) and ribavirin 
(RBV) further diminishes HRQL due to its side effects. The introduction of  PEGIFN pro-
vided a significant improvement over standard IFN, with the result that the decrease of  
HRQL during treatment with PEGIFN is less than with standard IFN (8,9,10,11). In case of  
successful treatment (obtaining a sustained virological response (SVR)) an improvement 
of  HRQL-scores is observed (2,8,9,10). 
In the Ditto-study (12) a dynamically individualized treatment schedule depending on the 
on-treatment response was compared to a standard combination therapy with PEGIFN 
alfa-2a (180 µg qw) plus RBV (1000-1200 mg qd) for 48 weeks (Figure 1). The primary 
aim of  the Ditto study was to improve the SVR rate by individualizing the treatment sched-
ule, but this could not be established. 
This large scale, multi-centre, international trial, firstly, provides the opportunity to ex-
plore a variety of  factors associated with HRQL in HCV patients at baseline (treatment 
naïve; t=0). Secondly, although type of  treatment, treatment intensity and treatment dura-
tion were heterogeneous this study enabled us to investigate the course of  HRQL during 
PEGIFN-based treatment and to add to the existing knowledge on the impact of  cytokine-
based antiviral treatment on HRQL. (E.g. do patients recover 24 weeks after completion of  
therapy (follow up) and which factors are associated with the course of  HRQL?)
Long-term effects of  treatment and response in patients with chronic hepatitis C on quality of  life. An internatio-
nal, multicenter, randomized, controlled study.
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metHoDs 
Patients 
273 patients were included in the study, after informed consent was obtained, and 270 
patients were randomized after 6 weeks of  standard treatment. The ethical review boards 
of  the participating centers approved the study. After randomization, 134 patients re-
ceived standard treatment and 136 patients were treated according to an individualized 
treatment schedule depending on the response at week 4 and 12 of  treatment. 216 pa-
tients completed the treatment per protocol and 249 patients completed the end of  fol-
low up. At t=0 HRQL was measured in 192 patients (not every center participated in the 
HRQL-analysis) and at follow up (24 weeks after completion of  therapy) in 128 patients. 
In 120 patients, HRQL could be assessed at both time points.
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Figure 1|Treatment allocation of  patients with chronic hepatitis C according to initial virologic response pattern in 
the Ditto study
Abbreviations: Ribavirin (RBV), Rapid viral response (RVR), Slow partial response (SPR), Flat partial response (FPR), 
null response (NUR), Standard combination therapy (STD)
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Long-term effects of  treatment and response in patients with chronic hepatitis C on quality of  life. An internatio-
nal, multicenter, randomized, controlled study.
table 1|Determinants of  Health Related Quality of  Life on t=0 and course of  Health Related Quality of  Life
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Results of  statistical analysis of  the influence of  age (ANoVA), presence of  cirrhosis (t-test), gender (t-test) and in-
come in Euros (correlation analysis: Spearman) on Health Related Quality of  Life at start of  treatment (t=0) and the 
course of  Health Related Quality of  Life  (scores at 24 weeks after treatment (Follow up) minus scores at baseline). 
Data were shown if  relationships were statistically significant.
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Study Design 
This phase III, open-label, randomized, multicenter trial was conducted by the DITTo-HCV 
study group between February 2001 and November 2003 at 9 centers in France, Germany, 
Greece, Israel, Italy, the Netherlands, Spain, Sweden, and Switzerland.
Assessments
The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a 
profile of  HRQL outcomes by measuring health across eight different dimensions: physical 
functioning, role limitation because of  physical health, social functioning, vitality, bodily 
pain, mental health, role limitation because of  emotional problems and general health. 
Responses to each question within a dimension are combined to generate a score from 
0 to 100, where 100 indicates “good health”. The eight multi-item subscales were also 
converted into a physical component summary scale and a mental component summary 
scale [13]. Demographic (such as age, gender, and income in Euros) and disease related 
factors were assessed before start of  treatment. At the moment the SF-36 was completed 
at follow up both patients and the treating physician were unaware of  the response to the 
treatment because HCV-RNA testing results were not known yet, however non-responders 
were aware of  their (positive) HCV-RNA status at relevant time points during treatment.
DAtA ANALYsis 
Power calculation
The HRQL-analysis was part of  the main study which was powered on signifi-
cant differences in SVR-rates between standard and individualized treatment. 
Therefore no separate power analysis was performed for this analysis. 
Determinants of HRQL before treatment 
To investigate the influence of  different characteristics such as age, grade of  fibrosis, and 
income in Euros, t-test analysis for dichotomous categorical, univariate analysis for multicat-
egorical and correlation analysis (Spearman) for continuous data were performed (n=192).
Course of HRQL 
The differences between HRQL at t=0 and follow up were investigated with analysis of  vari-
ance (ANoVA) and t-tests for Equality of  Means (n=120).
Explanatory variables on the course of HRQL
a) Effects of response to treatment on the course of HRQL 
The course of  HRQL was analyzed separately for patients with SVR, relapse or non-re-
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sponse with t-tests. Comparison between patients with SVR, with relapse and non-re-
sponse was assessed by means of  ANoVA. 
b) Effects of treatment schedule 
The mean differences in quality of  life between t=0 and follow up were compared between 
patients treated with standard and individualized treatment using ANoVA and t-tests for 
Equality of  Means. Also the mean differences were compared between the groups with 
RVR (A1, A2 and standard treatment with RVR) and the groups B2, D and A2 (extended 
versus shortened therapy, see Figure 1).
c) Effects of patient characteristics on the course of HRQL 
With t-test analysis for dichotomous categorical, univariate analysis for multicategorical 
and correlation analysis (Spearman) for continuous data, the influence on the differences 
between HRQL at t= 0 and follow up was determined for the factors age (<20, 20-29, 30-39, 
Long-term effects of  treatment and response in patients with chronic hepatitis C on quality of  life. An internatio-
nal, multicenter, randomized, controlled study.
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Figure 2|Mean scores of  the different SF36 dimensions at t = 0 from the participating centers
Barcelona; Spain, Paris; France, Geneva; Switzerland, Gothenburg; Sweden, Parma; Italy, Rotterdam; The Nether-
lands, Rehovot; Israel
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40-49, 50-59, 60-69 years), gender, participating center, presence of  cirrhosis, genotype (1, 
4, and 5 versus 2 and 3) and income in Euros.
d) Multivariate analysis 
For further exploration of  the influence of  the different factors mentioned above on the 
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Figure 3|Mean scores with 95 % confidence intervals of  the different dimensions of  the SF-36 in men at baseline and 
at 24 weeks after completion of  treatment (follow up)
Figure 4|Mean scores with 95 % confidence intervals of  the different dimensions of  the SF-36 in females at baseline 
and at 24 weeks after completion of  treatment (follow up)
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course of  HRQL, a multivariate analysis was performed with a correction for age and 
baseline values of  the SF-36. 
resULts
Baseline host and virus-related variables were similar in the standard and the individual-
ized treatment groups (data not shown). 
Determinants of HRQL before treatment 
HRQL varied with age, participating center, severity of  liver disease and income in Euros 
(Table 1). As might be expected, younger patients had a better performance compared 
to older patients, especially on the physical components of  HRQL. Surprisingly, cirrhotic 
patients had a better performance than non-cirrhotic patients, having significantly higher 
scores on several dimensions of  the SF-36, mostly on mental components. Higher income 
in Euros had a weak positive effect on the physical component summary scale and role 
limitation because of  physical health scale of  HRQL, with a correlation coefficient of  
0.30 (p=.003) and 0.23 (p=.002) respectively. Finally, HRQL differed among the different 
participating centers: the mental component summary scale and the dimensions physical 
functioning, role limitation because of  physical health, general health, bodily pain, vitality, 
social functioning and mental health were all significantly different between the participat-
ing centers (Figure 2).
Course of HRQL 
General health improved significantly at follow up compared to general health at start of  
treatment (mean improvement 3.5, p =.04). The subscale physical functioning tended to 
worsen with a mean decrease of  – 3.4 (p =.06) compared to t=0. other dimensions did 
not change.
Explanatory variables on the differences between HRQL at baseline and at follow up  
a) Effect of response to treatment on course of HRQL
In patients with SVR, as well as with a relapse or non-response, HRQL did not change 
compared to t=0 after treatment with PEGIFN antiviral therapy, except for an increase 
in social functioning in sustained viral responders (78.8 at baseline, 83.3 at follow up, p 
=.04). Among the different groups changes compared to baseline in the dimensions gen-
eral health differed significantly (p =.02) between patients with a relapse (+ 5.3), SVR (+ 
6.1) and non-response (- 6.3) to treatment.
Long-term effects of  treatment and response in patients with chronic hepatitis C on quality of  life. An internatio-
nal, multicenter, randomized, controlled study.
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b) Effect of treatment schedule on course of HRQL 
No significant differences were observed in 
changes in the different dimensions of  the SF-
36 between standard and individualized treat-
ment. A sub-analysis comparing responders 
and non-responders separately in standard and 
individualized treatment showed no difference, 
either. Patients treated for 24 weeks and pa-
tients treated with double dose PEGIFN showed 
a decline on the dimensions mental health 
whereas patients treated for 72 weeks had an 
increase on this dimension: respectively – 7.9, 
- 2.0 and + 18.5.
c) Effects of patient characteristics on course of 
HRQL
Neither age, genotype nor grade of  fibrosis 
had an influence on changes in the different 
dimensions of  HRQL. A significant difference 
was seen between men and women in the di-
mensions bodily pain (males: + 4.1, females: 
- 7.2, p =.02), social functioning (males: + 6.3, 
females: - 5.8, p =.008), vitality (males: + 7.2, 
females: - 2.7, p =.03) and role limitations due 
to emotional problems (males: + 9.3, females: 
- 8.3, p=.05). There was a weak significant posi-
tive correlation between income in Euros and 
increase in vitality and mental health between 
baseline and follow up: correlation coefficient 
.30 (p =.02) for vitality and .21 (p =.03) for 
mental health. See figure 3 and figure 4.
d) Multivariate analysis 
Also in a multivariate analysis gender was a sig-
nificant factor on the course of  HRQL. All differ-
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table 2|Multivariate analysis
  
P
h
ys
ic
al
 
co
m
p
on
en
t 
su
m
m
ar
y 
sc
al
e 
 
M
en
ta
l 
co
m
p
on
en
t 
su
m
m
ar
y 
sc
al
e 
P
h
ys
ic
al
 
fu
n
ct
io
n
in
g
R
ol
e 
lim
it
a-
ti
on
 b
ec
au
se
 
of
 p
h
ys
ic
al
 
h
ea
lt
h
G
en
er
al
 
h
ea
lt
h
B
od
ily
 p
ai
n
V
it
al
it
y
S
oc
ia
l 
fu
n
c-
ti
on
in
g
R
ol
e 
lim
it
a-
ti
on
 b
ec
au
se
 
of
 e
m
ot
io
n
al
 
p
ro
b
le
m
s 
M
en
ta
l 
h
ea
lt
h
G
en
d
er
.0
4
3
.0
5
0
.0
3
0
.0
0
6
.0
0
9
.0
0
1
.0
2
4
.0
2
3
S
V
R
.0
4
7
S
ta
n
d
ar
d
  
vs
  
In
d
i-
vi
d
u
al
iz
ed
 t
re
at
m
en
t
.0
3
1
.0
1
9
.0
2
7
.0
3
1
.0
7
5
M
u
lt
iv
ar
ia
te
 a
n
al
ys
is
 (
co
rr
ec
te
d
 f
or
 b
as
el
in
e 
va
lu
e 
an
d
 a
ge
) 
of
 t
h
e 
in
fl
u
en
ce
 o
f 
ge
n
d
er
, 
re
sp
on
se
 t
o 
tr
ea
tm
en
t 
an
d
 k
in
d
 o
f 
th
er
ap
y 
on
 t
h
e 
m
ea
n
 d
if
fe
re
n
ce
 b
et
w
ee
n
 b
as
el
in
e 
an
d
 f
ol
lo
w
 u
p
 (
co
u
rs
e 
of
 H
ea
lt
h
 R
el
at
ed
 Q
u
al
it
y 
of
 L
if
e)
 o
f 
th
e 
d
if
fe
re
n
t 
d
im
en
si
on
s 
of
 t
h
e 
S
F-
3
6
.
o
n
ly
 s
ig
n
if
ic
an
t 
p
-v
al
u
es
 a
re
 s
h
ow
n
 i
n
 t
h
is
 t
ab
le
.
A
b
b
re
vi
at
io
n
s:
 S
u
st
ai
n
ed
 V
ir
ol
og
ic
al
 R
es
p
on
se
 (
S
V
R
).
 
1204304 Proefschrift Erasmus Universiteit.indd   132 06-06-12   07:48
133
ent dimensions, except for physical component summary scale and general health, were 
significantly different between men and women (Table 2). Response to treatment was 
again significantly influencing general health.
In the multivariate analysis, individualized treatment had a significantly negative influence on 
the course of  HRQL on the dimensions physical component summary scale, bodily pain, vital-
ity and social functioning, compared to patients treated with standard treatment (Table 2).
The presence or absence of  cirrhosis and grade of  fibrosis did not play a role in the course 
of  HRQL in this analysis. Also different kind of  genotypes (1, 4 and 5 versus 2 and 3) did 
not influence changes in HRQL. 
DisCUssioN 
In this study we explored the influence of  PEGIFN-based antiviral treatment with various 
regimens and of  patients characteristics on HRQL before as well as at 24 weeks after 
completion of  treatment. Main determinants of  HRQL in this study were the severity of  
liver disease (non-cirrhosis vs. cirrhosis), age, gender and participating center and – to 
some extent - response to treatment. With regard to the severity of  the liver disease, 
patients with cirrhosis did better compared to those without cirrhosis. We are unable to 
explain this difference.
In our study almost all dimensions of  the SF-36 did not change regardless of  response, indic-
ative of  a satisfying recovery of  patients after cytokine-based therapy. However, a significant 
increase was found on the subscale general health despite a therapy-induced worsening of  
the subscale physical functioning. This improvement was seen in patients with both SVR and 
relapse, whereas non-responders showed a decrease in general health. In our study, interest-
ingly the relapsers who were ignorant of  treatment effect when filling in the questionnaire, 
had a far more higher score on general health compared to the non-responders who were 
aware of  their previous non-response to therapy. This underlines the mental aspects of  the 
impact on HRQL in this disease (14). The observed recovery in HRQL is in line with previous 
studies reporting an improvement on (almost) all different dimensions of  the SF-36 after a 
successful treatment with PEGIFN and RBV compared to baseline scores (2,8,9,10). 
The presence of  cirrhosis did not influence the course of  HRQL during treatment, but 
patients with a cirrhosis had higher scores on some, mostly mental, dimensions of  the 
SF-36 at t=0 and at follow up, which is in contrast with earlier studies (8,15). Patients with 
decompensated cirrhosis were excluded to participate in the study, but still we cannot 
Long-term effects of  treatment and response in patients with chronic hepatitis C on quality of  life. An internatio-
nal, multicenter, randomized, controlled study.
1204304 Proefschrift Erasmus Universiteit.indd   133 06-06-12   07:48
134
C
h
ap
te
r 
7
explain this difference. Higher age was associated with a decrease in HRQL, according to 
literature data (16).
Men and women differed in the course of  HRQL with an increase on scores for men on 
several dimensions and women experiencing a decrease. These differences between men 
and women were also significant in a multivariate analysis for all dimensions except for 
general health. In the general population, men report a higher HRQL (16,17,18), a finding 
possibly of  relevance for our findings. But also, therapy with PEGIFN and RBV might have 
a more intense and more prolonged impact on females. Studies show more severe anemia 
in women during treatment with PEGIFN and RBV (19). As anemia plays an important role 
in HRQL during antiviral treatment this could be one of  the explanations for the observed 
difference (20). With the fixed doses of  PEGIFN women may be treated with higher doses 
of  PEGIFN per kg, which may contribute to more side-effects and a lower HRQL during 
treatment and at 24-weeks follow-up. To our knowledge, only one study found sex differ-
ences in recovery, with males doing slightly worse (21).
HRQL at baseline was found to be differing between the participating centers (in this 
case different countries/cultural regions). In the study by Ware et al (9) a similar observa-
tion was made. Although much attention has been devoted to assure the comparability 
between different cultures and languages, this observation suggests that studies from 
different countries concerning side effects (for instance decrease of  HRQL, but also psy-
chopathology) should be interpreted with caution (22,23). 
An important limitation of  this study is the large number of  variables in relation to the 
number of  participants and the many different treatment schedules. Also the relative high 
number of  drop-outs with data of  192 patients at baseline and of  128 patients at follow 
up could be of  importance, however non-responders or relapsers were not significantly 
more non-compliant compared to responders (data not shown). In retrospect an addi-
tional time point at the end of  treatment would have given more insight.
In conclusion: our findings support the observation, that in general patients exposed to 
PEGIFN-based treatment do recover to their pre-treatment level of  baseline, six months 
after completion of  antiviral therapy or even surpass that level. This underlines again the 
safe profile of  this intensive treatment, irrespective of  the used dosage and/or duration 
in this study. Before treatment and after treatment with PEGIFN in patients chronically in-
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fected with HCV health related quality of  life is mostly influenced by presence of  cirrhosis, 
age, gender, participating center (or country) and response to treatment. Also, awareness 
of  response status to therapy seems important.
Long-term effects of  treatment and response in patients with chronic hepatitis C on quality of  life. An internatio-
nal, multicenter, randomized, controlled study.
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optimal adherence to antiviral treatment for a chronic Hepatitis C virus (HCV) infection 
is crucial for complete eradication of  the virus (as indicated by the attainment of  a sus-
tained virological response). However the current therapy with peginterferon (PEGIFN) and 
ribavirin (RBV) is hindered by many side effects. one of  the most frequently observed, 
severe side effects is psychiatric disturbance such as depression, anger, anxiety and cog-
nitive impairment. This thesis focuses on the manifestation, the underlying pathophysi-
ological mechanisms, the prevention, detection and treatment of  psychiatric disturbances 
due to cytokine-based treatment (as PEGIFN is). Cytokine-based treatment influences a 
variety of  other organ systems apart from the central nervous system. A separate chapter 
is included on the effects of  PEGIFN on semen quality. 
Antiviral treatment  and psychopathology - review –
Chapter 1 reviews both the psychopathology in the natural history of  HCV patients and 
in patients during therapy with PEGIFN, and theories about the pathophysiology underly-
ing these psychiatric disorders. Psychopathology appears to be a common phenomenon 
in HCV, not only because of  the social background and associated problems of  these 
patients but probably also due to the chronic infection itself. This psychopathology com-
plicates the start and completion of  antiviral treatment with PEGIFN, as these symptoms 
frequently exacerbate during the treatment. on top of  this, cytokine-induced psychiatric 
disturbance is one of  the main reasons to stop the antiviral therapy prematurely with the 
result that chances of  clearing the virus decline considerably.
Cytokine induced psychiatric side effects not only include depressive syndromes accord-
ing to current psychiatric standards such as the DSM-IV, but a wider range of  individual 
symptoms. For instance, increased irritability has been described as occurring frequently 
without a full depressive episode being present.
Several biochemical pathways are proposed by which PEGIFN might signal the brain to 
induce these psychiatric symptoms such as signaling at the blood-brain barrier, via the 
vagal nerve and by lowering of  the availability of  tryptophan (TRP) to the central ner-
vous system. This leads to central changes, such as changes in the cytokine network in 
the brain, in brain mono-aminergic activity and the hypopituitary-hypophysis-adrenal axis 
(which regulate adaptation to stress). Selective serotonin reuptake inhibitors (SSRI’s) play 
a key role in the treatment of  these psychiatric disturbances and are widely advocated in 
S
u
m
m
ar
y 
an
d
 d
is
cu
ss
io
n
1204304 Proefschrift Erasmus Universiteit.indd   140 06-06-12   07:48
141
this setting. This is perhaps surprising, in view of  the doubts that have been raised in the 
last decade about the efficacy of  modern antidepressants.
Antiviral treatment and psychopathology - Clinical studies –
Prophylactic treatment with SSRIs in patients treated with high doses of  interferon was 
effective in an earlier study with oncology patients. Also some studies in selected HCV pa-
tients suggested a beneficial effect of  prophylactic treatment with SSRIs in patients who 
had (PEGIFN-induced) depressive syndromes during previous antiviral treatment. Never-
theless, the efficacy and beneficial effect of  prophylactic SSRI use in unselected and treat-
ment naive HCV patients during therapy with PEGIFN is still to be determined. Chapter 2 
reports on a double-blind placebo controlled randomized clinical trial to explore this. The 
incidence of  a clinically relevant PEGIFN/ribavirin induced increase of  individual symp-
toms (of  lowered mood, hostile feelings and inner tension), but also of  the (syndromal) 
major depression was lower in patients who received prophylactic treatment with the SSRI 
escitalopram compared to those who received placebo. one other large study confirms the 
beneficial effect of  prophylactic use of  an SSRI; however, several smaller studies could not 
confirm this. Identification of  patients who are most at risk to develop psychopathology 
due to the treatment with PEGIFN gives us the opportunity to select patients who benefit 
the most from prophylaxis with an SSRI. In Chapter 3 an analysis of  the trial mentioned 
before demonstrated that patients with a previous history of  intravenous drug use and 
depression were most at risk to develop a depression due to PEGIFN. This is in accordance 
with previous studies. More important, in this trial patients at risk were partly protected 
from developing (more) depressive symptoms due to PEGIFN by the use of  escitalopram.
Concluding, SSRIs do not only play an important role in the treatment of  PEGIFN-induced 
psychopathology, but probably also in the prevention of  these side effects if  given pro-
phylactically as our results strongly suggested. This study closely resembled daily clinical 
practice of  unselected HCV patients and we consider the observed decrease in psychiatric 
complaints as clinically relevant. The prevention of  a major depression (syndromal de-
pression, our secondary endpoint) by prophylaxis with escitalopram was most in line with 
existing data and is clinically relevant anyway. This is less clear for our primary endpoint 
as there is no equivalent of  it in the literature on PEGIFN-induced psychiatric disturbance. 
However, at the outset, we were particularly interested to gain insight into the prevalence 
Summary and discussion
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and prevention of  psychiatric symptomatology defined broader then only major depres-
sion. In our view, this could be clinically relevant most notably in view of  the long duration 
of  antiviral treatment. For instance, we assumed that increased irritability during many 
months of  treatment resulting in marital conflicts or severe concentration difficulties re-
sulting in underperformance at work, again over a period of  many months, need not to go 
along with the presence of  a full-blown depressive syndrome but yet might well compro-
mise quality of  life of  patients and add to the burden of  treatment. To our knowledge, no 
other studies took this standpoint. At the end, we feel justified in taking this approach as 
the cumulative incidence of  clinically relevant increase of  the selected individual target 
symptoms (lowered mood, concentration difficulties, hostile feelings and increased ten-
sion) clearly exceeded the incidence of  major depression.
Form a standpoint of  ethics, one might argue that a group of  patients – and perhaps 
even a considerable percentage of  it - in the study was treated with an SSRI although 
they would not have developed psychopathology anyway. This is true, but the side effects 
of  this treatment seemed not to outweigh the side effects PEGIFN and RBV cause. No 
patient stopped because of  side effects of  the SSRI. However this study was not designed 
to monitor these side effects properly. A much larger study is needed to do this before 
standard prophylaxis with an SSRI is to be introduced. However, for the selected patients 
at risk (the patients with a previous history of  intravenous drug use and depression) the 
introduction of  prophylactic treatment seems to be very reasonable.
Antiviral treatment and psychopathology – Biochemical background –
The high incidence of  psychiatric symptoms during antiviral immunotherapy and the ef-
fectiveness of  SSRIs at least suggest an influence of  PEGIFN on the brain function: periph-
erally administrated cytokine-based treatment leads to central changes. For this reason 
PEGIFN-induced psychopathology has been used as a model to study the interaction/
communication of  the immune system with the brain. Several theories have been intro-
duced on the effector mechanisms underlying this interaction: alterations in brain mono-
aminergic activity, alterations in brain cytokines, accumulation of  neurotoxic metabolites 
and changes in the hypothalamic-pituitary-adrenal (HPA) axis.
Several previous studies explored peripheral changes reflecting the above mentioned ef-
fector mechanisms in patients treated with PEGIFN. We focussed on different peripheral 
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parameters reflecting brain metabolism in relation to tryptophan and monoaminergic 
neurotransmission in a broader sense. In Chapter 4 and 5 we describe the biochemical 
changes in two different patient groups treated with PEGIFN and RBV. As observed before, 
PEGIFN decreases peripheral levels of  TRP. TRP is the precursor of  the monoamine sero-
tonin (5-hydroxytryptamine; 5-HT), and as a consequence PEGIFN could inhibit peripheral 
and central 5-HT synthesis. The Phenylalanine/Tyrosine (PHE/TYR) ratio was used as a 
marker of  the availability of  tetrahydrobiopterin, an important co-factor of  the synthesis 
of  5-HT but also of  the monoamines dopamine and noradrenaline. A consistent rise in 
PHE/TYR-ratio was seen, correlating with development of  psychopathology. Strikingly, 
this rise in the PHE/TYR-ratio was consistently seen in other studies done in oncology 
patients treated with (PEG)IFN. Also levels of  the neurotoxic metabolite kynurenin in-
creased during PEGIFN treatment. The level of  the hormone prolactine is influenced by 
dopamine synthesis. The observed rise in prolactin levels correlated with emerging symp-
toms of  anger and depression. At last the decreased ratio between citruline and arginine 
is thought to reflect an impaired nitric oxide synthesis, which in turn influences the 5-HT 
release. Concluding PEGIFN might not only influence 5-HT synthesis (via decreased levels 
of  TRP), but could also induce psychopathology (or increase the vulnerability to develop 
psychiatric symptoms) by influencing the synthesis of  dopamine and noradrenaline and 
by formation of  neurotoxic metabolites. However, in our research, few relationships were 
observed between biochemical alterations and the emergence of  psychic complaints
Notably only minor differences were seen in these biochemical parameters between pa-
tients treated with the SSRI escitalopram or placebo. However, in the escitalopram group 
significantly less psychopathology was observed. This strongly suggests that the effect of  
the SSRI is downstream in the cascade of  the switched systems of  the brain.
Earlier studies on the pathophysiology of  (PEGIFN-induced) depressive syndromes fo-
cussed mainly on TRP depletion. More recent studies, like ours, show that the effector 
mechanism is far more complex. PHE/TYR ratio was the most consistent changed pa-
rameter with the most consistent relation to clinical changes. Therefore this parameter 
needs to be more studied in PEGIFN treated patients, leading to more focus on changes 
in dopamine and adrenaline synthesis. However correlation with clinical observed psycho-
pathology was not only small but also studied in peripheral parameters reflecting brain 
metabolism. Still further research in PEGIFN induced psychopathology remains interest-
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ing as it gives the opportunity to study the role of  (peripheral) cytokines (as part of  the 
immune system) in the pathogenesis of  psychiatric symptoms in a rather fixed setting. 
Functional brain imaging could be of  help to clarify this pathogenesis.
Antiviral treatment and semen quality
Because of  the unknown effects of  PEGIFN on semen double contraception during and 
until six months after treatment with PEGIFN is required. Chapter 6 is a descriptive study 
on semen quality performed in 20 HCV patients. Semen abnormalities were frequently 
seen in men prior to treatment with PEGIFN but did not increase during treatment. Also 
decreased sperm DNA integrity, which is associated with poor reproductive outcome and 
with a higher miscarriage risk, was not observed due tovan treatment with PEGIFN and 
RBV. These results raise doubts about the standard contraception that is advised. Larger 
studies are needed to get more details on this subject.
Antiviral treatment and quality of life
Hepatitis C decreases health related quality of  life (HRQL) which is further diminished by 
antiviral therapy with PEGIFN due to the side effects. However earlier studies also show an 
improvement of  HRQL after successful treatment. Chapter 7 explores the course of  and 
factors associated with HRQL in patients given individualized or standard treatment based 
on early treatment response (Ditto-study). Main determinants of  HRQL were severity of  
liver disease, age, gender, participating center and response to treatment. Antiviral ther-
apy might have a more intense and more prolonged negative impact on female patients 
because of  the fixed and sometimes high doses of  PEGIFN used in the trial.
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sAmeNVAttiNG eN DisCUssie
Bij de antivirale behandeling van een chronische hepatitis C virus (HCV) infectie is opti-
male therapietrouw van cruciaal belang voor de complete eradicatie van het virus (aange-
duid als een blijvende virologische repsons). Bij de huidige behandeling met peginterferon 
(PEGIFN) en ribavirine (RBV) treden echter frequent bijwerkingen op die het niet gemakke-
lijk maken de behandeling te volgen. De meest frequent optredende groep bijwerkingen is 
psychiatrisch van aard: depressie, agressie, angst en cognitieve veranderingen. Dit proef-
schrift richt zich op de manifestatie, het onderliggende pathofysiologische mechanisme, 
de preventie, detectie en behandeling van deze psychiatrische ontregeling ten gevolge van 
behandeling met het cytokine PEGIFN. Therapieën met cytokines hebben naast invloed op 
het centraal zenuwstelsel ook invloed op verscheidene andere organen. Een apart hoofd-
stuk is daarom gewijd aan het effect van PEGIFN op de kwaliteit van sperma.
Antivirale behandeling en psychopathologie – bespreking-
Hoofdstuk 1 bespreekt zowel de psychopathologie zoals die beschreven is in het natuurlijk 
beloop van patiënten met een HCV-infectie (dus zonder behandeling) en bij patiënten die 
behandeld worden met PEGIFN, alsook theorieën over de onderliggende pathofysiologie 
van deze psychiatrische stoornissen. Psychopathologie is een veel voorkomend probleem 
onder HCV-patiënten. Dat heeft niet alleen te maken met de sociale achtergrond met 
bijhorende problematiek van deze patiënten (velen liepen hun infectie op door intrave-
neus drugsgebruik), maar waarschijnlijk ook met de gevolgen van een chronische infectie 
zelf. Deze psychopathologie compliceert het volbrengen van de antivirale behandeling met 
PEGIFN, te meer omdat deze voor de behandeling aanwezige psychiatrische symptomen 
gedurende de antivirale behandeling vaak verergeren. Deze cytokine-geïnduceerde psy-
chiatrische klachten zijn dan ook één van de voornaamste redenen is om de behandeling 
voortijdig te stoppen, en voortijdig stoppen resulteert weer in een sterk verminderde kans 
om het virus definitief  te klaren.
Cytokine-geïnduceerde psychiatrische klachten behelzen niet alleen depressieve syndro-
men (bijvoorbeeld de depressieve episode zoals die beschreven is volgens de huidige DSM-
IV criteria), maar ook een scala aan individuele psychische symptomen. Toegenomen geïr-
riteerdheid bijvoorbeeld, zonder dat er verder een depressieve episode aanwezig is, komt 
bijvoorbeeld frequent voor.
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Er zijn verschillende voorgestelde routes beschreven waarlangs PEGIFN het brein kan be-
reiken en de hersenfunctie kan beïnvloeden om deze psychiatrische symptomen te veroor-
zaken. Bijvoorbeeld via de bloed-hersenbarrière (waar cytokines in het bloed boodschap-
pen kunnen afgeven die worden doorgeleid naar de hersenen zelf), via de nervus vagus 
of  door verminderde beschikbaarheid van tryptofaan aan het centrale zenuwstelsel. Dit 
leidt waarschijnlijk weer tot veranderingen in de hersenen zoals activatie van het cytokine 
netwerk in het brein, veranderingen in de mono-aminerge activiteit (een aantal van de 
prikkeloverdrachtstoffen die de zenuwcellen gebruiken om boodschappen over te brengen) 
of  in de hypothalamus-hypofyse-bijnierschors as (die de adaptatie aan stress reguleert). 
Specifieke serotonineheropnameremmers (SSRI’s) spelen een hoofdrol in de behandeling 
van deze psychiatrische klachten en worden daarom voor deze indicatie aanbevolen. Dit is 
misschien verrassend gezien de twijfels die er de laatste decennium gerezen zijn over de 
effectiviteit van de moderne antidepressiva.
Antivirale therapie en psychopathologie – klinische studies- 
Profylactische behandeling met een SSRI was effectief  in eerdere studies met oncologi-
sche patiënten die behandeld werden met hoge dosis interferon. ook enkele studies met 
geselecteerde HCV patiënten suggereren een gunstig effect van profylactische behande-
ling met een SSRI bij patiënten die een (PEGIFN-geïnduceerde) depressie hadden ten tijde 
van eerdere antivirale therapie. 
Desondanks is de effectiviteit en het gunstige effect van profylactisch gebruik van SSRI’s 
in niet-geselecteerde, niet-eerder behandelde HCV patiënten nog onbekend. Hoofdstuk 2 
beschrijft een dubbelblinde, gerandomiseerde en met placebo gecontroleerde studie die dit 
onderzoekt. De incidentie van een klinisch relevante, door PEGIFN-geïnduceerde, toename 
van individuele symptomen (zoals verminderde stemming, vijandige gevoelens en innerlijke 
spanning) evenals de incidentie van een depressieve episode (depressief  syndroom) was la-
ger in patiënten die profylactisch behandeld werden met de SSRI escitalopram vergeleken 
met patiënten die placebo kregen.
Een andere, grotere studie bevestigt het gunstig effect van profylactisch gebruik van een 
SSRI; andere studies tonen dit echter niet aan. Het identificeren van patiënten die het 
grootste risico hebben om depressieve klachten te ontwikkelen ten gevolge van behande-
ling met PEGIFN stelt ons in staat patiënten te selecteren die het meest baat zullen heb-
ben van profylactische behandeling met een SSRI. In Hoofdstuk 3 laat een aanvullende 
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analyse van de hiervoor genoemde studie zien dat patiënten die eerder intraveneus drugs 
gebruikten en eerder in hun leven een depressie hadden, het grootste risico lopen op het 
ontwikkelen van een depressief  syndroom ten gevolge van PEGIFN. Dit komt overeen met 
eerdere studies. Nog belangrijker, in deze studie waren deze ‘at risk’ patiënten gedeeltelijk 
beschermd door het gebruik van escitalopram tegen het ontwikkelen van (meer) depres-
sieve klachten ten gevolge van PEGIFN.
Concluderend spelen SSRI’s niet alleen een belangrijke rol in de behandeling van PEGIFN-
geïnduceerde psychopathologie, maar waarschijnlijk ook, zo is de sterke indruk op grond 
van onze resultaten, in de preventie van deze bijwerkingen als deze SSRI’s profylactisch 
worden gegeven. De patiënten die aan deze studie deelnamen kwamen sterk overeen met 
de niet-geselecteerde HCV patiënten die men in de dagelijkse klinische praktijk ziet. ook 
beschouwen we de geobserveerde afname in psychiatrische klachten zoals gedaalde stem-
ming en prikkelbaarheid als klinisch relevant. De preventie van een klinische depressie 
(depressieve episode volgens DSM-IV-criteria, ons secundaire eindpunt) door profylaxe 
met escitalopram was het meest in overeenkomst met al eerder beschreven data en is in 
ieder geval klinisch relevant. Dit is misschien minder duidelijk voor ons primaire eindpunt, 
omdat hiervan geen equivalent te vinden is in de literatuur over PEGIFN-geïnduceerde 
psychopathologie. Echter, bij de opzet van de studie, waren we vooral geïnteresseerd om 
meer inzicht te krijgen in de prevalentie en preventie van psychiatrische symptomen die 
een breder gebied beslaan dan alleen een depressief  syndroom. Vanuit ons standpunt is 
de studie van individuele symptomen klinisch relevant gezien de lange behandelduur van 
de antivirale therapie. onze veronderstelling was bijvoorbeeld dat de ernst en het ermee 
gepaard gaande lijden van bijvoorbeeld toegenomen geïrriteerdheid gedurende vele maan-
den resulterend in huwelijksproblemen, of  van ernstige concentratieproblemen resulte-
rend in onderprestaties op werk (ook voor vele maanden) misschien niet overeenkomen 
met de ernst en het lijden van een klinische depressie. We veronderstelden dat deze indivi-
duele symptomen wel degelijk van grote invloed zouden zijn op de kwaliteit van leven van 
patiënten en de zwaarte van de behandeling en ook bij méér patiënten zullen voorkomen 
dan een volledig depressief  syndroom. Voor zover wij weten zijn er geen andere studies 
van dit standpunt uitgegaan. Uiteindelijk voelen wij ons gesteund in onze benadering ge-
zien het feit dat de cumulatieve incidentie van de gekozen symptomen (stemmingsdaling, 
concentratieproblemen, agressieve gevoelens en toegenomen angst en spanning) duidelijk 
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de incidentie van een klinische depressie overschrijdt.
Vanuit ethisch oogpunt kan men tegenwerpen dat een groep patiënten – en misschien 
zelfs een aanzienlijk percentage – in de studie profylactisch behandeld is met SSRI’s 
terwijl zij hoe dan ook geen psychopathologie ontwikkeld hadden. Dit is zeker waar, maar 
het alternatief  zou geweest zijn dat de patiënten eerst een zekere mate van depressieve 
of  andere psychiatrische symptomen ontwikkeld zouden moeten hebben voordat we ze 
behandeld zouden hebben met een antidepressivum. En zoals eerder gesteld, psychiatri-
sche bijwerkingen zijn een voorname reden om de antivirale behandeling te stoppen, wat 
ook ongunstig zou zijn voor de patiënt. Verder houdt een depressie ook een zeker risico in, 
bijvoorbeeld op suïcide. Gelukkig bleken de bijwerkingen van deze interventie de bijwerkin-
gen ten gevolge van PEGIFN en RBV niet te overstijgen. Geen van de patiënten stopte de 
behandeling ten gevolge van de bijwerkingen van de SSRI. Aan de andere kant was deze 
studie niet ontworpen om alle mogelijke bijwerkingen gericht te inventariseren. Het geheel 
overziend zijn meer en veel grotere studies nodig alvorens profylactische behandeling met 
een SSRI ingevoerd kan worden. Daarentegen lijkt voor geselecteerde patiënten (de patiën-
ten met een voorgeschiedenis van intraveneus drugsgebruik en depressie) de introductie 
van profylactische behandeling op grond van onze resultaten wel plausibel.
Antivirale behandeling en psychopathologie- Biochemische achtergrond- 
De toegenomen incidentie van psychiatrische symptomen ten tijde van antivirale immuno-
therapie en de effectiviteit van SSRI’s suggereert tenminste invloed van PEGIFN op het func-
tioneren van het brein: perifeer toegediende cytokines leiden tot centrale veranderingen. 
om deze reden werd PEGIFN-geïnduceerde psychopathologie gebruikt als een model om de 
interactie/communicatie tussen het immuunsysteem en het brein te onderzoeken. Verschil-
lende theorieën zijn geïntroduceerd over de effector-systemen die ten grondslag liggen aan 
deze interactie: vooral wordt gedacht aan activatie van immuunactiviteit in de hersenen zelf, 
aan veranderingen in monoaminerge activiteit in het brein, opstapeling van neurotoxische 
metabolieten en veranderingen in de hypothalamus-hypofyse-bijnierschors as.
Verschillende eerdere studies verkenden perifere parameters (laboratorium onderzoek in 
perifeer bloed) in patiënten die met PEGIFN werden behandeld, waarvan men aanneemt 
dat die parallel lopen aan deze hierboven vermelde veranderingen in de effectorsyste-
men in de hersenen. Wij richtten ons vooral op de verschillende perifere parameters die 
het metabolisme van het brein weerspiegelen in relatie tot tryptofaan en monoaminerge 
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neurotransmissie in bredere zin. In Hoofdstuk 4 en 5 beschrijven we de biochemische ver-
anderingen die optraden in twee verschillende groepen van patiënten die behandeld wer-
den met PEGIFN en RBV. Zoals al eerder werd beschreven, verlaagde PEGIFN de perifere 
spiegels van tryptofaan. Tryptofaan is de voorloper van de monoamine serotonine (5-hy-
droxytryptamine; 5-HT), en dientengevolge zou PEGIFN de perifere en centrale synthese 
van 5-HT remmen met als mogelijk gevolg psychiatrische verschijnselen zoals depressie. 
De phenylalanine/tyrosine (PHE/TYR) ratio werd gebruikt als een marker voor de beschik-
baarheid van tetrahydrobiopterine, een belangrijke cofactor in de synthese van 5-HT, maar 
ook de aanmaak van de monoamines dopamine en noradrenaline. Een consistente toena-
me in de PHE/TYR ratio werd gemeten, correlerend met de ontwikkeling van sommige as-
pecten van de opgetreden psychopathologie. opvallend genoeg werd deze toename in de 
PHE/TYR ratio ook bij herhaling gezien in studies met oncologiepatiënten die met (PEG)
IFN werden behandeld. Dus mogelijk beïnvloedt therapie met cytokines de activiteit van 
tetrahydrobiopterine en via tetrahydrobiopterine ook de neurotransmissie met stoffen als 
5-HT en dopamine. De spiegel van perifeer dopamine staat onder invloed van prolactine. 
De gemeten toename van de spiegel van prolactine correleerde met toenemende klachten 
van boosheid en depressie. ook spiegels van de neurotoxische metaboliet kynurenine ste-
gen gedurende de behandeling met PEGIFN. Tenslotte werd de waargenomen afname in 
de ratio tussen citrulline en arginine verondersteld de aangedane nitride oxide-synthese te 
weerspiegelen. Stikstof  beïnvloedt weer de 5-HT afgifte.
Samenvattend – op basis van deze gevonden veranderingen gemeten in perifeer bloed – 
zou PEGIFN in de hersenen niet alleen de 5-HT synthese (via bijvoorbeeld verminderde 
spiegels van tryptofaan) kunnen beïnvloeden, maar zou PEGIFN ook psychopathologie 
kunnen induceren (of  de kwetsbaarheid om psychiatrische symptomen te ontwikkelen 
verhogen) door de synthese van dopamine en noradrenaline te beïnvloeden en door de 
vorming van neurotoxische metabolieten. Echter werden er maar weinig consistente corre-
laties gezien tussen biochemische perifere veranderingen en de toename in psychiatrische 
klachten.
opmerkelijk genoeg werden er maar weinig verschillen in de biochemische parameters 
gezien tussen de patiënten die met escitalopram of  placebo werden behandeld, terwijl 
er in de placebogroep meer psychopathologie werd gezien. Dit wekt sterk de indruk dat 
de SSRI weliswaar werkt op de serotonerge neurotransmissie in de hersenen maar zijn 
Samenvatting en discussie
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uiteindelijke therapeutische effect verderop in een cascade van geschakelde systemen in 
het brein heeft.
Eerder verrichte studies naar de pathofysiologie van (PEGIFN-geïnduceerde) depressieve 
symptomen richtten zich vooral op de depletie van tryptofaan. Daar konden we in onze 
studies geen aanwijzingen voor vinden. Mogelijk illustreren studies als de onze dat het ef-
fector mechanisme veel complexer is en dat er diverse effector mechanismes tegelijkertijd 
bij betrokken zijn, zoals misschien een effector mechanisme waarvan tetrahydriobiopte-
rine deel uitmaakt. PHE/TYR ratio was namelijk de meeste consistente parameter die 
veranderde met ook hierbij de meest consistente correlatie met klinische veranderingen. 
Daarom zou deze parameter verder onderzocht dienen te worden in patiënten die met 
PEGIFN behandeld worden, zodat er meer aandacht komt voor de veranderingen in de 
synthese van dopamine en noradrenaline. Desondanks blijft de studie naar de PEGIFN-
geïnduceerde psychopathologie interessant omdat het de mogelijkheid biedt om ten tijde 
van toediening van (perifere) cytokines met seriële metingen de pathogenese van door 
die cytokines uitgelokte psychiatrische symptomen te onderzoeken. Functionele beeldvor-
ming van de hersenen zou hierbij een rol kunnen spelen om deze psychopathologie verder 
te verklaren.
Antivirale behandeling en de kwaliteit van sperma
Vanwege de onbekende effecten van PEGIFN op sperma is dubbele anticonceptie beno-
digd gedurende de behandeling met PEGIFN en tot zes maanden nadien. Hoofdstuk 6 is 
een beschrijvende studie van twintig HCV patiënten over kwaliteit van sperma. Afwijkingen 
in sperma werden frequent gezien in mannen met een HCV infectie voor behandeling met 
PEGIFN, dit nam echter niet toe ten tijde van de behandeling. ook een afname in DNA in-
tegriteit van sperma, dat geassocieerd is met verminderde spontane zwangerschappen en 
een toename van miskramen, werd niet gezien ten gevolge van behandeling met PEGIFN 
en RBV. Deze resultaten doen twijfelen aan het nu standaard advies tot dubbele anticon-
ceptie tijdens en na de behandeling met PEGIFN.
Antivirale behandeling en kwaliteit van leven
Een chronische HCV infectie vermindert de kwaliteit van leven. Vanwege de bijwerkingen 
van PEGIFN vermindert deze kwaliteit nog verder ten tijde van de behandeling. Echter, na 
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een succesvolle behandeling neemt deze kwaliteit van leven juist weer toe. Hoofdstuk 7 
verkent het beloop van en de factoren die een rol spelen op de kwaliteit van leven in patiën-
ten die dan wel standaard dan wel geïndividualiseerde behandeling kregen gebaseerd op 
vroege virologische respons (Ditto-studie). De belangrijkste determinanten voor kwaliteit 
van leven waren ernst van de leverziekte, leeftijd, participerend centrum en respons op 
behandeling. Antivirale behandeling heeft mogelijk een meer intens en meer aanhoudend 
negatief  effect op vrouwen mogelijk vanwege de vaste doseringen (vrouwen zijn gemiddeld 
lichter) van PEGIFN die gebruikt werden in deze studie.
Samenvatting en discussie
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Dit deel van het ‘boekje’ biedt me de gelegenheid de mensen te bedanken die een bijdrage 
hebben geleverd aan het promotietraject en het uiteindelijke proefschrift. Ik kan met alle 
recht zeggen dat ik nog nooit ergens zoveel moeite voor heb moeten doen. Maar niet alleen 
voor mij was het een kwestie van lange adem, zeker ook voor de mensen die, van dichtbij 
of  verderaf, een rol hebben gespeeld bij het afronden.
Allereerst co-promotor Dr. A.R. Van Gool. Beste Arthur, hartelijk dank voor je niet-afla-
tende inzet waarbij je van begin tot eind mij begeleid hebt. Van het opzetten van het 
studieprotocol, samen patiënten beoordelen, analyseren van resultaten tot het opstellen 
van de manuscripten, alles ging met grote precisie en kundigheid. ook na je vertrek uit de 
academie bleef  je regelmatig degene die de bijna-stilstaande kar weer in beweging kreeg. 
Dan mijn andere co-promotor, Dr. R.J. de Knegt. Beste Rob, dank voor alle tijd en energie 
die je in dit promotietraject gestoken hebt. Wat een prestatie dat je idee uit de Groningen-
periode uiteindelijk tot zo’n project is geworden. ondanks dat je wel eens moest zuchten 
als dingen niet liepen zoals gedacht of  afgesproken, bleef  je in de zaak geloven en opti-
mistisch. 
Prof.dr. H.L.A. Janssen, beste Harry. Als promotor ben je in de loop der jaren steeds meer 
betrokken geraakt bij het onderzoek. Indrukwekkend hoe je zo’n grote onderzoeksgroep 
steeds verder weet uit te breiden en op steeds hoger niveau weet te brengen. Door onder an-
dere je deadlines, die ik werkelijk nodig heb, is het er nu toch van gekomen. Dank daarvoor!
Prof.dr. M.W. Hengeveld, met u als promotor vanuit de afdeling Psychiatrie, is het nu wer-
kelijk een gezamenlijk effort geworden. Dank hiervoor.
Prof.dr. B. van Hoek, Prof.dr. W.J.G Hoogendijk, Prof.dr. J.J. van Busschbach dank voor het 
goedkeuren van het manuscript en uw deelname in de promotiecommissie.
Dr. D. Fekkes, beste Durk, dank voor al het werk dat je verrichtte bij de biochemische be-
palingen, de beoordelingen van de manuscripten en het uiteindelijk zitting nemen in de 
commissie.
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Prof.dr. H.J. Metselaar (beste Herold) en Prof.dr. K. Brinkman dank voor uw deelname in 
de commissie.
Prof.dr.J.P.Drenth, beste Joost. Het was een altijd weer een waar genoegen om op de 
maandagen de reis naar Nijmegen te maken. Het welkom daar was warm en alles was 
goed georganiseerd. Hartelijk dank hiervoor. ook natuurlijk Karin hartelijk dank voor alle 
hulp.
ook dank voor Dr. C.J. Weegink voor de studiepatiënten in Amsterdam.
Dr. R.A. de Man, beste Rob. Zeker na contact met collega’s uit het land, vind ik het steeds 
meer een voorrecht om de opleiding tot MDL-arts in het Rotterdamse te doen. Als oplei-
der bent u voor een groot deel betrokken bij de kwaliteit van deze opleiding. Daarnaast 
waardeer ik het ook erg dat ik binnen de opleiding de gelegenheid heb gekregen om een 
periode extra tijd te steken in het afronden van het promotietraject. Dank hiervoor.
ook veel dank voor het CRB. om een studie te doen volgens alle huidige nationale en in-
ternationale richtlijnen is hulp van ons CRB zo ongeveer onontbeerlijk geworden. Eerst de 
trial nurses. Cokkie, veel dank voor alles. Het was altijd een genoegen met je te werken. Je 
betrokkenheid was groot, zelfs buiten de studie om (ritjes naar Leiden voor reparaties aan 
auto’s etc). ook heb ik met veel plezier samengewerkt met Anneke en Lucille. Heleen, onze 
reis naar Rome was de kers op de taart. Dan de dames van het bureau boven: Gaalda, 
Wanda, Elke en Irene hartelijk dank voor al jullie hulp.
Ans, Elly en Marieke bedankt voor de nauwkeurige verwerking en bepalingen uit de vele 
buisjes bloed die ik langs kwam brengen.
ook iedereen van de polikliniek wil ik hartelijk bedanken voor hun ‘special treatment’ die 
studiepatiënten en zeker HCV-patiënten wel eens nodig hebben.
Bettina, zonder jou zouden vele manuscripten stranden op de klippen van onder andere 
multivariate analyses en correcties voor meerdere metingen. Gelukkig stond je steeds 
klaar om alles er weer veilig doorheen te loodsen. Met de cursus voor beginnende promo-
vendi wordt je steeds meer de mater familias van de arts-onderzoekers waarmee je ook 
nog eens heel goed kan shoppen of  een feestje vieren! Geweldig!
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Last, but not least alle lof  aan M en M. Margriet, ik moet toegeven dat ik na de afgelopen 
jaren niet meer bang voor je ben. Daarom promoveer ik gewoon op de verjaardag van je 
zoon. Samen met Marion zijn jullie een super-duo dat bergen werken verzet. Ik kan met 
werkelijk alles bij jullie terecht en altijd ga ik weer met een lach weg uit jullie kamer. 
Marion, seriously, zeker met de laatste ‘loodjes’ was al je inspanning onmisbaar. Enorm 
bedankt!
Promoveren op de dakpoli doe je niet alleen. omringd door ‘broeders en zusters in de ver-
drukking’ als bijvoorbeeld je protocol opnieuw naar de METC moet of  de inclusie maar niet 
wil vlotten. Maar ook de vele kopjes koffie, borrels in Dizzy en congresbezoeken samen met 
jullie maken de periode als arts-onderzoeker een unieke tijd. Collega’s hartelijk dank! In het 
bijzonder mijn, inmiddels vele, roomies; Aafke, Bart, Els, Erik, Hajo, Joyce en Paul. En mijn 
hepatitis C-buddies Ad, Daphne, Mark, Robert en Jilling (ik zie uit naar je terugkeer uit het 
verre Deventer). Annemarie, Claudia, Dew, Edith, Jildou, Jolanda, Jurriën, Lieke, Manon, 
Martijn, Marion, Sanna en Sarwa wat leuk dat jullie nog steeds mijn collega’s zijn.
Het leven naast promoveren gaat gelukkig gewoon door. 
Maria en Naomi, na al die jaren, blijkt onze vriendschap wel tegen wat bestand. Steeds 
weer pakken we na kortere of  langere tijd de draad weer op.
´De Antwerpenaren´ Janneke & Wouter, Willeke & Frank, Anneke, Peter & Corien, Albert & 
Hanna, Arian & Jessica, Marjan & Martijn. Daar begon het allemaal, nu over het hele land 
(en daarbuiten) verspreid. Een onvergetelijke tijd.
De ‘oude ballen’ Jaco, Lydia, Willem, Goseline, Robin en Dik. Van studenten tot burgers, 
we gaan gewoon op oude voet door. 
Naast semi-filosofische bespiegelingen ook goed eten en mooie reisjes, wat een geweldige 
combinatie. Menno, Marian, Janna Marie, Henk en Corné, ik hoop dat we dit lang volhou-
den. Annelieke, je deed even niet mee vanwege je vertrek naar Zuid-Afrika. Wat leuk om je 
daar opgezocht te hebben. Zo goed dat je weer terug bent! Al je goede ideeën voor koken, 
film, theater etc zijn veel te leuk, dus alsjeblieft niet die boerderij in het oosten van het land.
Sport verbroedert, tennis dus ook. Joost, Willem, Sander, Janneke en Hanke dank voor de 
vele ontspanning op en naast de baan. Maarten (zoals beloofd), van jou leren we hoe het 
eigenlijk moet.
Dankwoord
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Bas & Jits, Caro & Ben, Gerda & Tijmen, Tinus & Jootje, Car en Boudie: de ‘tussencatego-
rie’ oud-huisgenoten, lief  en leed delen we. Ik hoop nog erg lang. Lieve Carina, dank dat je 
altijd klaar staat met onder andere al je praktische adviezen. Had ik maar iets meer van je 
discipline. Lieve Caro, wat leuk dat je tussen dit moment van schrijven en de uiteindelijke 
druk moeder zal zijn geworden. Dank voor je vriendschap! Spijkerboer, nu eindig je toch in 
Barneveld. Hoop wel dat ik je nog vaak zal blijven zien (rij wel voorzichtig…).
Lieve Boudie, al zoveel jaren vriendschap, we hebben ons eerste jubileum al gehad. En het 
wordt alleen maar beter en leuker. Ben nieuwsgierig hoe we er voor staan bij ons volgend 
jubileum. Dank voor de vele avonden, vakanties, je geduld, luisteren, het klussen etc…te 
veel om op te noemen.
Lieve Pa, Merthus, Janette, Astrid, Frank en Luc. Je familie is er altijd voor je, zeker in 
moeilijke tijden. Zo is het altijd goed thuiskomen. Dank! Wat missen we ma.
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157Curriculum Vitae
CUrriCULUm VitAe
De auteur van dit proefschrift werd geboren op 2 oktober 1978 te Hendrik-Ido-Ambacht. 
Na het behalen van zijn eindexamen VWo aan het Wartburg College te Rotterdam, startte 
hij in 1996 met de studie Geneeskunde aan de Medische Faculteit van de Universiteit 
Antwerpen. Na twee kandidaturen en na uiteindelijk ingeloot te zijn, vervolgde hij zijn 
studie Geneeskunde aan de Erasmus Universiteit te Rotterdam. In 2001 behaalde hij zijn 
doctoraal examen en volgden twee jaar co-schappen. Na het artsexamen in 2003 was hij 
drie maanden arts-assistent psychiatrie in de Delta Bouman Kliniek. Aansluitend was hij 
werkzaam als arts-assistent Inwendige Geneeskunde in het Ikazia ziekenhuis te Rotter-
dam tot december 2004. Nadien startte hij zijn promotieonderzoek op de afdeling Maag-, 
Darm- en leverziekten onder leiding van Prof. dr. H.L.A. Janssen, Dr. R.J. de Knegt en (van-
uit de afdeling psychiatrie) Dr. A.R. Van Gool naar de bijwerkingen van de behandeling van 
Hepatitis C. In 2008 startte hij de (voor)opleiding Inwendige Geneeskunde in het Erasmus 
Medisch Centrum te Rotterdam (opleider: Prof. J.L.C.M. van Saase). Vanaf  januari 2010 
tot nu vervolgt hij zijn opleiding tot Maag-, Darm- en Leverarts in het Erasmus Medisch 
Centrum te Rotterdam (opleider Dr. R.A. de Man).
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sUmmArY oF PHD trAiNiNG AND teACHiNG
Name PhD student: Geert Bezemer 
Erasmus MC Department: Gastroenterology and Hepatology
Promotor: Prof. Dr. H.L.A. Janssen
PhD period: 2005-2008
Summary of  PhD training activities
(Inter)national conferences
2005  40th Annual Meeting of  the European Association for the Study of  the Liver;  April 
13-17, 2005 - Paris, France
  20th Erasmus Liver Day; June 10, Rotterdam, the Netherlands
  Annual meeting of  the Dutch Society of  Gastroenterology and Hepatology; 
 October 6-7, Veldhoven, the Netherlands
2006  41st Annual Meeting of  the European Association for the Study of  the Liver; 
 April 26-30, 2006 - Vienna, Austria
 21st Erasmus Liver Day; November 23, Rotterdam, the Netherlands
  Annual meeting of  the Dutch Society of  Gastroenterology and Hepatology; 
 October 5-6, Veldhoven, the Netherlands
2007  Annual meeting of  the Dutch Society of  Gastroenterology and Hepatology; 
 October 4-5, Veldhoven, the Netherlands.
 22nd Erasmus Liver Day; December 6, Rotterdam, the Netherlands
2008  59th Annual Meeting of  the American Association for the Study of  Liver Diseases 
(AASLD); October 31-November 4, San Fransisco, CA, United States of America
 Annual meeting of  the Dutch Society of  Gastroenterology and Hepatology; 
 October 2-3, Veldhoven, the Netherlands.
 23rd Erasmus Liver Day; November 27, Rotterdam, the Netherlands
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159Summary of  PhD training and teaching
2009  60th Annual Meeting of  the American Association for the Study of  Liver Diseases 
(AASLD); october 30-November 3, 2009, Boston, Massachussets, USA
Oral and poster presentatations
2005  Use of  antidepressants during treatment of  Hepatitis C, National Hepatitis Day, Na-
tional Hepatitis Center, Amersfoort, the Netherlands (oral)
2006  Health Related Quality of  Life of  hepatitis C patients in the Ditto-study, NVGE, Veld-
hoven, the Netherlands (oral)
2007  Psychiatric side-effects and the fluctuations in related amino acids in the treatment 
of  chronic hepatitis C infection, NVGE, Veldhoven, the Netherlands (oral)
2008  A double blind, placebo-controlled trial with escitalopram to prevent psychiatric 
adverse events during treatment with pegylated interferon-alpha and ribavirin for 
chronic hepatitis C: The “Prevention of  Psychiatric Side effects (PoPS)-study” 
NVGE, Veldhoven, the Netherlands (oral) & AASLD, San Fransisco, United States of 
America (poster)
2009  Escitalopram prevents psychiatric side effects of  interferon-alfa in Hepatitis C, An-
nual meeting of the Dutch Society of Psychiatry, Groningen, the Netherlands, poster 
  Psychiatric side-effects and the fluctuation in serotonergic parameters during treat-
ment of  chronic hepatitis C-infection with peginterferon and ribavirin, NVGE, Veld-
hoven, the Netherlands (oral) & AASLD, Boston, United States of America (poster)
Courses
2005 Netherlands Insitute for Health Sciences (NIHES), Erasmus Summer Program, Sta-
tistics
Memberships 
2005  Dutch Society of  Gastroenterology (NVGE)
 Dutch Society of  Hepatology (NVH)
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